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Abstract	  
Background:	   	  The	  pathogenesis	   of	   bisphosphonate	   related	   osteonecrosis	   of	   the	  
jaw	   (BRONJ)	   is	   not	   well	   understood,	   although	   its	   clinical	   presentation	   and	  
response	  to	  treatment	  reflect	  a	  failure	  to	  heal.	  	  Vascular	  endothelial	  growth	  factor	  
(VEGF)	  is	  involved	  in	  both	  angiogenesis	  and	  osteogenesis	  and	  plays	  a	  role	  in	  tissue	  
formation,	  modelling	  and	  remodelling	  in	  response	  to	  injury.	  	  VEGF	  is	  upregulated	  
in	  zoledronic	  acid	  (ZA)	  treated	  cells	  and	  therefore	  any	  inhibition	  of	  this	  pathway	  
in	  BRONJ	  may	  be	  via	  the	  VEGF	  receptors.	  	  Protein	  prenylation	  is	  essential	  for	  VEGF	  
receptor	   intracellular	   transportation	   and	   anchorage	   to	   the	   cell	  membrane.	   	   The	  
mevalonate	   pathway	   (MVP)	   is	   an	   intracellular	   target	   for	   the	   nitrogen	  
bisphosphonates	   and	   disruption	   prevents	   protein	   prenylation.	   	   Aim:	   	   To	  
determine	   the	   role	   of	   the	   VEGF	   receptors	   (R1	   and	   R2)	   in	   human	   alveolar	  
osteoblast	   (HOB)	   growth	   and	   maturation	   and	   to	   investigate	   receptor	   protein	  
expression	  in	  the	  presence	  and	  absence	  of	  ZA	  and	  a	  downstream	  MVP	  metabolite,	  
geranylgeraniol	   (GGOH).	   	   Hypothesis:	   	   VEGF	   receptor	   inhibition	   will	   affect	  
mineralised	   nodule	   formation	   by	   HOBs	   and	   the	   mechanism	   of	   this	   effect	   is	   via	  
inhibition	  of	   the	  MVP.	   	  Materials	   and	  methods:	   	  An	  alizarin	  red	  mineralisation	  
assay	  was	  used	  to	  quantitatively	  analyse	  calcium	  deposition	  by	  HOBs	  after	  21	  and	  
28	   days	   of	   culture	   in	   the	   presence	   of	   a	   VEGFR1,	   VEGFR2	   or	   a	   dual	  
VEGFR1/VEGFR2	   inhibitor.	   Alizarin	   red	   and	   alkaline	   phosphatase	   staining	  were	  
used	   to	   identify	   the	   presence	   of	   nodules	   under	   these	   conditions	   at	   21	   days	   of	  
culture.	   	  HOBs	  were	  cultured	  and	  treated	  with	  various	  combinations	  of	  VEGF,	  ZA	  
and	  GGOH	  for	  48	  h.	   	   Immunofluorescence	  and	  confocal	  microscopy	  were	  used	  to	  
analyse	   VEGFR1	   protein	   expression	   under	   these	   conditions.	   	  Results:	   	   VEGFR1	  
and	  dual	  VEGFR1/VEGFR2,	  but	  not	  VEGFR2	   inhibition	   lead	   to	  a	  dose	  dependent	  
decrease	   in	   mineralisation	   by	   human	   alveolar	   osteoblasts.	   	   The	   present	  
experiment	   did	   not	   detect	   a	   difference	   in	   VEGFR1	   protein	   expression	   by	   HOBs	  
treated	  with	  combinations	  of	  ZA,	  VEGF	  and	   the	  mevalonate	  pathway	  constituent	  
GGOH.	  	  Conclusion:	  	  The	  VEGF/VEGFR1	  pathway	  is	  important,	  but	  not	  essential	  to	  
osteoblast	  growth	  and	  maturation	  in	  vitro.	   	  The	  mechanism	  of	  VEGFR1	  inhibition	  
by	  the	  potent	  nitrogen	  bisphosphonate,	  ZA,	  remains	  to	  be	  elucidated.	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  concentration	  on	  human	  alveolar	  osteoblast	  viability.	  	  Three	  
HOB	  cell	  cultures	  for	  each	  concentration	  graphed	  with	  mean	  ±	  SEM.	  	  Dotted	  line	  
represents	  an	  untreated	  control	  (Reproduced	  with	  permission	  from,	  Zafar,	  2014)	  .....	  58	  
Figure	  2-­‐6.	  	  Experimental	  layout	  for	  HOB2	  treatments	  1	  to	  8;	  to	  be	  replicated	  for	  each	  cell	  
culture	  (HOB3	  and	  HOB5)	  .....................................................................................................................	  60	  
Figure	  2-­‐7.	  	  Experimental	  layout	  for	  establishing	  an	  immunofluorescence	  protocol	  ..............	  64	  
Figure	  2-­‐8.	  	  Immunofluorescence	  experimental	  layout	  for	  VEGFR1	  antibody	  (ab32152)	  and	  
IgG	  control	  ................................................................................................................................................	  66	  
Figure	  3-­‐1.	  	  Human	  alveolar	  osteoblasts	  after	  4	  days	  of	  culture	  showing	  a	  characteristic	  lack	  
of	  contact	  inhibition	  (10x	  magnification)	  ......................................................................................	  68	  
Figure	  3-­‐2.	  	  Photograph	  of	  a	  96-­‐well	  plate	  at	  day	  21	  showing	  different	  media	  colours	  and	  
therefore	  different	  rates	  of	  media	  utilisation.	  	  A	  pink/red	  hue	  represents	  less	  media	  
	   viii	  
utilised	  and	  corresponds	  with	  slower	  cell	  growth	  compared	  with	  the	  yellow	  hue,	  which	  
represents	  greater	  media	  utilisation	  and	  therefore	  faster	  cell	  growth.	  .............................	  70	  
Figure	  3-­‐3.	  Experimental	  layout	  for	  96-­‐well	  plates	  indicating	  the	  treatment	  (ZM	  306416,	  
ZM323881	  and	  KRN	  633),	  dose	  and	  culture	  (HOB2,	  HOB3	  or	  HOB5)	  corresponding	  to	  the	  
wells	  above	  in	  Figure	  3–2	  ....................................................................................................................	  70	  
Figure	  3-­‐4.	  Mean	  HOB2,	  HOB3	  and	  HOB5	  ARS	  levels	  at	  21	  days,	  expressed	  as	  a	  %	  of	  control,	  
for	  the	  log	  value	  of	  each	  VEGFR1	  inhibitor	  concentration.	  	  	  	  Slope	  mean	  across	  all	  
cultures	  =	  -­‐9.68	  .......................................................................................................................................	  73	  
Figure	  3-­‐5.	  Mean	  HOB2,	  HOB3	  and	  HOB5	  ARS	  levels	  at	  21	  days,	  expressed	  as	  a	  %	  of	  control,	  
for	  the	  log	  value	  of	  each	  VEGFR2	  inhibitor	  concentration.	  	  Slope	  mean	  across	  all	  
cultures	  =	  0.54	  ........................................................................................................................................	  74	  
Figure	  3-­‐6.	  	  Mean	  HOB2,	  HOB3	  and	  HOB5	  ARS	  levels	  at	  21	  days,	  expressed	  as	  a	  %	  of	  control,	  
for	  the	  log	  value	  of	  each	  dual	  VEGFR1/VEGFR2	  inhibitor	  concentration.	  	  Slope	  mean	  
across	  all	  cultures	  =	  -­‐7.36	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  75	  
Figure	  3-­‐7.	  	  Graph	  showing	  the	  ARS	  means	  for	  three	  HOB	  cell	  cultures	  in	  the	  presence	  of	  four	  
different	  VEGFR1	  inhibitor	  concentrations	  after	  21	  days	  of	  exposure,	  expressed	  as	  a	  %	  
of	  control	  (control=dotted	  line).	  	  Two-­‐tailed	  paired	  t	  tests	  for	  differences	  between	  
untreated	  controls	  and	  each	  dose	  concentration;	  the	  ARS	  values	  were	  significantly	  
different	  from	  control	  for	  0.01	  μM,	  1	  μM	  and	  10	  μM.	  	  For	  two-­‐tailed	  paired	  t	  tests	  for	  
differences	  between	  each	  dose	  concentration,	  there	  were	  significant	  differences	  
between	  0.01	  μM	  and	  10	  μM,	  0.01	  μM	  and	  1	  μM,	  and	  1	  μM	  and	  10	  μM.	  	  P-­‐values:	  
*≤0.05	  	  **≤	  0.01	  	  ***≤0.001.	  	  Standard	  deviations	  are	  given.	  ..................................................	  78	  
Figure	  3-­‐8.	  Graph	  showing	  the	  ARS	  means	  for	  three	  HOB	  cell	  cultures	  in	  the	  presence	  of	  four	  
different	  VEGFR2	  inhibitor	  concentrations	  after	  21-­‐days	  of	  exposure,	  expressed	  as	  a	  %	  
of	  control	  (control=dotted	  line).	  	  	  Two-­‐tailed	  pairwise	  t	  tests	  showed	  a	  significant	  
difference	  between	  ARS	  values	  for	  the	  0.1	  μM	  concentration	  when	  compared	  to	  the	  
untreated	  control.	  	  There	  were	  no	  significant	  differences	  in	  ARS	  values	  between	  any	  of	  
the	  other	  doses	  and	  that	  of	  the	  control,	  or	  between	  each	  of	  the	  doses.	  P-­‐value:	  *≤0.05.	  	  
Standard	  deviations	  are	  given.	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  79	  
Figure	  3-­‐9.	  Graph	  showing	  the	  ARS	  means	  for	  three	  HOB	  cell	  cultures	  in	  the	  presence	  of	  four	  
different	  VEGFR1/R2	  inhibitor	  concentrations	  after	  21	  days	  of	  exposure,	  expressed	  as	  
a	  %	  of	  control	  (control=dotted	  line).	  	  For	  two-­‐tailed	  paired	  t	  tests,	  the	  ARS	  values	  for	  
the	  0.1	  μM	  and	  1	  μM	  doses	  were	  significantly	  different	  from	  control.	  	  There	  was	  a	  
significant	  difference	  in	  ARS	  value	  only	  between	  doses	  0.1	  μM	  and	  1	  μM.	  	  P-­‐values:	  
**≤	  0.01	  	  ***≤0.001.	  	  Standard	  deviations	  are	  given.	  .................................................................	  80	  
Figure	  3-­‐10.	  Mean	  HOB2,	  HOB3	  and	  HOB5	  ARS	  levels	  at	  28	  days,	  expressed	  as	  a	  %	  of	  control,	  
for	  the	  log	  value	  of	  each	  VEGFR1	  inhibitor	  concentration.	  	  Slope	  mean	  across	  all	  
cultures	  =	  -­‐18.55	  ....................................................................................................................................	  84	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Figure	  3-­‐11.	  Mean	  HOB2,	  HOB3	  and	  HOB5	  ARS	  levels	  at	  28	  days,	  expressed	  as	  a	  %	  of	  control,	  
for	  the	  log	  value	  of	  each	  VEGFR2	  inhibitor	  concentration.	  	  Slope	  mean	  across	  all	  
cultures	  =	  -­‐0.32	  .......................................................................................................................................	  85	  
Figure	  3-­‐12.	  	  Mean	  HOB2,	  HOB3	  and	  HOB5	  ARS	  levels	  at	  28	  days,	  expressed	  as	  a	  %	  of	  
control,	  for	  the	  log	  value	  of	  each	  dual	  VEGFR1/VEGFR2	  inhibitor	  concentration.	  	  Slope	  
mean	  across	  all	  cultures	  =	  -­‐22.49	  .....................................................................................................	  86	  
Figure	  3-­‐13.	  Graph	  showing	  the	  ARS	  means	  for	  three	  HOB	  cell	  cultures	  in	  the	  presence	  of	  
four	  different	  VEGFR1	  inhibitor	  concentrations	  after	  28	  days	  of	  exposure,	  expressed	  as	  
a	  %	  of	  control	  (control=dotted	  line).	  	  For	  two-­‐tailed	  paired	  t	  tests,	  only	  the	  ARS	  value	  
for	  the	  10	  μM	  dose	  was	  significantly	  different	  from	  control.	  	  There	  were	  significant	  
differences	  between	  ARS	  values	  for	  doses	  0.01	  μM	  and	  10	  μM,	  0.01	  μM	  and	  1	  μM,	  
and	  1	  μM	  and	  10	  μM.	  P-­‐values:	  *≤0.05	  	  **≤	  0.01.	  	  Standard	  deviations	  are	  given.	  .......	  89	  
Figure	  3-­‐14.	  Graph	  showing	  the	  ARS	  means	  for	  three	  HOB	  cell	  cultures	  in	  the	  presence	  of	  
four	  different	  VEGFR2	  inhibitor	  concentrations	  after	  28	  days	  of	  exposure,	  expressed	  as	  
a	  %	  of	  control	  (control=dotted	  line).	  	  There	  were	  no	  significant	  differences	  (two-­‐tailed	  
paired	  t	  tests)	  in	  ARS	  value	  between	  any	  of	  the	  doses	  and	  the	  control,	  or	  between	  each	  
of	  the	  doses.	  	  Standard	  deviations	  are	  given.	  ...............................................................................	  90	  
Figure	  3-­‐15.	  Graph	  showing	  the	  ARS	  means	  for	  three	  HOB	  cell	  cultures	  in	  the	  presence	  of	  
four	  different	  VEGFR1/R2	  inhibitor	  concentrations	  after	  28	  days	  of	  exposure,	  
expressed	  as	  a	  %	  of	  control	  (control=dotted	  line).	  	  There	  were	  no	  significant	  
differences	  (two-­‐tailed	  paired	  t	  tests)	  in	  ARS	  value	  between	  any	  of	  the	  doses	  and	  the	  
control,	  or	  between	  each	  of	  the	  doses.	  	  Standard	  deviations	  are	  given.	  ..............................	  91	  
Figure	  3-­‐16.	  	  Graph	  showing	  the	  mean	  number	  of	  nodules	  observed	  by	  two	  independent	  
examiners	  for	  each	  HOB	  culture	  (2,	  3	  and	  5)	  after	  21	  days	  of	  culture	  with	  the	  VEGFR1	  
inhibitor.	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  95	  
Figure	  3-­‐17.	  	  ARS	  and	  alkaline	  phosphatase	  staining	  at	  21	  days	  of	  culture	  (scale	  bar	  100	  μ
M)	  HOB2	  cell	  culture	  exposed	  to	  VEGFR1	  inhibitor	  at	  different	  concentrations:	  A=0.01	  
μM,	  B=0.1	  μM,	  C=1	  μM,	  D=10	  μM,	  E=control	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  96	  
Figure	  3-­‐18.	  Graph	  showing	  the	  mean	  number	  of	  nodules	  observed	  by	  two	  independent	  
examiners	  for	  each	  HOB	  culture	  (2,	  3	  and	  5)	  after	  21	  days	  of	  culture	  with	  the	  VEGFR2	  
inhibitor.	  ...................................................................................................................................................	  97	  
Figure	  3-­‐19.	  ARS	  and	  alkaline	  phosphatase	  staining	  at	  21	  days	  of	  culture	  (scale	  bar	  100	  μ
M)	  HOB2	  cell	  culture	  exposed	  to	  VEGFR2	  inhibitor	  at	  different	  concentrations:	  A=0.001	  
μM,	  B=0.01	  μM,	  C=0.1	  μM,	  D=1	  μM,	  E=control	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  98	  
Figure	  3-­‐20.	  Graph	  showing	  the	  mean	  number	  of	  nodules	  observed	  by	  two	  independent	  
examiners	  for	  each	  HOB	  culture	  (2,	  3	  and	  5)	  after	  21	  days	  of	  culture	  with	  the	  
VEGFR1/R2	  inhibitor.	  ...........................................................................................................................	  99	  
Figure	  3-­‐21.	  ARS	  and	  alkaline	  phosphatase	  staining	  at	  21	  days	  of	  culture	  (scale	  bar	  100μM)	  
HOB2	  cell	  culture	  exposed	  to	  VEGFR1/R2	  inhibitor	  at	  different	  concentrations:	  A=0.01	  
	   x	  
μM,	  B=0.1	  μM,	  C=0.5	  μM,	  D=1	  μM,	  E=control.	  	  Haematoxylin	  counterstaining	  is	  seen	  
in	  well	  E.	  .................................................................................................................................................	  100	  
Figure	  3-­‐22.	  	  HOB4	  exposed	  to	  ZA	  10	  μM	  for	  48	  h	  and	  fixed	  in	  acetone.	  The	  slide	  depicted	  in	  
the	  left	  image	  (a)	  was	  treated	  with	  VEGFR1	  antibody	  and	  Alexa	  Fluor	  488	  secondary	  
antibody,	  while	  the	  slide	  on	  the	  right	  (b)	  was	  treated	  with	  an	  IgG	  control	  and	  Alexa	  
Fluor	  488	  secondary	  antibody	  (Scale	  bar	  =	  50	  μM).	  	  Positive	  staining	  for	  slide	  (a)	  
compared	  with	  negative	  staining	  for	  slide	  (b)	  confirms	  the	  specificity	  of	  the	  VEGFR1	  
antibody	  for	  the	  protein	  of	  interest	  ..............................................................................................	  101	  
Figure	  3-­‐23.	  Images	  taken	  with	  a	  Zeiss	  LSM	  710	  confocal	  laser	  scanning	  microscope	  of	  
immunofluorescence	  for	  VEGFR1	  on	  human	  alveolar	  osteoblasts	  (1a=HOB2,	  1b=HOB3,	  
1c=HOB5)	  cultured	  in	  osteoblast	  mineralisation	  media	  and	  a	  PBS	  control	  carrier	  for	  48	  
hrs.	  	  Image	  1d	  is	  the	  IgG	  control	  (HOB2).	  	  Scale	  bar=50	  μm.	  ...............................................	  102	  
Figure	  3-­‐24.	  	  Images	  taken	  with	  a	  Zeiss	  LSM	  710	  confocal	  laser	  scanning	  microscope	  of	  
immunofluorescence	  for	  VEGFR1	  on	  human	  alveolar	  osteoblasts	  (2a=HOB2,	  2b=HOB3,	  
2c=HOB5)	  cultured	  in	  osteoblast	  mineralisation	  media	  and	  VEGF	  for	  48	  hours.	  	  Image	  
2d	  is	  the	  IgG	  control	  (HOB2).	  Scale	  bar=50	  μm.	  .....................................................................	  103	  
Figure	  3-­‐25.	  	  Images	  taken	  with	  a	  Zeiss	  LSM	  710	  confocal	  laser	  scanning	  microscope	  of	  
immunofluorescence	  for	  VEGFR1	  on	  human	  alveolar	  osteoblasts	  (3a=HOB2,	  3b=HOB3,	  
3c=HOB5)	  cultured	  in	  osteoblast	  mineralisation	  media,	  VEGF	  and	  ZA	  for	  48	  hrs.	  	  Image	  
3d	  is	  the	  IgG	  control	  (HOB2).	  Scale	  bar=50	  μm.	  .....................................................................	  104	  
Figure	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Chapter	  1	  
1 Introduction	  
BRONJ:	  The	  effects	  of	  zoledronic	  acid	  on	  the	  VEGF	  receptors	  and	  implications	  for	  
osteoblast	  growth	  and	  maturation.	  	  
In	   2003,	   bisphosphonate	   related	   osteonecrosis	   of	   the	   jaw	   (BRONJ)	   was	   first	  
described	   as	   a	   clinically	   significant,	   yet	   poorly	   understood	   complication	   of	  
bisphosphonate	   therapy	   (Marx,	  2003).	   	  Today,	  more	   than	  a	  decade	   later,	   little	   is	  
known	  of	  the	  precise	  aetiology	  and	  pathogenesis	  of	  BRONJ	  despite	  the	  continued	  
prescription	  of	  bisphosphonates	   in	   the	  community.	   	  An	  effective,	  evidence	  based	  
prevention	  and	  treatment	  strategy	  remains	  elusive.	  	  	  
Recent	   attempts	   at	   describing	   the	   pathogenesis	   of	   BRONJ	   revolve	   around	   the	  
central	   concept	   of	   impaired	  healing	   (Ziebart	   et	   al.,	   2011,	  Kobayashi	   et	   al.,	   2010,	  
Ruggiero	   et	   al.,	   2014).	   	  Wound	   healing	   is	   a	   complex	   and	   co-­‐ordinated	   series	   of	  
events	  involving	  the	  initial	  inflammatory	  response	  to	  injury,	  tissue	  formation	  and	  
maturation,	  and	  concurrent	  remodelling.	   	  Growth	   factors	   interact	  with	  receptors	  
on	  target	  cells	  to	  tightly	  regulate	  and	  direct	  these	  events.	  	  Angiogenesis	  describes	  
the	  formation	  of	  new	  blood	  vessels	  from	  existing	  blood	  vessels.	  	  Given	  the	  role	  of	  
the	  vasculature	  in	  the	  transport	  and	  delivery	  of	  inflammatory	  cells,	  hematopoietic	  
stem	  cells	  and	  nutrients	   to	   the	   target	   tissue,	   angiogenesis	   is	  a	   critical	  process	   in	  
wound	   healing.	   	   The	   present	   research	   is	   concerned	   with	   the	   effects	   of	   the	  
bisphosphonate	   zoledronic	   acid	   (ZA),	   on	   vascular	   endothelial	   growth	   factor	  
(VEGF)	   receptor,	   an	   important	   pro-­‐angiogenic	   growth	   factor	   receptor	   that	   is	  
expressed	  on	  human	  alveolar	  osteoblasts.	  	  	  	  
The	  specific	  objectives	  and	  hypotheses	  will	  be	   introduced	   in	   the	  context	  of	  bone	  
biology	   and	   wound	   healing,	   bisphosphonate	   structure	   and	   its	   therapeutic	  
applications,	   and	   potential	   pathogenic	   mechanisms	   underlying	   BRONJ.	   	   To	  
appreciate	   the	  wider	   significance	   of	   this	   research,	   it	   is	   also	   necessary	   to	   review	  
currently	  accepted	  BRONJ	  diagnostic	  criteria	  and	  epidemiology.	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The	  results	  of	  this	  study	  will	  contribute	  to	  our	  understanding	  of	  the	  mechanisms	  
leading	  to	  BRONJ,	  with	  the	  underlying	  goal	  to	  ultimately	  provide	  an	  effective	  and	  
evidence	  based	  treatment	  strategy.	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1.1 BRONJ	  
To	  emphasise	  the	  importance	  of	  developing	  an	  effective	  treatment	  and	  prevention	  
strategy,	   it	   is	   essential	   to	   look	   at	   how	   BRONJ,	   as	   a	   failure	   of	   wound	   healing,	  
manifests	  clinically	  and	  to	  critically	  evaluate	   the	  current	  management	  strategies.	  	  
It	   is	   also	   important	   to	   review	   the	   prevalence	   and	   incidence	   of	   BRONJ	   in	   the	  
community	   and	   the	   associated	   risk	   factors.	   	   The	   clinical	  management	   of	   BRONJ	  
patients	   and	   identification	   of	   a	   high-­‐risk	   profile	   provides	   some	   insight	   into	   the	  
factors	  that	  contribute	  to	  its	  pathogenesis	  and	  helps	  identify	  potential	  therapeutic	  
targets.	  
1.1.1 Current	  Definition	  
A	   Special	   Committee	   comprising	   experienced	   clinicians	   and	   researchers	   first	  
published	   a	   Position	   Paper	   on	   BRONJ	   in	   2007	   on	   behalf	   of	   The	   American	  
Association	   of	   Oral	   and	   Maxillofacial	   Surgeons	   (AAOMS).	   	   This	   was	   updated	   in	  
2009	   (Ruggiero	   et	   al.,	   2009),	   and	  most	   recently	   in	   2014.	   	  A	  proposed	   change	   in	  
nomenclature	   was	   the	   most	   significant	   modification	   in	   the	   2014	   update.	   	   This	  
paper	  advocated	  changing	  the	  name	  from	  bisphosphonate	  related	  osteonecrosis	  of	  
the	   jaw	   (BRONJ),	   to	   medication-­‐related	   osteonecrosis	   of	   the	   jaw	   (MRONJ)	   to	  
reflect	   the	   increasing	   incidence	   of	   osteonecrosis	   of	   the	   jaws	   in	   patients	   taking	  
antiresorptive	   and	   antiangiogenic	   therapies	   (Ruggiero	   et	   al.,	   2014).	   	   Grouping	  
these	   medications	   together	   could	   be	   interpreted	   as	   suggesting	   a	   common	  
pathogenic	   mechanism.	   	   However,	   despite	   obvious	   similarities	   in	   therapeutic	  
applications	   (antiresorptive)	   and	   proposed	   inhibitory	   effects	   on	   wound	   healing	  
(antiangiogenic),	  a	  common	  name	  seems	  premature	  given	  that	  the	  pathogenesis	  of	  
the	   disease	   is	   not	   completely	   understood.	   	   BRONJ	  will	   therefore	   continue	   to	   be	  
referred	  to	  as	  a	  separate	  clinical	  entity	  for	  the	  purposes	  of	  this	  review.	  	  	  	  
BRONJ	  may	   be	   included	   in	   a	   differential	   diagnosis	   for	   a	   patient	   presenting	  with	  
each	  of	  the	  following:	  
1) Current	  or	  previous	  treatment	  with	  bisphosphonates.	  
2) Exposed	  bone	  or	  bone	  that	  can	  be	  probed	  through	  an	  intraoral	  or	  extraoral	  
fistula(e)	  in	  the	  maxillofacial	  region	  that	  has	  persisted	  for	  more	  than	  eight	  
weeks;	  and	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3) No	  history	  of	  radiation	  therapy	  to	  the	  jaws	  or	  obvious	  metastatic	  disease	  to	  
the	  jaws.	  	  	  	  
1.1.2 Staging	  and	  Management	  
A	   clinical	   classification	   describing	   severity	   accompanies	   a	   BRONJ	   diagnosis	   and	  
ranges	   from	   the	   unaffected	   ‘at	   risk’	   stage	   to	   the	   severe	   and	  debilitating	   stage	   3.	  	  
Each	   category	   corresponds	   to	   a	   management	   strategy	   as	   shown	   in	   Table	   1–1.	  	  
Stages	  1,	  2	  and	  3	  are	  shown	  in	  Figures	  1–1,	  1–2	  and	  1–3.	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Table	   1-­‐1.	   	   BRONJ/MRONJ	   classification	   and	  management	   (Modified	   from	   Ruggiero	   et	   al.,	  
2014)	  
Stage Presentation  Management strategy 
At risk No signs or symptoms of necrosis 
Exposure to bisphosphonates 
Information and education on risks 
and symptoms 
Stage 0 Non-exposed bone variant 
Non-specific symptoms OR 
combined clinical and radiographic 
findings that cannot be explained 
by any other organic cause e.g. dull 
aching bone pain, tooth mobility, 
no new bone in extraction sockets 
Symptom driven treatment, including 
analgesics 
Conservative caries and periodontal 
disease management 
Monitor closely for signs of 
progression and exclusion of other 
diagnoses 
Stage 1 Exposed and necrotic bone, or 
fistula that probes into bone 
No evidence of infection  
Asymptomatic 
Oral antimicrobial rinses 
(chlorhexidine 0.12%) 
No operative treatment required 
Stage 2 Exposed and necrotic bone, or 
fistula that probes into bone 
Evidence of infection  
Usually symptomatic 
Oral antimicrobial rinses and 
antibiotic therapy to treat secondary 
infection of exposed, necrotic bone 
Stage 3 Exposed and necrotic bone, or 
fistula that probes into bone 
Evidence of infection 
At least one of the following: 
• Extensive necrosis 
extending beyond the 
alveolar bone 
• Pathologic fracture 
• Extra-oral fistula 
• Oral antral/oral nasal 
communication 
• Osteolysis extending to the 
inferior border of the 
mandible or sinus floor 
Debridement and/or resection 
combined with antibiotic therapy 
An immediate reconstruction plate or 
obturator my be required after 
resection 
Immediate reconstruction with 
vascularized bone holds promise 
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Figure	  1-­‐1.	  Asymptomatic	  Stage	  1	  BRONJ	  
	  
	  









Figure	  1-­‐3.	  (a)	  Extensive	  and	  infected	  Stage	  3	  BRONJ,	  
(b)	   with	   pathological	   fracture	   (Figures	   1-­‐3	  
reproduced	   with	   permission	   from	   John	   Wiley	   and	  
Sons,	  Ruggiero,	  2011)	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1.1.3 Prevalence	  and	  Incidence	  
Several	   factors	   impede	  an	  accurate	  estimate	  of	  BRONJ	  prevalence	  and	   incidence,	  
reflected	   in	   the	   wide	   range	   of	   figures	   reported	   in	   epidemiological	   studies.	  	  
Confounding	   issues	   include	   small	   sample	   sizes	   for	   a	   low	   frequency	   event,	   the	  
broad	   clinical	   diagnostic	   spectrum	   from	   stage	   0	   to	   stage	   3	   BRONJ,	   the	   frequent	  
prescription	  of	   oral	   bisphosphonates	   in	   the	   community,	   the	  potential	   for	   loss	   to	  
follow-­‐up	  and	  the	  proposed	  cumulative	  effect.	  	  Even	  so,	  epidemiological	  evidence	  
suggests	   that	   those	  patients	  with	   the	  most	   to	  gain	   from	  bisphosphonate	   therapy	  
appear	   to	   be	   most	   at	   risk	   for	   developing	   this	   rare	   and	   debilitating	   condition.	  	  
Prevalence	  estimates	   should	   therefore	  be	   reported	   in	   the	   context	  of	  patient	   risk	  
factors.	  	  This	  provides	  guidance	  for	  the	  management	  of	  specific	  at-­‐risk	  groups	  and	  
hints	   at	   possible	   underlying	   pathogenic	   mechanisms.	   	   Risk	   factors	   for	   the	  
development	   of	   BRONJ	   include	   medication-­‐related	   factors,	   local	   factors,	  
demographic	  factors	  and	  genetic	  factors	  (Ruggiero	  et	  al.,	  2014).	  
1.1.3.1 Medication-­‐Related	  Factors	  
Medication-­‐related	   factors	   reference	   the	   type	   of	   bisphosphonate,	   treatment	  
duration,	   dose	   and	   mode	   of	   administration,	   and	   the	   underlying	   condition	   for	  
which	   the	   bisphosphonate	   is	   prescribed	   (Ruggiero	   et	   al.,	   2014).	   	   Nutritional	  
deficiencies	  and	  immunocompromise	  occur	  with	  malignancy	  due	  to	  the	  nature	  of	  
the	  condition	  and	  the	  accompanying	  treatment	  (Marx	  et	  al.,	  2005).	   	   It	   is	  possible	  
that	   this	   systemic	   compromise	   may	   influence	   the	   initiation	   and	   progression	   of	  
BRONJ	  at	  the	  individual	  level.	   	  There	  is	  some	  evidence	  to	  suggest	  that	  the	  type	  of	  
malignancy	   may	   affect	   the	   incidence	   of	   BRONJ.	   	   Multiple	   myeloma	   has	   been	  
associated	  with	  higher	  incidence	  than	  metastatic	  breast	  cancer	  or	  prostate	  cancer	  
(Vahtsevanos	  et	  al.,	  2009,	  Bamias	  et	  al.,	  2005,	  Durie	  et	  al.,	  2005,	  Woo	  et	  al.,	  2006,	  
Hoff	   et	   al.,	   2011).	   	   However,	   incidence	   values	   for	   different	   types	   of	   cancer	   are	  
frequently	   reported	   together,	   possibly	   to	   increase	   the	   population	   size	   for	  
statistical	   purposes.	   	   It	   is	   also	   difficult	   to	   identify	   and	   control	   for	   confounding	  
medication	  factors	  when	  details	  regarding	  bisphosphonate	  type,	  cumulative	  dose	  
and	  mode	  of	  administration	  are	  unknown	  and/or	  inconsistent.	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1.1.3.1.1 Total	  Dose	  
The	  risk	   for	  developing	  BRONJ	   is	   largely	  attributed	   to	   the	   type	  and	   total	  dose	  of	  
bisphosphonate	   administered	   (Hoff	   et	   al.,	   2011,	   Woo	   et	   al.,	   2006).	   	   This	   is	   an	  
important	  consideration	  when	  comparing	  the	  risk	  associated	  with	  bisphosphonate	  
treatment	   for	   different	   types	   of	   malignancy	   and	   the	   risk	   for	   patients	   with	  
osteoporosis/osteopenia.	   	   As	  part	   of	   the	  palliative	  management	   of	   patients	  with	  
multiple	   myeloma	   or	   metastatic	   breast	   cancer,	   a	   bisphosphonate	   regime	  
consisting	  of	  a	  4	  mg	  ZA	  infusion	  administered	  over	  5	  minutes	  every	  four	  weeks	  for	  
10	   months	   has	   been	   recommended	   (Berenson	   et	   al.,	   2001).	   	   This	   is	   12	   times	  
greater	  than	  the	  recommended	  dose	  of	  up	  to	  4	  mg	  (IV)	  administered	  annually	  as	  a	  
preventative	  treatment	  for	  post-­‐menopausal	  women	  with	  low	  bone	  density	  (Reid	  
et	  al.,	  2002,	  Woo	  et	  al.,	  2006).	  	  The	  discrepancy	  in	  total	  dose	  may	  explain	  some	  of	  
the	  variation	  in	  BRONJ	  incidence	  values	  between	  osteoporotic	  patients	  and	  cancer	  
patients.	   	   The	   incidence	   of	   BRONJ	   in	   cancer	   patients	   undergoing	   IV	  
bisphosphonate	  therapy	  with	  the	  amino-­‐bisphosphonate	  zoledronate	  is	  estimated	  
to	  be	  between	  0.7	  and	  6.7%	  (Coleman,	  2011,	  Vahtsevanos	  et	  al.,	  2009,	  Ruggiero	  et	  
al.,	   2014).	   	   This	   estimate	   was	   further	   refined	   to	   approximately	   1%	   when	   only	  
randomized	  control	  trials	  were	  evaluated	  in	  the	  2014	  position	  paper	  (Ruggiero	  et	  
al.,	  2014).	  	  
1.1.3.1.2 Treatment	  Duration	  
As	  the	  duration	  of	  IV	  zoledronate	  exposure	  for	  a	  cancer	  patient	  increases,	  so	  does	  
the	  risk	  of	  developing	  BRONJ.	  	  After	  1	  year	  of	  exposure,	  the	  incidence	  of	  BRONJ	  is	  
approximately	  0.5-­‐0.6%	  (Ruggiero	  et	  al.,	  2014).	  	  This	  increases	  to	  0.9-­‐1.0%	  after	  2	  
years	   and	   1.3%	   after	   3	   years	   (Henry	   et	   al.,	   2011).	   However,	   patients	   with	  
metastatic	  bone	  cancer	  have	  a	  comparatively	  high	  short-­‐term	  mortality	  rate	  that	  
may	   complicate	   long-­‐term	   risk	   estimates.	   	   The	   risk	   of	   developing	   BRONJ	   for	  
osteoporotic	  patients	   treated	  with	   yearly	   IV	   zoledronate	   infusions	   for	  3	   years	   is	  
approximately	  0.017%	  (Grbic	  et	  al.,	  2010).	  	  This	  is	  not	  significantly	  different	  from	  
the	  risk	  associated	  with	  placebo	  (0-­‐0.02%)	  and	  does	  not	  increase	  with	  6	  years	  of	  
exposure	  (Ruggiero	  et	  al.,	  2014,	  Black	  et	  al.,	  2012).	   	  This	   is	  a	  paradoxical	   finding	  
given	  that	  ZA	  has	  a	  long	  half-­‐life	  and	  its	  effects	  are	  therefore	  expected	  to	  increase	  
over	  time	  with	  the	  accumulating	  total	  dose	  (Woo	  et	  al.,	  2006,	  Grey	  et	  al.,	  2010).	  	  In	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contrast,	   exposure	  duration	  appears	   to	  be	  a	   risk	   factor	   for	  osteoporotic	  patients	  
taking	  oral	  bisphosphonates.	  	  The	  reported	  incidence	  of	  BRONJ	  among	  this	  group	  
is	   highly	   variable.	   	   Figures	   range	   from	   0.1%,	   increasing	   to	   0.21%	   as	   exposure	  
duration	   extends	   beyond	   4	   years	   (Lo	   et	   al.,	   2010,	   Ruggiero	   et	   al.,	   2014).	   	   More	  
conservative	  estimates	  range	  from	  0.00038	  (Felsenberg	  and	  Hoffmeister,	  2006)	  to	  
<0.004%	  per	  drug	  patient	   years	   (Malden	  and	  Lopes,	  2012).	  While	   a	  precise	   and	  
generalisable	  estimate	   is	  not	  possible	   from	   this	  data,	   it	   is	   evident	   that	   incidence	  
among	  osteoporotic	  patients	  taking	  oral	  bisphosphonates	  is	  low.	  	  However,	  a	  low	  
incidence	  in	  the	  context	  of	  a	  frequently	  prescribed	  drug	  (Ruggiero	  et	  al.,	  2014)	  can	  
equate	  to	  a	  large	  number	  of	  cases	  over	  time.	  	  A	  retrospective	  case	  study	  identified	  
91	   osteoporosis-­‐related	   BRONJ	   cases	   in	   a	   single	   metropolitan	   US	   city	   between	  
2003	   and	   2012.	   	  More	   than	   80%	  of	   cases	   had	   been	   exposed	   to	   the	   oral	   amino-­‐
bisphosphonate,	  alendronate	  (Fosamax)	  (Mercer	  et	  al.,	  2013).	  	  	  
1.1.3.2 Local	  Factors	  
Local	   factors	   are	   particularly	   relevant	   in	   the	   dental	   setting	   when	   treatment	  
planning	  for	  the	  patient	  with	  a	  history	  of	  bisphosphonate	  exposure.	  	  They	  include	  
operative	   treatment,	   anatomic	   factors	   and	   concomitant	   oral	   disease.	   	   The	   most	  
obvious	  operative	  treatment	  associated	  with	  BRONJ	  incidence	  is	  tooth	  extraction.	  	  
A	   recent	   retrospective	   cohort	   study	   of	   3216	   extraction	   patients	   over	   3	   years	  
included	  126	  patients	  who	  were	  also	  exposed	  to	  bisphosphonates	  (oral	  n=99,	   IV	  
n=27).	   	   Five	   of	   these	   126	   patients	   developed	   BRONJ	   following	   an	   extraction,	  
resulting	  in	  an	  unadjusted	  risk	  ratio	  of	  122.6	  (95%	  CI:	  14.4-­‐1041.8)	  (Yamazaki	  et	  
al.,	  2012).	  	  However,	  the	  associated	  risk	  for	  developing	  BRONJ	  must	  be	  considered	  
in	   relation	   to	   medication-­‐related	   factors.	   	   Patients	   taking	   oral	   bisphosphonates	  
have	   approximately	   a	   0.5%	   risk	   of	   developing	   BRONJ	   following	   an	   extraction	  
(Kunchur	   et	   al.,	   2009).	   	   The	   corresponding	   risk	   following	   extraction	   for	   cancer	  
patients	  exposed	   to	   IV	  bisphosphonates	   is	   substantially	  higher.	   	  Estimates	   range	  
from	   1.6	   to	   14.8%	   and	   are	   based	   on	   both	   prospective	   and	   retrospective	   cohort	  
studies	   (Ruggiero	   et	   al.,	   2014).	   There	   is	   insufficient	   data	   to	   report	   the	   risk	  
associated	   with	   other	   operative	   procedures.	   	   However,	   any	   procedure	   that	  
involves	   bone	   exposure,	   including	   periodontal	   flap	   access	   surgery,	   should	   be	  
approached	  with	  similar	  caution.	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It	   is	  difficult	   to	  estimate	   the	   risk	  associated	  with	  pre-­‐existing	  oral	   infection	  as	   it	  
often	   shares	   a	   close	   temporal	   relationship	  with	   tooth	   extraction.	   	   A	   recent	   case	  
report	  described	  a	  single,	  severe	  case	  of	  grade	  3	  MRONJ	  in	  an	  82-­‐year-­‐old	  female	  
patient	  with	  a	  15-­‐year	  history	  of	  weekly	  oral	  risedronate	  (35mg)	  for	  the	  treatment	  
of	  osteoporosis	  (Fernández	  Ayora	  et	  al.,	  2014).	  	  The	  patient	  had	  periodontitis	  and	  
peri-­‐implantitis	   was	   diagnosed	   in	   association	   with	   a	   lower	   left	   implant.	   	   The	  
implant	  was	  removed	  uneventfully.	  	  The	  site	  failed	  to	  heal	  and	  rapidly	  progressed	  
from	  grade	  2	  to	  grade	  3	  MRONJ.	  	  Despite	  eventual	  involvement	  of	  the	  entire	  body	  
of	   the	   mandible,	   pathological	   fracture,	   spontaneous	   exfoliation	   of	   all	   remaining	  
mandibular	   teeth	   and	   progression	   to	   the	   left	   condyle,	   extensive	   reconstructive	  
therapy	  was	  prohibited	  due	  to	  the	  patient’s	  age	  and	  general	  health.	  	  Although	  this	  
case	   study	   does	   not	   allow	   generalization,	   it	   is	   a	   reminder	   of	   the	   potential	  
complications	  that	  may	  be	  encountered	  when	  managing	  an	  aging	  population	  with	  
periodontal	  and	  peri-­‐implant	  disease	  and	  a	  long	  history	  of	  bisphosphonate	  use.	  	  It	  
is	  evident	  from	  this	  case	  that	  severe	  oral	  infection	  cannot	  presently	  be	  separated	  
from	  its	  management	  in	  a	  clinical	  context.	  	  In	  the	  absence	  of	  an	  effective,	  evidence	  
based	   treatment	   strategy	   the	   relative	   importance	   of	   pre-­‐existing	   infection	   and	  
explantation/extraction	   in	   the	   pathogenesis	   of	   BRONJ	   looses	   significance.	   	   The	  
emphasis	   instead	   is	   on	   preventative	   and	   conservative	   management	   at	   the	  
individual	  level.	  	  
1.1.3.3 Anatomic	  Factors	  
Anatomic	  factors	  that	  appear	  to	  influence	  BRONJ	  incidence	  include	  localization	  to	  
the	  mandible	  or	  maxilla	  and	   the	  presence	  of	  dentures.	   	  Almost	   three	  quarters	  of	  
cases	   occur	   exclusively	   in	   the	  mandible	   (73%).	   	   The	  maxilla	   alone	   is	   affected	   in	  
22.5%	   of	   cases	   and	   a	   minority	   of	   cases	   involve	   both	   jaws	   (4.5%)	   (Saad	   et	   al.,	  
2011).	   	   The	   presence	   of	   dentures	   is	   estimated	   to	   impose	   twice	   the	   risk	   of	  
developing	  BRONJ	  amongst	  cancer	  patients	  exposed	  to	  IV	  amino-­‐bisphosphonates	  
(Vahtsevanos	  et	  al.,	  2009).	  	  A	  plausible	  explanation	  for	  this	  increase	  in	  incidence	  is	  
that	  ill-­‐fitting	  dentures	  provide	  a	  constant	  source	  of	  trauma.	   	  For	  example,	  in	  the	  
resorbed,	  edentulous	  mandible	  the	  superior	  mental	  spine	  presents	  as	  a	  superficial	  
bony	  prominence	  with	  a	   thin	  mucosal	   covering	  and	   is	  particularly	  vulnerable	   to	  
trauma.	  	  Like	  the	  tooth	  extraction	  socket,	  resolution	  of	  a	  traumatic	  lesion	  involves	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both	  the	  oral	  soft	  tissues	  and	  underlying	  bone	  and	  is	  dependent	  upon	  the	  patient’s	  
innate	   ability	   to	   heal.	   	   Exposure	   to	   bisphosphonates	   appears	   to	   inhibit	   essential	  
healing	   processes	   including	   osteogenesis	   and	   angiogenesis.	   In	   patients	   with	   ill-­‐
fitting	  dentures	   this	   leads	   to	   the	  classic	  BRONJ	  presentation	  of	  exposed,	  necrotic	  
bone	  and	  a	  non-­‐healing	  oral	  wound.	  
1.1.4 BRONJ	  Summary	  
BRONJ	   is	   an	   infrequent,	   yet	   occasionally	   severe	   complication	   of	   bisphosphonate	  
therapy.	   	   Although	   from	   this	   review	   the	   key	   risk	   factors	   for	   developing	   BRONJ	  
seem	   to	   be	   exposure	   to	   a	   high	   cumulative	   dose	   of	   IV	   amino-­‐bisphosphonates	   -­‐	  
specifically	   ZA	   -­‐	   and	   the	   presence	   of	   an	   oral	   wound,	   it	   is	   difficult	   to	   draw	  
conclusions	  regarding	  prevalence	  and	  risk	  factors	  based	  on	  the	  current	  evidence.	  	  
In	  addition,	  cases	  of	  spontaneous	  BRONJ	  have	  been	  reported	  (Vescovi	  et	  al.,	  2011).	  	  
A	   spontaneous	   case	   is	   defined	   in	   the	   absence	   of	   any	   (retrospectively)	   identified	  
pre-­‐existing	   trauma,	   surgery,	   oral	   disease	   or	   specific	   anatomical	   feature.	   	   The	  
inclusion	  of	   these	  cases	   is	  a	   reminder	   that	  processes	   involved	   in	  wound	  healing,	  
such	   as	   bone	   modelling	   and	   remodelling,	   also	   underlie	   bone	   turnover	   and	  
metabolism	  –	  the	  therapeutic	  targets	  of	  the	  bisphosphonates.	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1.2 Bone	  Biology	  	  
Attempts	   to	   elucidate	   the	   pathophysiology	   of	   disease	   will	   benefit	   from	   an	  
evaluation	  of	   the	   tissues	   involved	   and	   the	  physiological	   processes	   that	  maintain	  
health.	  	  BRONJ	  involves	  alveolar	  bone	  and	  its	  soft	  tissue	  covering.	  	  The	  vasculature	  
plays	  an	  important	  role	  in	  the	  maintenance	  of	  both	  the	  hard	  and	  soft	  tissues.	  	  The	  
soft	   tissues	  consist	  of	  epithelium	  and	  connective	   tissue.	   	  The	  present	  research	   is	  
concerned	  with	  bone	  formation,	  modelling	  and	  remodelling	  in	  the	  jaws.	  	  	  
1.2.1 Bone	  Formation	  
Much	  of	  the	  skeleton	  is	  formed	  by	  the	  replacement	  of	  a	  cartilage	  model	  with	  bone	  
(endochondral	  ossification).	  	  This	  is	  not	  the	  case	  for	  the	  jaw	  bones.	  	  The	  mandible	  
and	  maxilla	   are	   derived	   from	   the	   first	   pharyngeal	   arch	   and	   each	   forms	   directly	  
within	   a	   mesenchymal	   mass	   (intramembranous	   ossification).	   The	   immature	  
woven	  bone	  seen	  in	  embryonic	  development	  has	  an	  irregular	  arrangement	  that	  is	  
also	   present	   in	   the	   initial	   stages	   of	   rapid	   bone	   repair	   and	   growth	   (Kardos	   and	  
Keiser,	  2000).	   	   In	  contrast,	  mature	   lamellar	  bone	  has	  a	  distinct	  architecture	   that	  
provides	   strength	   and	   houses	   the	   vasculature.	   	   In	   the	   adult,	   the	   alveolus	   is	   the	  
component	  of	  the	  jaw	  bones	  that	  supports	  the	  dentition	  and	  consists	  of	  different	  
lamellar	   bone	   arrangements;	   trabecular	   bone,	   an	   outer	   shell	   of	   densely	   packed	  
cortical	   bone,	   and	   bundle	   bone	   lining	   the	   tooth	   socket.	   	   Bundle	   bone	   provides	  
continuity	  between	  the	  tooth	  and	  the	  bony	  socket	  via	  the	  connective	  tissue	  fibres	  
(Sharpeys	   fibres)	   of	   the	   periodontal	   ligament.	   	   Irrespective	   of	   developmental	  
differences,	   once	   bone	   has	   formed	  modelling	   and	   remodelling	   occur	   throughout	  
life	   via	   apposition	   and	   resorption	   at	   the	   surfaces	   (Kardos	   and	   Keiser,	   2000).	  	  
Modelling	  describes	  the	  process	  of	  structural	  adaptation	  to	  changes	  in	  stress	  and	  
load	  and	  occurs	  due	  to	  apposition	  at	  some	  surfaces	  and	  resorption	  at	  others.	   	   In	  
contrast,	   remodelling	   involves	   the	   replacement	   of	   old	   bone	  with	   new	   bone	   at	   a	  
particular	  site	  (Gerhard	  et	  al.,	  2009).	  
1.2.2 Bone	  Modelling	  and	  Remodelling	  
Bone	  modelling	   and	   remodelling	   occur	   in	   the	   presence	   of	   an	   adequate	   vascular	  
supply	   and	   represent	   a	   complex	   interplay	   between	   osteoblasts	   and	   osteoclasts.	  
Osteoblasts	   are	   responsible	   for	   bone	   apposition.	   	   An	   increase	   in	   the	   alkaline	  
phosphatase	  (ALP)	  enzyme	  signifies	  early	  osteoblast	  differentiation	  (Owen	  et	  al.,	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1990).	   	   Osteocalcin	   (OCN)	   is	   a	   glycoprotein	   that	   forms	   part	   of	   the	   extracellular	  
matrix	  produced	  and	  secreted	  by	  mature	  osteoblasts.	   	  OCN	  is	  therefore	  used	  as	  a	  
phenotypic	   marker	   for	   mature	   osteoblasts	   and	   indicates	   the	   level	   of	   osteoblast	  
activity	   (Auf'mkolk	   et	   al.,	   1985).	   	   In	   keeping	   with	   the	   body’s	   overwhelming	  
tendency	   to	   maintain	   balance,	   osteoblasts	   are	   also	   important	   stimulators	   and	  
regulators	   of	   osteoclast	   differentiation	   via	   the	   release	   of	   receptor	   activator	   of	  
nuclear	  factor-­‐κB	  ligand	  (RANKL)	  and	  the	  decoy	  receptor,	  osteoprotegerin	  (OPG)	  
(Lacey	   et	   al.,	   1998).	   	   RANKL	   binds	   to	   its	   receptor,	   RANK	   (receptor	   activator	   of	  
nuclear	   factor-­‐κB),	   on	   monocytes/macrophages	   to	   initiate	   osteoclast	  
differentiation.	   	   The	   mature	   osteoclast	   is	   a	   multinucleated	   cell	   with	   a	   ruffled	  
border	  adjacent	  to	  the	  resorption	  lacunae	  on	  the	  bone	  surface	  (Bonucci,	  1981).	  	  To	  
limit	  the	  number	  of	  osteoclasts	  and	  therefore	  the	  amount	  of	  resorption,	  OPG	  binds	  
to	   RANKL	   blocking	   the	   interaction	   between	   RANKL	   and	   RANK	   on	   the	  
monocyte/macrophage	   cell	   surface	   (Hsu	   et	   al.,	   1999).	   	  While	   ALP	   and	   OCN	   are	  
useful	   for	   identifying	   osteoblast	   differentiation	   and	   maturation,	   RANKL	   to	   OPG	  
ratios	  regulate	  the	  level	  of	  bone	  remodelling	  and	  turnover	  (Khosla,	  2001,	  Delmas,	  
1993).	  	  
1.2.3 Angiogenesis	  and	  Osteogenesis	  
The	   influence	   of	   angiogenesis	   on	   osteogenesis	   has	   been	   investigated	   in	   fracture	  
healing	   and	   endochondral	   bone	   formation	   models	   for	   many	   years	   (Trueta	   and	  
Morgan,	   1960,	   Trueta,	   1963,	   Glowacki,	   1998,	   Gerber	   et	   al.,	   1999,	   Carano	   and	  
Filvaroff,	  2003,	  Street	  et	  al.,	  2002,	  Keramaris	  et	  al.,	  2008).	   	  A	  possible	  underlying	  
mechanism	  coupling	  these	  two	  processes	  was	  recently	  described	  (Kusumbe	  et	  al.,	  
2014).	  	  Endothelial	  cells	  are	  ubiquitous,	  yet	  have	  been	  shown	  to	  express	  an	  array	  
of	   specializations	   depending	   on	   the	   specific	   nature	   of	   the	   surrounding	   micro-­‐
environment.	   	   In	   a	  murine	  model,	   Kusumbe	   et	   al.	   identified	   a	   capillary	   subtype	  
that	  was	  able	  to	  couple	  angiogenesis	  and	  osteogenesis.	  The	  newly	  discovered	  type	  
‘H’	  endothelial	  cells	  were	  shown	  to	  maintain	  a	   local	  environment	  that	  supported	  
bone	  formation,	  including	  the	  ability	  to	  form	  new	  vessels	  and	  paracrine	  signalling	  
to	  perivascular	  osteoprogenitor	   cells.	   	  Aged	  animals	  were	   shown	   to	  have	  both	  a	  
decreased	   ‘H’	  cell	  number	  and	  osteoprogenitor	  cell	  number	   in	  bone.	   	   In	  humans,	  
bone	   modelling	   and	   remodelling	   are	   physiological	   processes	   that	   occur	   in	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response	   to	   functional	   demands	   and	   have	   an	   important	   role	   in	   calcium	  
metabolism.	   	   These	  processes	   becomes	   less	   efficient	  with	   age	   and	   lead,	   in	   some	  
patients,	   to	  a	  decrease	   in	  bone	  mass	   typical	  of	  osteoporosis	   (Harada	  and	  Rodan,	  
2003).	  The	  age	  related	  changes	  observed	  in	  this	  animal	  model	  might	  partly	  explain	  
the	   disruption	   of	   bone	   homeostasis	   that	   occurs	   in	   the	   aged	   population	   and	   the	  
mechanism	  linking	  osteogenesis	  and	  angiogenesis	  in	  time,	  space	  and	  function.	  
1.2.4 Bone	  Biology	  Summary	  
Bone	   is	   a	   dynamic	   tissue.	   	   Angiogenesis	   and	   osteogenesis	   are	   two	   essential	  
processes	   that	   allow	   bone	   to	   develop	   and	   to	   change	   over	   time	   in	   response	   to	  
stress,	   trauma	   and	   load.	   	   Perturbations	   in	   bone	   metabolism	   underlie	   the	  
prescription	  of	  bisphosphonates.	  	  Clinical	  effects	  may	  be	  due	  to	  multiple	  targets	  in	  
these	  processes.	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1.3 Wound	  Healing	  
Surgical	  treatment	  provided	  by	  dentists	  is	  directed	  at	  removing	  the	  cause	  of	  tissue	  
injury,	   providing	   relief	   of	   pain	   and	   supporting	   the	   patient’s	   own	   ability	   to	   heal.	  	  
Ultimately,	  whether	  it	  is	  reduction	  and	  fixation	  of	  a	  fractured	  bone,	  removal	  of	  an	  
infected	  tooth	  or	  raising	  and	  repositioning	  a	  mucoperiosteal	  flap,	  the	  coordinated,	  
continuous	  processes	  that	  characterize	  wound	  healing	  determine	  recovery.	  	  	  
1.3.1 Failure	  to	  Heal	  
A	  failure	  to	  heal	  can	  be	  catastrophic.	   	  In	  these	  cases,	  surgical	  intervention	  results	  
in	   additional	   tissue	   trauma.	   	   Wound	   margins	   are	   extended	   and	   the	   size	   of	   the	  
necrotic/non-­‐healing	  defect	  increases.	  	  The	  non-­‐healing	  patient	  represents	  a	  true	  
treatment	  dilemma.	  	  In	  this	  context,	  BRONJ	  may	  be	  broadly	  defined	  by	  its	  clinical	  
features	  and	  response	   to	   treatment	  as	  a	   failure	   to	  heal.	   	  However,	   it	   is	   apparent	  
that	  wound	  healing	  is	  a	  complex	  process.	  	  ‘Failure	  to	  heal’	  reveals	  little	  with	  regard	  
to	   the	   precise	   aetiology	   and	   pathogenesis	   –	   and	   therefore	   possible	   treatment	  
strategies	  –	  of	  BRONJ.	  	  A	  review	  of	  the	  many	  events	  involved	  in	  wound	  healing	  is	  
necessary	   to	   elucidate	   potential	   underlying	   mechanisms	   that	   warrant	   further	  
investigation	  as	  potential	  therapeutic	  targets.	  
1.3.2 Extraction	  Healing	  Model	  
Extraction	  socket	  healing	  involves	  both	  hard	  and	  soft	  tissues.	  	  Although	  relatively	  
rare,	  BRONJ	   is	  more	   frequently	  associated	  with	   tooth	  extraction	  (Vahtsevanos	  et	  
al.,	  2009,	  Saad	  et	  al.,	  2011,	  Fehm	  et	  al.,	  2009).	  	  The	  extraction	  socket	  will	  therefore	  
be	  used	  as	  a	  model	  to	  discuss	  wound	  healing	  in	  the	  maxillofacial	  region.	  
1.3.2.1 Human	  Extraction	  Model	  
In	   1969,	   Amler	   described	   socket	   healing	   up	   to	   50	   days	   post-­‐extraction	   (Amler,	  
1969).	   	   Importantly,	   Amler	   recognized	   the	   need	   to	   examine	   healthy	   human	  
subjects	   and	   screened	   for	   systemic	   illnesses	   that	   could	   potentially	   affect	  wound	  
healing.	  	  Observations	  of	  biopsied	  extraction	  site	  soft-­‐tissue	  specimens	  lead	  to	  the	  
development	  of	  a	  schematic	  representing	  the	  time	  sequence	  and	  different	  stages	  
of	   socket	   healing	   in	   healthy	   subjects.	   	   The	   main	   events	   described	   and	   the	  
corresponding	  time	  sequence	  begins	  with	  the	  formation	  of	  a	  clot	  in	  the	  extraction	  
socket	   immediately	   following	   extraction.	   	   The	   clot	   is	   replaced	   by	   granulation	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tissue	   after	   7	   days	   and	   the	   granulation	   tissue	   is	   in	   turn	   replaced	   by	   connective	  
tissue	  after	  20	  days.	  	  Osteoid	  appears	  at	  the	  base	  of	  the	  socket	  after	  7	  days	  and	  the	  
socket	  is	  at	  least	  2/3	  filled	  by	  trabeculae	  after	  38	  days.	  	  Four	  days	  after	  extraction	  
there	  is	  evidence	  of	  epithelialization	  and	  the	  advancing	  epithelial	   fronts	  typically	  
fuse	  between	  days	  24	  to	  35.	  	  In	  summary,	  a	  highly	  vascular	  granulation	  tissue	  was	  
replaced	   with	   provisional	   connective	   tissue	   and	   bone	   tissue	   in	   a	   continuous	  
process	  that	  occurred	  at	  the	  same	  time	  as	  epithelialization.	  	  	  
1.3.2.2 Animal	  Model	  
Although	   using	   a	   healthy	   human	   model	   is	   a	   major	   strength	   of	   Amler’s	  
observational	  study,	  therein	  also	  lies	  its	  weakness.	  	  Biopsies	  were	  confined	  to	  soft	  
tissues	   in	   order	   to	   avoid	   the	   possibility	   of	   patient	   disfigurement.	   	   In	   2003	   the	  
limitations	   of	   observing	   a	   restricted,	   superficial	   soft	   tissue	   region	   of	   a	   healing	  
socket	   and	   not	   including	   observations	   of	   the	   later	   stages	   of	   hard	   tissue	  
remodelling	  were	   recognized	   and	   addressed	   in	   a	   dog	  model	   (Cardaropoli	   et	   al.,	  
2003).	  	  In	  this	  study,	  mongrel	  dogs	  were	  sacrificed	  at	  intervals	  between	  1	  and	  180	  
days	   following	   tooth	   extraction,	   allowing	   several	   representative	   sections	   of	   the	  
entire	  extraction	  socket	   from	  each	  biopsy.	   	  The	  results	   resemble	  Amler’s	  human	  
study	   in	   that	   healing	   begins	   with	   a	   clot	   and	   thereafter	   involves	   concomitant	  
formation	   of	   different	   tissues	   at	   different	   rates.	   	   However,	   the	   2003	   study	   also	  
provided	   more	   site-­‐specific	   detail	   and	   will	   be	   used	   to	   describe	   the	   essential	  
features	  of	  extraction	  socket	  healing.	  	  	  
1.3.2.3 Histology	  	  
Figure	   1–4	   demonstrates	   histology	   at	   each	   stage	   of	   healing.	   	   Initially,	   the	  
extraction	   socket	   was	   filled	   with	   a	   clot	   mainly	   consisting	   of	   erythrocytes	   and	  
platelets	  in	  a	  fibrin	  network.	  The	  clot	  was	  separated	  from	  the	  oral	  environment	  by	  
a	   layer	   of	   inflammatory	   cells	   and	   the	   socket	   wall	   (bundle	   bone)	   was	   lined	   by	  
severed	  periodontal	   ligament	  fibres	  and	  blood	  vessels,	  along	  with	  large	  numbers	  
of	   mesenchymal	   cells.	   	   At	   three	   days	   post-­‐extraction,	   a	   highly	   vascularized	  
granulation	   tissue	   started	   to	   replace	   the	   clot.	   	   At	   seven	  days,	   the	   healing	   socket	  
contained	   a	   provisional	  matrix.	   	   The	   provisional	  matrix	   consisted	   of	   new	   blood	  
vessels,	  immature	  mesenchymal	  cells,	  white	  blood	  cells	  and	  collagen	  fibres.	  	  Bone	  
resorbing	  osteoclasts	  were	  present	  on	  the	  socket	  walls	  and	  within	  the	  Volkmann	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canals.	  	  At	  day	  14,	  epithelium	  partially	  lined	  the	  marginal	  connective	  tissue,	  which	  
consisted	   predominantly	   of	   blood	   vessels	   and	   inflammatory	   cells.	   	   Neither	   the	  
periodontal	   ligament	   nor	   the	   bundle	   bone	   was	   present,	   resulting	   in	   continuity	  
between	  the	  bone	  marrow	  spaces	  in	  the	  adjacent	  alveolus	  and	  the	  healing	  socket.	  	  
Highly	   cellular	  woven	   bone	   therefore	   extended	   into	   the	   socket	   from	   the	   former	  
socket	   wall.	   	   The	   woven	   bone	   was	   adjacent	   to	   newly	   formed	   blood	   vessels.	  
Centrally,	  the	  socket	  still	  consisted	  of	  provisional	  connective	  tissue.	  	  After	  30	  days,	  
a	  keratinized	  epithelium	  lined	  the	  marginal	  portion	  of	  the	  socket	  and	  osteoclasts	  
were	  present	  on	  the	  crestal	  lamellar	  bone.	  	  The	  socket	  was	  largely	  filled	  with	  new	  
bone.	  	  After	  60	  days	  the	  socket	  was	  composed	  of	  bone	  marrow	  and	  was	  separated	  
from	  the	  marginal	  mucosa	  by	  a	  hard	  tissue	  bridge	  consisting	  of	  woven	  bone.	  	  After	  
180	   days,	   the	   hard	   tissue	   bridge	   consisted	   of	   lamellar	   and	   woven	   bone	   with	  
inserting	   collagen	   fibres	   from	   the	   overlying	   mucosa.	   	   The	   remaining	   socket	  
consisted	  of	  bone	  marrow	  rich	  in	  adipocytes	  with	  few	  inflammatory	  cells.	  
	  
Figure	  1-­‐4.	  H	  &	  E	  staining	  of	  mesio-­‐distal	  sections	  from	  healing	  extraction	  sockets	  in	  a	  dog	  
model	   between	   1	   (a)	   and	   180	   (i)	   days	   of	   healing	   as	   described	   above	   (Reproduced	   with	  
permission	  from	  Jonh	  Wiley	  and	  Sons,	  Cardaropoli	  et	  al.,	  2003)	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The	   observations	   from	   superficial	   sections	   of	   healthy	   post-­‐extraction	   human	  
tissue,	   combined	  with	   long-­‐term	   observations	   of	   the	   entire	   socket	   in	   an	   animal	  
model	   have	   been	   useful	   in	   describing	   the	   major	   events	   in	   socket	   healing.	   	   Key	  
histological	   observations	   include	   the	   presence	   of	   vascular	   structures	   and	  
inflammatory	   cells,	   closure	   of	   the	   soft	   tissue	   wound	   with	   epithelium,	   and	   hard	  
tissue	  formation	  and	  maturation.	  	  However,	  histological	  observations	  describe	  the	  
cells	  present	  and	  tissue	  architecture	  at	  discrete	  moments	  in	  time;	  they	  do	  not	  give	  
insight	   into	   the	   cellular	   and	   molecular	   control	   of	   the	   healing	   process.	   	   It	   is	  
essential	   to	   not	   only	   identify	   the	   underlying	   processes	   of	   inflammation,	  
angiogenesis	  and	  osteogenesis,	  but	   to	   investigate	   the	  key	   regulatory	   factors	   that	  
govern	  these	  processes.	  	  	  
1.3.3 Regulatory	  Mechanisms	  
Bone	  is	  a	  highly	  vascular,	  dynamic	  tissue	  with	  unique	  regenerative	  properties	  that	  
allow	  structural	  integrity	  to	  be	  maintained	  following	  injury	  and	  stress.	  	  Extraction	  
and	   bone	   injury	   both	   result	   in	   vascular	   disruption,	   cytokine	   release	   and	  
haematoma	   formation.	   	   This	   represents	   a	   localized	   hypoxic	   area	   that	   thus	  
provides	   the	   stimulus	   for	   new	   vessel	   formation	   as	   the	   fundamental	   event	   in	  
healing	  (Street	  et	  al.,	  2000,	  Street	  et	  al.,	  2002).	  	  	  
1.3.3.1 Vascular	  Endothelial	  Growth	  Factor	  
In	   support	   of	   this	   concept,	   low	  oxygen	   tension	   and	   specific	   growth	   factors	   have	  
been	   associated	   with	   mRNA	   and	   protein	   upregulation	   of	   the	   pro-­‐angiogenic	  
cytokine,	   vascular	   endothelial	   growth	   factor	   (VEGF)	   (Ferrara	   and	   Davis-­‐Smyth,	  
1997,	  Dor	  et	  al.,	  2001,	  Ferrara	  et	  al.,	  2003).	  	  VEGF	  was	  first	  characterized	  in	  1989	  
and	  named	  after	  its	  apparent	  selectivity	  for	  endothelial	  cells	  (Ferrara	  and	  Henzel,	  
1989),	  although	  this	  selectivity	  has	  since	  been	  challenged.	  VEGF	  has	  been	  shown	  
to	   primarily	   target	   endothelial	   cells	   and	   to	   also	   affect	   other	   cell	   types	   including	  
bone	  marrow	  derived	  cells	  and	  oocytes	  (Ferrara	  et	  al.,	  2003,	  Clauss	  et	  al.,	  1990).	  	  	  
Specific	  membrane	  bound	  receptor	   tyrosine	  kinases	   (RTKs)	  have	  been	  shown	  to	  
mediate	   the	  effects	  of	  VEGF	  on	   target	   cells	   (Ferrara	  et	  al.,	  2003).	   	  The	   two	  main	  
RTKs	  are	  VEGF	  Receptor	  1	   (VEGFR1,	  also	  known	  as	  Flt-­‐1)	  and	  VEGF	  Receptor	  2	  
(VEGFR2,	   also	   known	   as	   Flk-­‐1	   or	   Kdr)	   (Ferrara	   et	   al.,	   2003)	   traverse	   the	   cell	  
membrane	  and	  share	  several	  structural	  features	  including	  seven	  immunoglobulin-­‐
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like	  domains	  extracellularly,	  a	  transmembrane	  region	  and,	  as	  the	  name	  suggests,	  a	  
tyrosine	  kinase	  with	  a	  kinase-­‐insert	  domain.	  	  Despite	  these	  structural	  similarities,	  
the	   functional	   effects	   of	   VEGFR1	   or	   VEGFR2	   activation	   depend	   on	   the	   type	   of	  
target	  cell	  and	  the	  developmental	  stage	  of	  the	  host	  (Ferrara	  et	  al.,	  2003).	  	  A	  precise	  
evaluation	  of	  the	  differential	  functions	  of	  each	  receptor	  in	  each	  tissue	  is	  presently	  
incomplete.	  
In	   combination	   with	   these	   RTK’s,	   VEGF	   has	   several	   important	   regulatory	  
functions.	   	   It	   has	   an	   essential,	   rate-­‐determining	   role	   in	   angiogenesis,	   with	  
downstream	  effects	   on	   diverse	   processes	   such	   as	   tumour	   growth,	   endochondral	  
bone	   formation	   and	   ovulation	   (Ferrara	   et	   al.,	   2003).	   	   VEGF	   also	   assists	   in	  
regulating	   inflammation	   via	   changes	   to	   vascular	   permeability.	   	   In	   addition	   to	  
regulating	  discrete	  events,	  VEGF	  and	  its	  receptors	  have	  been	  shown	  to	  co-­‐ordinate	  
closely	   linked	   processes.	   	   Osteogenesis	   and	   angiogenesis	   are	   both	   intimately	  
involved	  in	  wound	  healing	  and	  there	  is	  evidence	  to	  support	  VEGF	  and	  its	  receptors	  
as	   a	   common	   regulatory	   mechanism.	   	   In	   2005,	   Mayer	   et	   al.	   demonstrated	   that	  
mineralisation	   of	   human	   adult	   mesenchymal	   stem	   cells	   from	   trabecular	   bone	  
(hTBCs)	  was	  dependant	  on	  the	  expression	  of	  VEGF-­‐A	  and	  the	  naturally	  occurring	  
antagonist	   sFLT-­‐1	   was	   associated	   with	   regulation	   of	   this	   process	   (Mayer	   et	   al.,	  
2005).	  	  The	  ‘s’	  indicates	  that	  the	  antagonist	  receptor	  is	  a	  soluble	  form	  of	  Flt-­‐1,	  or	  
VEGFR1	   as	   it	   is	   now	   more	   commonly	   known.	   	   The	   role	   of	   this	   receptor	   in	  
regulating	   angiogenesis	   was	   identified	   in	   an	   in	   vivo	   study	  whereby	   secretion	   of	  
sFlt-­‐1	  by	  the	  placenta	  was	  shown	  to	  be	  an	  essential	  part	  of	  angiogenic	  regulation	  
in	  pregnancy	  (Clark	  et	  al.,	  1998).	   	   In	  Mayer’s	  study,	  high	  VEGF-­‐A	  expression	  was	  
associated	  with	  increased	  mineralization.	  	  It	  followed	  that	  high	  sFLT-­‐1	  expression	  
was	  associated	  with	  reduced	  mineralisation.	   	  In	  addition	  to	  this	  autocrine	  role	  in	  
osteogenesis,	   a	   paracrine	   role	   was	   also	   demonstrated	   in	   angiogenesis,	   whereby	  
the	  VEGF-­‐A	  from	  hTBCs	  also	  induced	  endothelial	  cells	  to	  sprout.	  	  VEGF	  is	  therefore	  
a	  key	  regulatory	  factor	  in	  wound	  healing	  involving	  hard	  and	  soft	  tissue	  injury,	  and	  
a	  potential	   target	   for	  BRONJ	   research.	   	  There	   is	  a	  growing	  body	  of	   experimental	  
work	   directed	   at	   understanding	  VEGF,	   its	   receptors,	   the	   effects	   on	   different	   cell	  
types	  and	  the	  regulatory	  mechanisms	  that	  determine	  these	  effects.	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1.3.3.1.1 VEGF	  Receptor	  Inhibition	  
The	   role	   of	   VEGF	   in	   angiogenesis	   has	   been	   convincingly	   established.	   	   Tan	   et	   al.	  
acknowledged	   the	   close	   correlation	   between	   angiogenesis	   and	   osteogenesis	   and	  
proposed	  the	  VEGF-­‐VEGFR2	  interaction	  as	  a	  common	  regulator	  of	  both	  processes.	  
To	   investigate	   the	   regulatory	   effects	   of	  VEGF	  on	  osteoblast	  phenotype	  and	  bone	  
turnover,	  a	  murine	  osteoblast	  cell	  line	  was	  cultured	  in	  the	  presence	  and	  absence	  of	  
VEGF.	   	  The	  expression	  of	  mRNA	  for	  VEGFR2	  transiently	  increased	  at	  24	  hours	  in	  
the	   presence	   of	   VEGF,	   however	   at	   48	   hours	   no	   difference	   from	   controls	   was	  
observed.	   An	   increase	   in	  mRNA	   expression	   for	   osteocalcin	   and	   osteoprotegerin	  
was	  observed	  after	  72	  hours	  of	  exposure	  to	  VEGF	  indicating	  that	  this	  pathway	  was	  
involved	   in	   targeting	   genes	   associated	  with	   osteogenesis	   (Tan	   et	   al.,	   2010).	   	   No	  
functional	  studies	  were	  undertaken	  targeting	  the	  VEGFR2	  receptor	  and	  thus	  there	  
was	  no	  data	   linking	  VEGFR2	  to	   increases	   in	  the	  expression	  of	  osteogenic	   factors.	  
The	   role	   of	   VEGFR2	   mediated	   pathways	   in	   osteoblast	   maturation	   and	  
mineralisation	  therefore	  remains	  to	  be	  established.	  	  	  
1.3.3.1.2 VEGFR2	  and	  Endothelial	  Cells	  
The	   study	   by	   Zhao	   et	   al.,	   2010	   examined	   a	   possible	   mechanism	   of	   receptor	  
inhibition	  with	  a	  focus	  on	  VEGFR2.	  	  Lovastatin	  is	  commonly	  prescribed	  to	  inhibit	  
cholesterol	  synthesis.	  	  Like	  all	  statins,	  it	  is	  an	  HMG	  CoA	  reductase	  inhibitor	  and	  has	  
a	   downstream	   effect	   on	   mevalonate	   pathway	   (MVP)	   metabolites.	   	   The	   MVP	  
products	  are	  important	  for	  the	  post-­‐translational	  lipid	  modification	  (prenylation)	  
of	   a	   subset	   of	   proteins	   important	   to	   many	   cellular	   processes	   (Goldstein	   and	  
Brown,	   1990).	   	   Some	   membrane	   bound	   receptors	   are	   dependent	   on	   post-­‐
translational	   modification	   for	   transportation	   to	   and	   anchorage	   within	   the	   cell	  
membrane.	   	  Following	  on	  from	  a	  previous	  study	  that	  demonstrated	  an	  inhibitory	  
effect	  on	  ligand-­‐induced	  epidermal	  growth	  factor	  receptor	  (EGFR)	  activation	  and	  
downstream	  signalling	   (Mantha	  et	  al.,	  2005),	   it	  was	  hypothesised	   that	   lovastatin	  
would	   inhibit	   VEGFR2	   in	   a	   similar	   way.	   	   The	   anticipated	   therapeutic	   effects	   on	  
tumour	   angiogenesis	   would	   be	   significant	   as	   a	   novel	   anti-­‐tumour	   drug.	   	   To	  
investigate	   this	   effect,	   human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   and	  
malignant	   mesothelioma	   cells	   (MM)	   were	   cultured	   with	   or	   without	   exogenous	  
VEGF.	   	   Immunofluorescence	   was	   used	   to	   visualize	   the	   unstimulated	   (without	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VEGF)	  cell	  surface	  localization	  of	  VEGFR2,	  as	  compared	  with	  the	  stimulated	  (with	  
VEGF)	   intracellular	   pattern	   representing	   VEGFR2	   activation	   and	   internalization.	  	  
Both	  the	  extracellular	  expression	  of	  VEGFR2	  and	  its	  internalization	  were	  reduced	  
when	   cells	   were	   treated	  with	   lovastatin	   and	   stimulated	  with	   VEGF	   (Zhao	   et	   al.,	  
2010).	   	   Two	   possible	  mechanisms	   involving	   disruption	   of	   the	  MVP	  may	   explain	  
these	   observations.	   	   Firstly,	   inhibition	   of	   rab	   protein	   geranylgeranylation	  
(prenylation)	   may	   thus	   affect	   intracellular	   VEGFR2	   transportation	   to	   the	   cell	  
membrane.	   	   Secondly,	   ligand	   activation	   is	   dependant	   on	   membrane	   bound	  
proteins	  such	  as	  actin	  to	  mediate	  receptor	  internalization.	   	  Inhibition	  of	  the	  MVP	  
can	   affect	   protein	   anchorage	   in	   the	   cell	   membrane	   and	   therefore	   the	   ability	   of	  
actin	   to	   mediate	   this	   step.	   	   Amino-­‐bisphosphonates	   also	   inhibit	   the	   MVP.	  	  
However,	   the	   effect	   on	   bone	   cells	   may	   be	   mediated	   by	   different	   membrane	  
anchored	   receptors.	   	   The	   results	   of	   this	   study	   support	   further	   investigation	   into	  
the	  specific	  effects	  of	  N-­‐BPs	  on	  osteoblasts	  and	  their	  receptors.	  
1.3.3.1.3 VEGF,	  VEGF	  Receptors	  and	  Osteoblast	  Differentiation	  
VEGF	   exists	   in	   several	   different	   isoforms	  defined	   by	   the	   number	   of	   amino	   acids	  
present.	   	   VEGF165	   has	   165	   amino	   acids	   and	   is	   the	  most	   common	   isoform	  with	  
optimal	  bioavailability	  and	  potency	  characteristics	  (Ferrara	  et	  al.,	  2003).	  	  In	  2011,	  
Hah	  et	   al.	   investigated	   the	   role	  of	  4	  different	  VEGF	   isoforms	   (121,	  165,	  189	  and	  
206)	   and	   the	   receptors	   VEGFR1	   and	  VEGFR2	   on	   osteoblast	   differentiation.	   	   The	  
experimental	  design	  involved	  culturing	  human	  periosteal-­‐derived	  cells	  harvested	  
from	  the	  mandible.	  	  The	  cells	  were	  exposed	  to	  either	  an	  inhibitor	  for	  both	  the	  R1	  
and	   R2	   receptors	   (KRN633),	   or	   a	   VEGFR2	   specific	   inhibitor	   (VEGFR2	   Kinase	  
Inhibitor	   IV)	   for	   21	   days.	   	   The	   VEGFR2	   specific	   inhibitor	   was	   ten	   times	   more	  
selective	  for	  VEGFR2	  (IC50	  =	  19	  nM)	  than	  for	  VEGFR1	  (IC50	  =	  190	  nM).	  	  ALP	  activity	  
was	   examined	   at	   day	   10	   as	   an	   early	   osteoblast	   marker.	   	   Mineralization	   was	  
assessed	   at	   day	   21	   to	   investigate	   osteoblast	   maturation.	   	   VEGFR2	   inhibition	  
affected	  neither	  ALP	  activity	  nor	  mineralization.	  	  However,	  the	  combined	  VEGFR1	  
and	   VEGFR2	   inhibitor	   decreased	   both	   the	   ALP	   activity	   and	   the	   extent	   of	  
mineralization.	   	   This	   suggests	   a	   dominant	   role	   for	   VEGFR1	   in	   osteoblast	  
differentiation	   and	  maturation;	   however	   a	   specific	   inhibitor	   of	   VEGFR1	  was	   not	  
investigated	   and	   the	   VEGFR2	   inhibitor	   appears	   to	   have	   been	   discontinued.	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Treatment	  of	  cultured	  periosteal-­‐derived	  cells	  with	  exogenous	  VEGF165	  increased	  
ALP	   and	   mineralization.	   	   This	   study	   also	   looked	   at	   the	   expression	   of	   VEGF	  
isoforms,	   VEGFR1	   and	   VEGFR2.	   	   Real	   time	   polymerase	   chain	   reaction	   (RT-­‐PCR)	  
was	  used	   to	   assess	  VEGF	   and	  VEGFR	   expression.	   	   All	   four	   of	   the	  VEGF	   isoforms	  
were	  expressed	  throughout	   the	  experiment	  and	   increased	  over	   time	   from	  day	  7.	  	  
VEGFR1	  was	   expressed	   at	   day	   7	   and	   remained	   constant	   throughout	   the	   culture	  
period.	  	  VEGFR2	  expression	  increased	  from	  the	  start	  of	  the	  culture	  period	  up	  until	  
day	  21,	  decreasing	  thereafter	  (Hah	  et	  al.,	  2011).	   	  These	  results	  provided	  support	  
for	  VEGF	  as	  an	  autocrine	  molecule	  in	  osteoblast	  differentiation	  and	  highlighted	  the	  
potential	   significance	   of	   VEGFR1	   to	   this	   process.	   	   However,	   it	   is	   not	   possible	   to	  
determine	  from	  this	  study	  if	  VEGFR1	  functions	  independently,	  or	   in	  combination	  
with	   VEGFR2.	   	   The	   use	   of	   a	   specific	   VEGFR1	   inhibitor	   is	   indicated	   for	   future	  
investigations	  into	  the	  role	  of	  VEGF	  in	  osteoblast	  growth	  and	  maturation.	  
1.3.4 Wound	  Healing	  Summary	  
Wound	   healing	   involves	   multiple	   continuous	   and	   co-­‐ordinated	   processes	  
including	  angiogenesis	  and	  osteogenesis.	  	  Vascularity	  has	  a	  central	  role	  in	  each	  of	  
these	  processes	  and	  is	  under	  the	  regulation	  of	  growth	  factors	  such	  as	  VEGF.	  	  This	  
important	  pro-­‐angiogenic	   growth	   factor	  has	  been	   shown	   to	   act	   via	   receptors	  on	  
target	  cells	  including	  endothelial	  cells,	  osteoclasts	  and	  osteoblasts.	  	  As	  such,	  VEGF	  
receptors	  are	  promising	  targets	  in	  elucidating	  BRONJ	  pathogenesis.	  	  	  
	   	  
	   23	  
1.4 Bisphosphonates	  
Bisphosphonates	   have	   important	   therapeutic	   applications	   that	   have	   evolved	  
alongside	  structural	  changes	  to	  the	  bisphosphonate	  backbone	  that	  have	  enhanced	  
efficacy.	   	  As	  with	  many	  drugs,	   fundamental	  properties	  have	  been	  recognized	  and	  
applied	  clinically	  without	  a	  complete	  understanding	  of	  all	  underlying	  mechanisms	  
of	   action.	   	   Bisphosphonates	   have	   a	   cumulative	   effect	   and	   a	   very	   long	   half-­‐life,	  
depending	  on	  the	  particular	  bisphosphonate	  administered	  (Woo	  et	  al.,	  2006,	  Grey	  
et	  al.,	  2010).	  	  Therefore,	  the	  importance	  of	  these	  obscure	  underlying	  mechanisms	  
becomes	   evident	  when,	   even	   years	   after	   the	   initial	   introduction,	   adverse	   effects	  
come	  to	   light	  (Edwards	  et	  al.,	  2008).	   	  To	  present	  a	  perspective	  that	  balances	  the	  
benefits	   of	   bisphosphonates	   with	   the	   potential	   for	   adverse	   outcomes,	   the	   key	  
structural	   features,	   known	   mechanisms	   of	   action	   and	   therapeutic	   applications	  
over	  time	  are	  discussed.	  
1.4.1 Initial	  Synthesis	  and	  Basic	  Structure	  
The	  more	  potent	  bisphosphonates	  associated	  with	  BRONJ	  have	  been	  in	  clinical	  use	  
for	  little	  over	  a	  decade.	  	  Bisphosphonates	  have	  a	  long	  history	  from	  initial	  synthesis	  
in	  the	   late	  1800’s	   to	  specific	   therapeutic	  applications	  today	  (Menschutkin,	  1865)	  
in	   (Fleisch,	   1998).	   	   The	   fundamental	   structural	   constant	   that	   has	   spanned	   this	  
evolution	   is	   a	   ‘planar	  W’	   backbone	  with	   two	   phosphonate	   groups	   (Figure	   1–5).	  	  
The	   C-­‐PO(OH)2	   groups	   give	   the	   bisphosphonates	   –	   and	   their	   precursors	   –	   their	  
chelating	  properties	  as	  they	  have	  a	  high	  affinity	  for	  binding	  di	  and	  trivalent	  metal	  
ions.	   	   Initially	   this	   was	   exploited	   in	   industry	   by	   using	   early	   bisphosphonates	  
(pyrophosphates)	   to	   sequester	   ions	   and	   prevent	   their	   precipitation	   (Blomen,	  
1995)	  in	  (Fleisch,	  1998).	  	  	  
	  
Figure	  1-­‐5.	  Basic	  structure	  of	  the	  bisphosphonates	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1.4.2 Biological	  Applications	  
The	   biological	   applications	   of	   bisphosphonates	   have	   their	   origins	   in	   dental	  
research	  in	  the	  1960’s.	   	  As	  a	  known	  calcium-­‐chelating	  agent,	  the	  bisphosphonate	  
etidronate	  was	  investigated	  for	  its	  ability	  to	  remove	  dental	  calculus	  from	  polished	  
enamel	  surfaces	  and	  to	  inhibit	  calculus	  formation	  (Sturzenberger	  et	  al.,	  1971).	  	  As	  
research	   in	   this	   field	   progressed,	   two	   important	   properties	  were	   identified	   that	  
would	   set	   the	   stage	   for	   bisphosphonates	   to	   be	   used	   in	   the	   treatment	   of	   bone	  
metabolism	   disorders.	   	   The	   first	   was	   that	   polyphosphates,	   which	   contained	   an	  
oxygen	   atom	   connecting	   two	   phosphate	   atoms,	   were	   rapidly	   hydrolysed	   by	  
alkaline	   phosphatases.	   	   Therefore	   a	   stable	   pyrophosphate	   analogue	   that	   shared	  
the	  planar	  w	  backbone	  but	  which	  resisted	  hydrolysis	  would	  be	  needed	  for	  use	  in	  
humans.	   	   In	   addition	   to	   fulfilling	   this	   requirement	   by	   substituting	   the	   central	  
oxygen	  atom	  (P-­‐O-­‐P)	  with	  a	  carbon	  atom	  (P-­‐C-­‐P),	  bisphosphonates	  had	  the	  ability	  
to	  block	  the	  dissolution	  of	  hydroxyapatite	  crystals	  and	  therefore	  could	  be	  useful	  in	  
preventing	  bone	  resorption	  (Fleisch	  et	  al.,	  1969,	  Francis	  et	  al.,	  1969)	   in	  (Russell,	  
2011).	  	  
1.4.3 Therapeutic	  indications	  
The	  first	  therapeutic	  application	  was	  born	  of	  necessity	  and	  recorded	  in	  1968.	  	  An	  
infant	   suffering	   from	   myositis	   ossificans	   progressiva	   (more	   recently	   named	  
fibrodysplasia	   ossificans	   progressive)	   was	   in	   a	   critical	   condition	   due	   to	   ectopic	  
calcification	   in	   the	   chest	  muscles,	   preventing	   normal	   respiratory	   function.	   	   This	  
patient’s	  condition	  was	  successfully	  managed	  with	  oral	  etidronate	  (Bassett	  et	  al.,	  
1969).	   	  Following	  on	   from	  the	  success	  of	   the	   first	  clinical	  application,	  etidronate	  
was	   trialled	  as	  a	   treatment	   for	  patients	  with	  Paget’s	  disease	  (Smith	  et	  al.,	  1971).	  	  
Paget’s	   disease	   is	   characterized	   by	   localized	   abnormal	   bone	   tissue	   remodelling.	  	  
Rapid	   resorption	   is	   followed	   by	   rapid	   apposition	   and	   loss	   of	   normal	   tissue	  
architecture	   (Siris,	   1998).	   	   More	   than	   40	   years	   since	   the	   original	   clinical	   trial,	  
bisphosphonates	   remain	   the	   gold	   standard	   in	   treatment	   for	   this	   condition	  
(Russell,	  2011).	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1.4.3.1 Application	  for	  Osteoporosis	  
Further	  clinical	  and	  diagnostic	  applications	  have	  since	  been	  developed	  to	  detect,	  
treat	   and	   prevent	   the	   sequelae	   of	   bone	   metabolism	   disorders.	   	   Of	   particular	  
interest	  is	  the	  increase	  in	  bone	  mineral	  density	  achieved	  with	  bisphosphonates	  in	  
osteoporotic	  patients,	  particularly	  in	  the	  lumbar	  spine	  and	  hip	  regions	  (Russell	  et	  
al.,	   2008).	   	   Osteoporosis	   is	   defined	   as	   ‘a	   progressive	   systemic	   disease	  
characterized	   by	   low	   bone	   density	   and	   the	   microarchitectural	   deterioration	   of	  
bone	   tissue,	   with	   a	   consequent	   increase	   in	   bone	   fragility	   and	   susceptibility	   to	  
fracture’	   (Genant	   et	   al.,	   1999).	   	   Susceptibility	   to	   bone	   fractures	   is	   critically	  
important	  with	  several	  studies	  reporting	  a	  decrease	  in	  osteoporotic	  fractures	  due	  
to	   bisphosphonate	   therapy	   (Liberman	   et	   al.,	   1995,	   Reginster	   et	   al.,	   2000).	   	   In	   a	  
meta-­‐analysis	   risedronate	   was	   shown	   to	   produce	   a	   substantial	   reduction	   in	  
vertebral	   and	   non-­‐vertebral	   fractures	   in	   women	   with	   postmenopausal	  
osteoporosis	   (Cranney	   et	   al.,	   2002).	   	   A	  40%	   reduction	   in	  hip	   fractures	  has	  been	  
reported	   following	   treatment	   with	   alendronate,	   risedronate	   and	   zoledronate	  
(Russell,	   2011).	   	   Considering	   the	   aging	   population,	   the	   potential	   benefits	   of	  
reducing	   the	   rate	   of	   osteoporotic	   fractures	   by	   increasing	   bone	   density	   are	  
significant	  both	  for	  the	  individual	  and	  the	  community	  disease	  burden.	  	  	  
1.4.4 Potential	  Complications	  
It	  has	  been	  noted	  that	  bisphosphonates	  have	  a	  cumulative	  effect	  and	  a	  half-­‐life	  of	  
months	   to	   years	   (Woo	   et	   al.,	   2006,	   Grey	   et	   al.,	   2010).	   	   While	   the	   benefits	   of	  
bisphosphonates	  in	  the	  prevention	  of	  osteoporotic	  fractures	  cannot	  be	  ignored,	  it	  
is	   important	   to	   consider	   the	   long-­‐term	   implications	   of	   managing	   a	   large	  
population	   of	   otherwise	   healthy	   patients	  with	   a	   long	   history	   of	   bisphosphonate	  
use	   and	   a	   high	   potential	   for	   loss	   to	   follow-­‐up.	   	   Whether	   this	   will	   eventually	  
translate	  into	  an	  epidemic	  of	  adverse	  outcomes	  is	  yet	  unknown.	  	  A	  more	  complete	  
understanding	  of	  bisphosphonates’	  underlying	  mechanisms	  of	  action	  will	   inform	  
the	   development	   of	   safer	   therapies	   and	   treatment	   strategies	   as	   complications	  
arise.	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1.4.4.1 Potential	  Risks	  Versus	  Therapeutic	  Benefits	  
Although	   it	   is	   not	   yet	   possible	   to	   quantify	   all	   potential	   adverse	   outcomes	   of	  
bisphosphonate	  use,	   in	   certain	   circumstances	   the	  benefits	   are	   so	  great	   that	   they	  
currently	  far	  outweigh	  the	  risks.	  	  To	  put	  the	  risk-­‐benefit	  equation	  into	  perspective,	  
a	   review	   of	   bisphosphonate	   use	   for	   patients	   with	   multiple	   myeloma	   and	  
metastatic	  bone	  cancer	  is	  essential.	  	  These	  patients	  were	  overrepresented	  (35	  out	  
of	  the	  36	  patients)	  in	  the	  original	  paper	  proposing	  osteonecrosis	  of	  the	  jaws	  as	  an	  
adverse	   outcome	   of	   bisphosphonate	   use	   (i.e.	   BRONJ)	   (Marx,	   2003).	   	   The	  
bisphosphonates	   in	   question	   were	   intra-­‐venous	   pamidronate	   and	   zoledronate.	  	  
Despite	  this	  well-­‐documented	  adverse	  effect,	  bisphosphonates	  continue	  to	  be	  used	  
for	  reducing	  skeletal	   related	  events	   (SREs).	   	  SREs	   include	  bone	  pain,	   spinal	  cord	  
compression,	   pathological	   fracture	   and	   hypercalcemia.	   	   These	   events	   have	  
reportedly	   been	   reduced	   by	   30-­‐50%	   with	   therapeutic	   use	   of	   the	   potent	  
bisphosphonates	  (Coleman,	  2008).	  	  Specifically,	  zoledronate	  has	  been	  reported	  to	  
increase	  the	  time	  to	  first	  SRE	  and	  reduce	  both	  the	  number	  and	  rate	  of	  SREs.	  	  In	  a	  
double-­‐blind,	   randomized	   dose-­‐response	   study,	   infusions	   with	   ZA	   (2.0mg	   or	  
4.0mg)	   or	   pamidronate	   (90mg)	   were	   reported	   to	   reduce	   both	   the	   frequency	   of	  
SREs	   and	   the	   need	   for	   radiation	   therapy	   in	   patients	   with	   osteolytic	   lesions	  
secondary	   to	   metastatic	   breast	   cancer	   or	   multiple	   myeloma	   (Berenson	   et	   al.,	  
2001).	   	   For	   the	  patient,	   this	  provides	   relief	   from	  pain	  and	   significant	  benefits	   in	  
terms	  of	   quality	   of	   life	   and	  preservation	   of	   function	   (Coleman,	   2008).	   	   It	   can	  be	  
concluded	   that,	   in	   the	  context	  of	  a	   cancer	   therapy	   for	   significantly	  compromised	  
patients,	   who	   would	   otherwise	   be	   faced	   with	   debilitating	   pain	   and	   skeletal	  
complications,	   the	   potential	   for	   severe	   adverse	   effects	   from	   bisphosphonate	  
therapy	   is	   tolerable.	   	  However,	  a	   severe	  adverse	  effect	  associated	  with	  palliative	  
treatment	  in	  such	  a	  compromised	  patient	  can	  be	  devastating	  and	  the	  development	  
of	  an	  effective	  treatment	  strategy	  is	  vital.	  	  	  
1.4.5 Structure	  and	  Function	  
The	   bisphosphonates	   discussed	   thus	   far	   have	   included	   a	   number	   of	   structural	  
variations	   involving	   the	   R1	   and	   R2	   side	   chains.	   	   Different	   structures	   lead	   to	  
different	   potencies,	   different	   clinical	   applications	   and	  different	   adverse	   outcome	  
profiles.	   	   A	   feature	   common	   to	   all	   bisphosphonates	   is	   the	   P-­‐C-­‐P	   structure	   and	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therefore	   the	   ability	   to	   resist	   metabolic	   breakdown	   and	   specifically	   target	   the	  
skeleton	  (Fleisch,	  1998).	  	  Bisphosphonates	  strongly	  bind	  to	  hydroxyapatite	  on	  the	  
bone	  surface.	  	  The	  R1	  side	  chain	  often	  consists	  of	  a	  hydroxyl	  group	  (OH).	  	  This	  acts	  
as	  a	  ‘bone	  hook’	  and	  enhances	  binding	  to	  hydroxyapatite.	  	  The	  structure	  of	  the	  R2	  
side	  chain	  has	  also	  been	  shown	  to	  affect	  hydroxyapatite	  binding	  affinity	  (Ebetino	  
et	   al.,	   1998).	   	   Osteoclasts	   reside	   on	   the	   surface	   of	   bone	   and	   are	   responsible	   for	  
bone	   resorption.	   	   When	   bone	   resorption	   occurs,	   an	   acidic	   environment	   is	  
established.	  	  In	  this	  acidic	  environment	  bisphosphonates	  lose	  their	  ability	  to	  bind	  
strongly	   to	   bone.	   	   They	   dissociate	   from	   hydroxyapatite	   and	   are	   taken	   up	   by	  
osteoclasts	   (Coxon	   et	   al.,	   2008).	   	   Both	   the	   initial	   binding	   strength	   and	   the	  
intracellular	  effects	  depend	  on	  the	  molecular	  structure	  of	  the	  bisphosphonate.	  
1.4.5.1 Nitrogen	  and	  Non-­‐nitrogen	  Bisphosphonates	  
Contemporary	   bisphosphonates	   fall	   into	   one	   of	   two	   main	   structural	   groups,	  
depending	  on	  the	  presence	  or	  absence	  of	  nitrogen	  on	  the	  R2	  side	  chain.	  	  When	  the	  
non-­‐nitrogen	   containing	   bisphosphonates	   are	   taken	   up	   by	   osteoclasts,	   they	   are	  
metabolised	   into	   non-­‐hydrolysable	   adenosine	   triphosphate	   (ATP)	   analogues	  
(Frith	   et	   al.,	   2001,	  Rogers	   et	   al.,	   2011).	   	   Intracellular	   accumulation	  of	   these	  ATP	  
analogues	   eventually	   leads	   to	   loss	   of	   function	   and	   osteoclast	   apoptosis,	   thus	  
inhibiting	  bone	  resorption.	  	  These	  non-­‐nitrogen	  containing	  bisphosphonates	  have	  
been	  commonly	  prescribed	  for	  the	  treatment	  of	  osteoporotic	  patients	  and	  patients	  
with	  Paget’s	  disease.	  	  More	  recently,	  however,	  the	  nitrogen	  bisphosphonates	  have	  
replaced	  some	  of	  these	  applications.	  	  
1.4.5.1.1 Nitrogen	  Bisphosphonates	  
Nitrogen	   containing	   bisphosphonates	   (amino-­‐bisphosphonates)	   have	   a	   nitrogen	  
atom	  on	  the	  R2	  side	  chain	  and	  are	  many	  orders	  of	  magnitude	  more	  potent	  than	  the	  
non-­‐nitrogen	  containing	  bisphosphonates	  (Rogers	  et	  al.,	  2011,	  Rogers	  et	  al.,	  2000).	  	  
However,	   not	   all	   N-­‐BP’s	   are	   equally	   potent.	   	   A	   gradient	   exists	  within	   this	   group	  
that	   also	   reflects	   the	   binding	   affinity	   of	   the	   specific	   bisphosphonate.	   	   Binding	  
affinity	   to	   both	  hydroxyapatite	   and	   the	   intracellular	   target	   is	   determined	  by	   the	  
structure	   of	   the	   nitrogen	   containing	   R2	   side	   chain.	   	   As	   the	   binding	   affinity	  
increases	  so	  too	  does	  the	  anti-­‐resorptive	  potency	  (Russell	  et	  al.,	  2008).	  	  Dunford	  et	  
al.,	   2001	   established	   a	   positive	   correlation	   between	   the	   ability	   of	   nitrogen	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containing	   bisphosphonates	   to	   inhibit	   both	   the	   MVP	   and	   osteoclastic	   bone	  
resorption.	  	  Small	  alterations	  in	  the	  position	  of	  the	  N	  in	  the	  R2	  side	  chain	  altered	  
the	  molecular	  structure	  sufficiently	   to	  affect	   the	   interaction	  with	   the	  MVP	   target	  
substrate	   and	   significantly	   affect	   antiresorptive	   potency	   (Dunford	   et	   al.,	   2001).	  	  
This	  concept	  focussed	  less	  on	  the	  ability	  to	  bind	  with	  HA	  on	  the	  surface	  of	  bone,	  
and	   more	   on	   the	   binding	   interaction	   with	   the	   intracellular	   target.	   	   Despite	   the	  
significance	   of	   even	   minor	   structural	   variations	   in	   determining	   biological	  
properties,	   the	   nitrogen	   bisphosphonates	   can	   be	   further	   subdivided	   into	   alkyl-­‐
amino	   and	   heterocyclic	   groups	   based	   on	   the	   basic	   R2	   side	   chain	   conformation	  
(Figure	  1–6).	  	  	  
	  
Figure	  1-­‐6.	  	  Classification	  of	  the	  bisphosphonates	  based	  on	  R2	  side	  chain	  conformation:	  non	  
N-­‐BPs,	  alkyl-­‐amino	  BPs,	  heterocyclic	  N-­‐BPs	  (Reproduced	  with	  permission	  from	  Jonh	  Wiley	  
and	  Sons,	  Russell	  et	  al.,	  2007)	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The	  presence	  of	  a	  nitrogen-­‐containing	  heterocyclic	  moiety	  confers	  a	  stability	  and	  
structural	   advantage	   that	   gives	   this	   group	   the	   most	   potent	   anti-­‐resorptive	  
properties.	  	  ZA	  is	  a	  heterocyclic	  amino-­‐bisphosphonate	  and	  was	  shown	  to	  have	  the	  
highest	   in	   vitro	   binding	   affinity	   to	   hydroxyapatite	   of	   six	   therapeutic	  
bisphosphonates	   examined	   (zoledronate	   >	   alendronate	   >	   ibandronate	   >	  
risedronate	   >	   etidronate	   >	   clodronate)	   (Nancollas	   et	   al.,	   2006).	   	   Nitrogen	  
bisphosphonates	   are	   more	   frequently	   associated	   with	   BRONJ	   and	   are	   typically	  
administered	   as	   a	   high	   dose	   infusion	   in	   the	   palliative	   management	   of	   severely	  
medically	  compromised	  cancer	  patients.	  	  The	  mechanisms	  of	  actions	  that	  give	  rise	  
to	   both	   therapeutic	   and	   adverse	   effects	   are	   not	   precisely	   understood	   and	   are	  
therefore	  the	  focus	  of	  this	  research.	  	  	  
1.4.5.1.2 Anti-­‐angiogenic	  Effects	  
Calcium	  binding	   is	  undoubtedly	  essential	   to	  the	  bisphosphonates’	  clinical	  effects.	  	  
However,	   in	  addition	  to	  the	  cells	  that	  comprise	  the	  skeleton,	  there	  is	  evidence	  to	  
support	  an	  inhibitory	  effect	  on	  the	  vasculature	  and	  soft	  tissues.	   	  In	  2002,	  ZA	  was	  
shown	   experimentally	   to	   inhibit	   HUVEC	   function.	   	   Parallel	   experiments	   were	  
conducted	  with	  the	  chelating	  agent	  EDTA,	  demonstrating	  that	  the	  anti-­‐angiogenic	  
effects	  were	  largely	  independent	  of	  the	  in	  vitro	  calcium	  binding	  properties	  (Wood	  
et	  al.,	  2002).	  	  In	  light	  of	  these	  results	  it	  was	  proposed	  that	  an	  anti-­‐resorptive	  effect	  
would	   compromise	   the	   highly	   vascular	   environment	   essential	   for	   bone	  
remodelling	  and	  may	  therefore	  be	  responsible,	  at	   least	   in	  part,	   for	  the	   inhibitory	  
effects	  of	  bisphosphonates	  on	  bone	  resorption.	  	  Although	  the	  precise	  mechanisms	  
and	  overall	  significance	  have	  not	  yet	  been	  fully	  realised,	  this	  was	  the	  first	  of	  many	  
studies	   to	   demonstrate	   the	   anti-­‐angiogenic	   effects	   of	   the	   bisphosphonates	   as	  
(Ziebart	  et	  al.,	  2011,	  Hamma-­‐Kourbali	  et	  al.,	  2003,	  Hashimoto	  et	  al.,	  2007).	  	  	  	  
1.4.5.1.3 MVP	  Inhibition:	  Statins	  
With	  regard	  to	  the	   intracellular	  effects	  on	  osteoclasts,	  N-­‐BPs	  act	  via	   inhibition	  of	  
the	   MVP	   (Luckman	   et	   al.,	   1998).	   	   The	   major	   products	   of	   the	   MVP	   include	  
cholesterol,	  farnesylated	  proteins	  and	  geranylgeranylated	  proteins	  (Goldstein	  and	  
Brown,	  1990).	  	  Statins	  (HMG	  Co-­‐A	  reductase	  inhibitors)	  target	  the	  first	  step	  in	  this	  
pathway	  and	  are	  widely	  prescribed	   to	  prevent	   cholesterol	   synthesis	   in	   the	   liver.	  	  
In	   2010,	   Zhao	   et	   al.	   investigated	   lovastatin	   as	   a	   novel	   treatment	   for	   malignant	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mesothelioma	   (MM)	   via	   inhibition	   of	   the	   MVP	   and	   the	   down-­‐stream	   effects	   on	  
tumour	  angiogenesis.	  	  Specifically,	  MM	  cells	  and	  human	  umbilical	  vein	  endothelial	  
cells	  (HUVECs)	  were	  exposed	  to	   lovastatin	  and	  a	  VEGFR	  inhibitor,	  KRN633.	   	  The	  
results	   showed	   that	   lovastatin	   inhibited	   VEGFR2	   internalization	   and	   activation	  
due	  to	  disruption	  of	  the	  MVP	  (Zhao	  et	  al.,	  2010).	  
1.4.5.1.4 MVP	  Inhibition:	  Osteoclasts	  
Despite	  their	  upstream	  effects,	  statins	  do	  not	  mimic	  the	  effects	  of	  bisphosphonates	  
in	  vivo	  as	  they	  lack	  the	  ability	  to	  specifically	  target	  the	  skeleton,	  emphasising	  the	  
importance	  of	   organ	   specificity	   on	   therapeutic	   outcomes	   (Russell,	   2011).	   	  When	  
bone	  surface	  bound	  N-­‐BP’s	  are	  taken	  up	  by	  osteoclasts,	  they	  target	  and	  inhibit	  the	  
enzyme	  farnesyl	  pyrophosphate	  synthase	  (FPP-­‐synthase)	  in	  the	  MVP,	  as	  shown	  in	  
Figure	   1–7.	   	   The	   downstream	   effect	   is	   to	   block	   prenylation	   of	   small	   GTPases	  
(Luckman	  et	  al.,	  1998).	  
	  	   	  
Figure	   1-­‐7.	   	   The	   mevalonate	   pathway:	   statins	   act	   on	   HMG	   CoA	   reductase	   to	   inhibit	  
cholesterol	   synthesis	   in	   the	   liver;	   the	   N-­‐BPs	   inhibit	   FPP-­‐synthase	   and	   have	   downstream	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effects	   on	   protein	   prenylation;	   GGOH	   (geranylgeraniol)	   is	   a	   naturally	   occurring	   MVP	  
constituent	  and	  restores	  the	  MVP	  downstream.	  
Prenylation	  describes	   the	  addition	  of	   lipids	   (hydrophobic	  molecules)	   to	  proteins	  
and	   is	   important	   for	   their	   correct	   intracellular	   transportation	  and	  attachment	   to	  
the	   (bilipid)	   cell	   membrane	   (Russell	   et	   al.,	   2008).	   	   The	   therapeutic	   effect	   is	   a	  
reduction	   is	   osteoclast	   function	   and	   resorptive	   function.	   	   Evidence	   of	   this	  
inhibitory	  effect	   includes:	  1)	   the	  accumulation	  of	  unprenylated	  GTPases	   in	  N-­‐BP	  
treated	  osteoclasts	  and	  2)	   in	  vitro	  reversal	  of	   this	  effect	  due	   to	   the	  addition	  of	  a	  
downstream	  MVP	  enzyme,	  geranylgeraniol	  (GGOH)(Russell	  et	  al.,	  2008).	  	  	  
1.4.5.1.5 ZA	  and	  VEGFR2	  Protein	  Expression	  
In	  2010,	  Basi	  et	  al.	  treated	  HUVECs	  with	  ZA	  and	  examined	  the	  effects	  on	  VEGFR2	  
protein	   expression	   and	   cell	   migration.	   	   After	   a	   48-­‐hour	   incubation	   period	   with	  
12.5μM	   ZA,	   intracellular	   VEGFR2	   protein	   expression	   increased	   significantly	  
compared	  with	  untreated	  controls.	  	  A	  corresponding	  increase	  in	  expression	  on	  the	  
cell	  surface	  was	  not	  observed.	  	  Reduced	  migration	  toward	  VEGF	  was	  also	  observed	  
for	   ZA	   treated	   cells.	   	   The	   addition	   of	   the	   downstream	   MVP	   component	  
geranylgeranyl	   pyrophosphate	   (GGPP)	   attenuated	   the	   effects	   of	   ZA	   on	   both	  
VEGFR2	  protein	  expression	  and	  cell	  migration	  (Basi	  et	  al.,	  2010).	  	  Although	  Basi	  et	  
al.	  did	  not	  examine	  osteoclasts,	  their	  work	  with	  endothelial	  cells	  supports	  the	  MVP	  
as	   an	   important	   N-­‐BP	   target	   due	   to	   the	   intracellular	   accumulation	   of	   VEGFR2	  
protein	  and	  the	  mitigating	  effect	  of	  restoring	  the	  MVP	  with	  GGPP.	  	  
1.4.5.1.6 ZA	  and	  Human	  Gingival	  Fibroblasts	  
Zafar	  et	  al.	  demonstrated	  the	  in	  vitro	  effects	  of	  ZA	  alone	  and	  in	  combination	  with	  
the	  MVP	  component/metabolite	  GGOH	  on	  human	  gingival	  fibroblast	  viability	  and	  
VEGFA	  gene	  expression.	  	  Cellular	  viability	  decreased	  significantly	  in	  the	  presence	  
of	  30μM	  ZA	  at	  72	  hrs.	  	  VEGFA	  gene	  and	  protein	  expression	  was	  upregulated	  in	  ZA	  
treated	  cells	  compared	  with	  controls.	   	  This	  effect	  was	  significant	  at	  24	  hours	  and	  
sustained	  over	  prolonged	  exposure	  (96hrs).	  	  In	  the	  presence	  of	  ZA	  and	  GGOH	  (10	  
or	   50μM)	   cellular	   viability	   significantly	   improved	   and	   VEGFA	   gene	   expression	  
decreased	   to	   near	   control	   levels	  with	   a	   p-­‐value	   approaching	   significance	   (Zafar,	  
2014,	  Zafar	  et	  al.,	  2014).	   	  These	  results	  provided	  further	  support	   for	  the	  MVP	  as	  
the	  target	  in	  amino-­‐bisphosphonate	  mediated	  cellular	  inhibition.	  	  VEGFA	  gene	  up-­‐
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regulation	   suggests	   a	   negative	   feedback	   mechanism	   whereby	   increased	   gene	  
expression	   occurred	   to	   compensate	   for	   downstream	   disruptions	   in	   protein	  
expression	   and	   intracellular	   trafficking	   essential	   to	   VEGF	   receptor	   location	   and	  
function.	   	   Replenishing	   the	   MVP	   with	   GGOH	   may	   therefore	   have	   therapeutic	  
applications	  in	  restoring	  the	  VEGF	  signalling	  pathway	  essential	  to	  wound	  healing.	  	  
1.4.5.1.7 ZA	  and	  Functional	  Effects	  on	  Osteoblasts	  
Evidence	   exists	   to	   suggest	   an	   MVP	   mediated	   inhibitory	   effect	   of	   the	   nitrogen-­‐
bisphosphonates	  on	  osteoblasts	  in	  vitro.	   	  Ziebart	  et	  al.	  investigated	  the	  effects	  on	  
cell	   viability	   and	   migration	   capacity	   when	   HUVECs,	   fibroblasts	   and	   osteoblasts	  
were	  exposed	  to	  three	  N-­‐BPs,	  with	  and	  without	  GGOH.	  	  Bisphosphonates	  inhibited	  
viability	   and	   migration	   for	   each	   cell	   type.	   	   Simultaneous	   exposure	   to	   GGOH	  
attenuated	   these	   inhibitory	  effects	  and	  restored	  normal	   cellular	   function.	   	  These	  
results	   provided	   tentative	   support	   for	   GGOH	   as	   a	   therapeutic	   agent	   in	   BRONJ	  
management.	   	   However,	   the	   potential	   for	   GGOH	   to	   exert	   pro-­‐angiogenic	   side	  
effects	   on	   malignant	   tumours	   in	   BRONJ	   patients	   requires	   further	   investigation	  
(Ziebart	   et	   al.,	   2011).	   	   Furthermore,	   bisphosphonate	   concentrations	  up	   to	  50μM	  
were	   used	   in	   this	   study.	   	   The	   difficulty	   in	   extrapolating	   evidence	   from	   in	   vitro	  
studies	   is	   that	   the	   corresponding	  bisphosphonate	   concentration	   that	  osteoblasts	  
are	  exposed	  to	  in	  vivo	  is	  unknown	  (Orriss	  et	  al.,	  2009).	  	  Despite	  this	  limitation	  the	  
present	   research	  will	   focus	   on	   a	   proposed	  MVP-­‐centred	  mechanism	  of	   action	   in	  
osteoblasts	  that	  could	  lead	  to	  the	  adverse	  effect,	  BRONJ.	  	  
1.4.6 Bisphosphonate	  Summary	  	  
The	   basic	   P-­‐C-­‐P	   structure	   is	   fundamental	   to	   bisphosphonates’	   clinical	  
effectiveness.	  	  It	  confers	  metabolic	  stability	  and	  the	  ability	  to	  specifically	  target	  the	  
skeleton.	  	  Once	  bound	  to	  hydroxyapatite	  on	  the	  bone	  surface	  bisphosphonates	  are	  
taken	   up	   by	   osteoclasts	   during	   bone	   resorption	   and	   exert	   their	   anti-­‐resorptive	  
effects	   intra-­‐cellularly.	   Variations	   in	   the	   R1	   and	   R2	   side	   chains	   have	   been	  
developed	  over	  time	  to	  enhance	  clinical	  effects.	  	  Zoledronate	  (ZA)	  is	  an	  example	  of	  
a	  nitrogen	  bisphosphonate	  used	  to	  reduce	  skeletal	  complications	  in	  patients	  with	  
multiple	  myeloma	  and	  metastatic	  bone	  cancer.	  	  The	  R2	  side	  chain	  is	  a	  heterocyclic	  
imidazole	   and	   it	   is	   the	   most	   potent	   bisphosphonate	   available	   and	   targets	   the	  
enzyme	   FPP-­‐synthetase	   in	   the	   MVP.	   	   This	   prevents	   prenylation	   of	   signalling	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molecules,	  leading	  to	  an	  intra-­‐cellular	  accumulation	  of	  unprenylated	  GTPases	  and	  
a	   reduction	   in	   osteoclast	   function.	   	   The	   amino-­‐bisphosphonates	   are	   responsible	  
for	   both	   therapeutic	   and	   adverse	   effects;	   however,	   the	   specific	   effects	   of	   ZA	  
inhibition	  of	  the	  MVP	  on	  VEGFR1	  and	  VEGFR2	  protein	  expression	  by	  osteoblasts	  
are	  yet	  to	  be	  established.	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1.5 Summary	  	  
BRONJ	   is	   an	   adverse	   effect	   of	   bisphosphonate	   use	   that	   has	   been	   perplexing	   the	  
dental	   community	   since	   it	   first	   came	   to	   light	   over	   a	   decade	   ago.	   	   While	  
bisphosphonates	  continue	  to	  be	  prescribed	  for	  their	  clinical	  benefits,	  an	  effective	  
prevention	   and	   treatment	   strategy	   for	   this	   rare	   but	   serious	   side	   effect	   remains	  
elusive.	   	   As	  previously	  highlighted,	   the	   aetiology	   and	  pathogenesis	   are	   yet	   to	   be	  
elucidated,	  although	  BRONJ	  can	  be	  broadly	  described	  as	  a	  failure	  to	  heal.	  	  A	  closer	  
examination	  of	  the	  complex	  and	  coordinated	  processes	  involved	  in	  wound	  healing,	  
alongside	   the	   structure	   and	   activity	   of	   bisphosphonates	   hint	   at	   possible	  
pathogenic	  mechanisms.	  	  In	  particular,	  the	  role	  of	  VEGF	  in	  wound	  healing	  and	  the	  
MVP	  as	  a	   therapeutic	   target	   for	  potent,	  nitrogen-­‐containing	  bisphosphonates	  are	  
significant	  areas	  of	  research	  that	  provide	  direction	  for	  further	  investigation.	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1.6 Objectives	  and	  Hypotheses	  
The	  present	   research	  will	   focus	   on	   the	   expression	   of	   VEGF	   receptors	   on	   human	  
alveolar	   osteoblasts	   and	   the	   effects	   of	   the	   potent	   nitrogen-­‐containing	  
bisphosphonate,	   zoledronate.	   	   Evidence	   exists	   to	   confirm	   the	   presence	   of	   VEGF	  
receptor	  1	   (and	   receptor	  2)	  on	  human	  alveolar	  osteoblasts	  and	   for	  an	  autocrine	  
function	  of	  endogenously	  produced	  VEGF	  (Hah	  et	  al.,	  2011).	  	  The	  first	  objective	  of	  
this	   research	   is	   to	   confirm	   the	   role	   of	   autogenously	   produced	   VEGF	   and	   the	  
membrane	  bound	  R1	  receptor	  in	  osteoblast	  differentiation	  and	  maturation.	   	  This	  
will	  be	  achieved	  by	  culturing	  three	  different	  human	  alveolar	  osteoblasts	  cell	  lines	  
with	  and	  without	  specific	  R1	  and	  R2	   inhibitors	  and	  a	  dual	  R1/R2	   inhibitor.	   	  The	  
assay	   endpoint	   will	   be	   nodule	   formation	   and	   matrix	   mineralization.	   	   Nodule	  
formation	  will	  be	  evaluated	  using	  alizarin	   red	  and	  alkaline	  phosphatase	  staining	  
within	  8-­‐well	  chamber	  slides.	  	  Mineralization	  will	  be	  quantified	  using	  alizarin	  red	  
staining	   in	   a	   96-­‐well	   mineralization	   assay	   against	   a	   standard	   curve.	   	   The	  
hypothesis	   is	   that	   osteoblast	   differentiation	   and	  maturation	  will	   be	   observed	   in	  
cells	  cultured	  without	  any	  inhibitors,	  due	  to	  the	  action	  of	  endogenously	  produced	  
VEGF	   and	   its	   membrane	   bound	   receptors.	   	   In	   contrast,	   nodule	   formation	   and	  
matrix	  deposition	  will	  be	  supressed	  in	  osteoblasts	  that	  are	  cultured	  in	  either	  the	  
presence	  of	  the	  R1,	  R2	  or	  dual	  R1/R2	  inhibitors.	  
The	   second	   objective	   is	   to	   determine	   the	   expression	   of	   the	   VEGF	   receptors	   by	  
human	   alveolar	   osteoblasts	   in	   the	   presence	   of	   ZA	   and	   the	   effect	   of	   a	   novel	  
therapeutic	  agent,	  geranylgeraniol	  (GGOH),	  on	  this	  expression.	  	  The	  hypothesis	  is	  
that	   ZA	   will	   prevent	   the	   VEGF	   receptors	   from	   being	   transported	   to	   and	  
incorporated	  into	  the	  osteoblast	  cell	  membrane.	  	  This	  will	  result	  in	  an	  intracellular	  
VEGF	   receptor	   accumulation.	   	   GGOH	   is	   a	   metabolite	   of	   the	   MVP	   that	   occurs	  
downstream	  to	  the	  N-­‐BP	  target,	  FPP-­‐synthetase.	   	  The	  hypothesis	  is	  that	  when	  an	  
osteoblast	  is	  exposed	  to	  both	  ZA	  and	  GGOH,	  the	  GGOH	  will	  reverse	  the	  inhibitory	  
effects	   of	   ZA.	   	   This	  will	   result	   in	  VEGFRs	  being	   transported	   to	   and	   incorporated	  
into	   the	   cell	   membrane.	   	   These	   endpoints	   will	   be	   evaluated	   using	  
immunohistochemistry	   to	   visualize	   the	   extracellular	   or	   intracellular	   location	   of	  
the	  VEGFRs.	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Chapter	  2	  
2 Materials	  and	  methods	  
2.1 Ethical	  Approval	  and	  Māori	  Consultation	  
The	  Ngāi	  Tahu	  Research	  Consultation	  Committee	  (Appendix	  1)	  and	  the	  University	  
of	  Otago	  Human	  Ethics	  Committee	  (H13/083)	  approved	  this	  study	  (Appendix	  2).	  	  
2.2 Study	  Participants	  
All	  participants	  were	  recruited	  for	  participation	  in	  a	  previous	  study	  (Zafar,	  2014).	  	  
In	   accordance	   with	   ethical	   approval	   LRS/10/09/038	   (Appendix	   3),	   each	  
participant	  received	  written	  (Appendix	  4)	  and	  verbal	  information	  on	  the	  research	  
project	  and	  provided	  written	  informed	  consent	  (Appendix	  5)	  for	  the	  use	  of	  tissue	  
collected	  in	  on-­‐going	  related	  research.	  	  	  
Patients	  were	  healthy,	   adult	   pre-­‐menopausal	  women	  attending	   the	  Oral	   Surgery	  
department	  at	  the	  University	  of	  Otago,	  Faculty	  of	  Dentistry	  for	  surgical	  removal	  of	  
impacted	  mandibular	  third	  molar	  teeth.	  	  	  
Table	  2-­‐1.	  	  Participant	  inclusion	  and	  exclusion	  criteria	  (Zafar,	  2014)	  
Inclusion	  
Healthy	  pre-­‐menopausal	  women	  aged	  between	  18	  and	  45	  years	  
Enrolled	  for	  surgical	  removal	  of	  impacted	  mandibular	  third	  molars	  
Exclusion	  
Smokers	  or	  former	  smokers	  (within	  2	  years)	  
Patients	  currently	  taking,	  or	  with	  a	  history	  of	  taking:	  anti-­‐hypertensive	  
medication,	  statins	  or	  long-­‐term	  corticosteroids	  or	  antibiotics	  
Pregnancy	  	  
Diabetes	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2.3 Establishment	  of	  Primary	  Human	  Osteoblast	  Cell	  Cultures	  
The	  previous	  author	  used	   the	  methods	  described	  by	  Dillon	  (2012)	   to	  generate	  a	  
primary	  human	  osteoblast	  (HOB)	  culture	  from	  mandibular	  trabecular	  bone	  tissue,	  
collected	  during	  surgical	   removal	  of	  a	   third	  molar,	   from	  each	  of	   the	  participants	  
(Dillon	  et	  al.,	  2012,	  Zafar,	  2014).	  
Oral	   surgeons	   at	   the	   University	   of	   Otago,	   Faculty	   of	   Dentistry	   performed	   the	  
surgery.	  	  For	  each	  patient,	  bone	  tissue	  that	  is	  routinely	  removed	  to	  facilitate	  third	  
molar	   extraction	   was	   conserved	   and	   collected	   in	   a	   sterile	   50	   ml	   universal	  
container	   (Cat	   No.	   227	   261,	   Cellstar	   tubes,	   Greiner	   Bio-­‐one).	   	   The	   tissue	   was	  
immediately	   transported	   in	   sterile	   phosphate	   buffered	   saline	   (PBS)	   (Cat	   No.	  
SALB010,	   Gibco/Life	   Technologies)	   without	   calcium	   or	   magnesium	   ions	   for	  
processing	  in	  the	  cell	  culture	  laboratory.	  
The	  tissue	  samples	  were	  handled	  using	  sterile	  equipment	  and	  solutions	  in	  a	  Class	  
II	   laminar	   flow	   hood.	   	   The	   samples	   were	   washed	   in	   PBS	   and	   any	   attached	   soft	  
tissue	  was	   removed.	   	   Cleaned	   bone	  was	   divided	   into	   3-­‐5	  mm	   fragments	   in	   PBS.	  	  
Bone	   fragments	   were	   washed	   thoroughly	   in	   PBS,	   and	   then	   placed	   in	   a	   50	   ml	  
universal	  container	  in	  20	  ml	  of	  PBS.	  	  The	  container	  was	  vortexed	  and	  the	  PBS	  was	  
decanted	   and	   discarded	   and	   replaced	   with	   fresh	   PBS	   approximately	   5	   times	   to	  
remove	   haematopoietic	   marrow	   and	   isolate	   ivory-­‐white	   bone	   fragments	   for	  
explant	  cultures.	  	  	  
Osteoblast	   culture	   media	   was	   prepared	   using	   DMEM	   with	   glutaMAX,	   FBS,	  
antibiotic-­‐antimycotic	   reagent,	   gentamycin,	   dexamethasone	   and	   2-­‐phospho-­‐L-­‐
ascorbic	   acid	   in	   the	   proportions	   described	   in	   Appendix	   7.	   	   The	   explants	   were	  
seeded	   into	  6-­‐well	   tissue	   culture	  plates	   (Cat	  No.	  657160,	  Greiner	  Bio-­‐one);	   each	  
well	   containing	   7	   ml	   of	   pre-­‐warmed	   osteoblast	   culture	   media.	   The	   plates	   were	  
incubated	  for	  7	  days	  in	  a	  humidified	  cell	  culture	  incubator	  at	  37°C	  in	  5%	  CO2/95%	  
air	   (Sanyo	   CO2	   Incubator,	   Cat	   No.	   MCO-­‐19AIC).	   	   The	   media	   was	   then	   replaced	  
twice	  weekly	  and	   the	   cells	  were	  observed	  under	  an	   inverted	  microscope	   (Nikon	  
Eclipse	   Ti).	   	   The	   explants	   were	   left	   until	   the	   cells	   approached	   80%	   confluence,	  
which	  occurred	  2-­‐4	  weeks	  after	  plating.	  	  Cells	  were	  then	  subpassaged	  using	  0.25%	  
Trypsin-­‐EDTA	   (Cat	   No.	   25200-­‐072,	   Life	   Technologies/Gibco)	   and	   transferred	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without	  the	  explants	  into	  T-­‐25	  flasks	  (Cat	  No.	  690175,	  Grenier	  Bio-­‐one)	  containing	  
5	  ml	  of	  media.	  	  When	  these	  cells	  approached	  80%	  confluence	  they	  were	  passaged	  
at	  a	  1:3	  split	  into	  T-­‐75	  cell	  culture	  flasks	  (Cat	  No.	  658175,	  Grenier	  Bio-­‐one).	  	  Once	  
sufficient	   cell	   numbers	   were	   obtained,	   the	   cells	   were	   frozen	   in	   liquid	   nitrogen	  
according	  to	  the	  protocol	  in	  Appendix	  10.	  
The	   human	   alveolar	   osteoblast	   phenotype	   was	   confirmed	   functionally	   and	  
immunohistochemically	   in	   the	   previous	   study	   (Zafar,	   2014).	   	   Functional	  
osteoblasts	   produce	   mineralised	   nodules	   as	   they	   mature.	   	   The	   three	   HOB	   cell	  
cultures	  were	  seeded	  and	  cultured	  in	  8-­‐well	  glass	  Lab-­‐Tek	  II	  chamber	  slides	  (Cat	  
No.	   12-­‐565-­‐8,	   Thermo	   Fisher	   Scientific)	   in	   osteoblast	   mineralisation	   media	  
(Appendix	  11)	  for	  28	  days,	  with	  media	  changes	  every	  3	  days.	  	  Slides	  were	  fixed	  in	  
acetone	  and	  stained	  with	  alizarin	  red	  S	  and	  alkaline	  phosphatase	  stains.	   	  Nodule	  
formation	  was	  found	  with	  all	  three	  HOB	  cultures	  and	  the	  retraction	  of	  cells	  around	  
the	  nodules	  was	  typical	  of	  an	  osteoblast	  phenotype.	  	  Positive	  alkaline	  phosphatase	  
staining	   indicated	  the	  early	  stages	  of	  osteoblast	  differentiation.	   	  Positive	  staining	  
for	   alizarin	   red	   confirmed	   the	   presence	   of	   calcium,	   and	   therefore	   mineralised	  
nodules.	  	  Immunofluorescence	  was	  used	  to	  detect	  osteocalcin	  following	  21	  days	  of	  
culture	  in	  osteoblast	  mineralisation	  media.	  	  Given	  that	  mature	  osteoblasts	  are	  the	  
only	  cells	  to	  produce	  this	  extra-­‐cellular	  matrix	  protein,	  intense	  immunoreactivity	  
for	   osteocalcin	   compared	  with	   IgG	   controls	   confirmed	   the	   osteoblast	   phenotype	  
(Zafar,	  2014).	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2.4 Cell	  Recovery	  
All	   cell	   culture	   work	   was	   conducted	   using	   sterile	   equipment	   and	   reagents	   in	   a	  
Class	  II	  laminar	  flow	  hood.	  	  A	  UV	  radiation	  cycle	  was	  undertaken	  prior	  to	  each	  use	  
and	  any	  objects	  introduced	  to	  the	  hood,	  including	  gloved	  hands,	  were	  first	  sprayed	  
with	  70%	  ethanol.	  	  Prior	  to	  osteoblast	  retrieval,	  500	  ml	  of	  base	  osteoblast	  culture	  
media	  was	  prepared	  with	  modified	  Dulbecco’s	  Modified	  Eagle	  Medium	   (DMEM),	  
foetal	  bovine	  serum,	  100x	  antibiotic-­‐antimycotic,	  and	  gentamicin,	  according	  to	  the	  
formula	  (Appendix	  6):	  
Table	  2-­‐2.	  	  Formula	  for	  base	  osteoblast	  culture	  media	  
Reagent	   Cat	  No.,	  Company	   Amount	  in	  500	  ml	  
DMEM,	  high	  glucose,	  GlutaMAX	  











units/ml	  penicillin;	  10,000	  









Sterile	  working	   stock	   solutions	  were	  made	   up	   for	   the	   osteogenic	   differentiation	  
factors	   2-­‐phospho	   L-­‐ascorbic	   acid	   trisodium	   salt	   and	   dexamethasone.	   	   A	   1	  M	  2-­‐
phospho	  L-­‐ascorbic	  acid	  stock	  solution	  was	  first	  made	  up	  by	  adding	  5	  ml	  of	  sterile	  
molecule	  water	  to	  1.61	  g	  of	  2-­‐phospho	  L-­‐ascorbic	  acid	  and	  sterile	  filtering	  at	  0.22	  
µm.	  	  This	  was	  used	  to	  make	  the	  100	  mM	  working	  stock	  solution	  by	  adding	  10µl	  to	  
90	  µl	  of	   sterile	  water.	   	  A	  10	  mM	  dexamethasone	  stock	  solution	  was	  made	  up	  by	  
adding	  3.925	  mg/ml	  of	  sterile	  molecule	  water	  and	  sterile	  filtering	  to	  0.22	  µm.	  	  To	  
make	  the	  100	  µM	  working	  stock,	  5	  µl	  of	  the	  10	  mM	  stock	  was	  added	  to	  495	  µl	  of	  
sterile	  water.	  	  Working	  stock	  solutions	  were	  added	  to	  50	  ml	  of	  the	  base	  osteoblast	  
culture	  media	   described	   above	   according	   to	   the	   formula	   in	   Table	   2–3.	   	   Unused	  
solution	  was	  stored	  in	  1	  ml	  aliquots	  at	  -­‐20°C	  (Appendix	  7).	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Table	  2-­‐3.	  	  Osteogenic	  differentiation	  factors	  to	  be	  added	  to	  base	  osteoblast	  culture	  media	  	  








in	  50	  ml	  
2-­‐phospho	  L-­‐ascorbic	  acid	  
















100	  µM	  	  	  	  	  	  	  	  	  	  	  
(in	  sterile	  
MQWater)	  
10	  nM	   5	  µl	  
	  
To	  recover	  cells	  from	  cryopreservation	  in	  liquid	  nitrogen,	  a	  vial	  of	  HOB2	  cells	  was	  
retrieved	  and	  held	  at	  37°C	  until	  nearly	  melted.	  	  It	  was	  then	  placed	  in	  the	  laminar	  
flow	  hood.	   	  One	  millilitre	  of	  osteoblast	   culture	  media	  was	   immediately	  added	   to	  
the	  defrosted	  HOB2	  cells.	  	  The	  cells	  and	  media	  were	  transferred	  to	  a	  sterile	  50	  ml	  
falcon	   tube	   and	   2	   ml	   of	   media	   were	   added.	   	   The	   falcon	   tube	   was	   placed	   in	   a	  
swinging	   bucket	   centrifuge	   (Cat	   No.	   392934,	   Beckman	   Coulter)	   at	   150	   g	   for	   5	  
minutes	  at	  25°C.	   	  The	  media	  was	  poured	  off	   the	  resultant	  cell	  pellet	  and	  1	  ml	  of	  
fresh	  media	  was	  added	  and	  gently	  pipetted	  to	  resuspend	  the	  pellet.	  	  A	  sterile	  T-­‐25	  
flask	  (Cat	  No.	  690175,	  Grenier	  Bio-­‐one)	  containing	  4	  ml	  of	  pre-­‐warmed	  osteoblast	  
cell	   culture	  media	  was	   prepared	   and	   labelled.	   	   The	   resuspended	   cell	   pellet	  was	  
transferred	   to	   the	  prepared	  T-­‐25	   flask.	   	  The	  above	  steps	  were	  repeated	   for	  HOB	  
cultures	  HOB3	  and	  HOB5.	   	  The	  T-­‐25	   flasks	  were	  each	  viewed	  under	   the	   inverted	  
microscope	   (Nikon	   Eclipse	   Ti)	   and	   incubated	   at	   37°C,	   100%	   humidity	   and	   5%	  
CO2/	  95%	  air	  (Sanyo	  Co2	  Incubator,	  Cat	  No.	  MCO-­‐19AIC)	  (Appendix	  8).	  
Three	  times	  a	  week	  the	  osteoblast	  culture	  media	  was	  replaced	  with	  5	  ml	  of	  new	  
media.	  	  When	  the	  cells	  approached	  80-­‐90%	  confluence,	  they	  were	  trypsinised	  and	  
split	   into	   sterile	   T-­‐75	   flasks	   (Cat	  No.	   658175,	   Grenier	   Bio-­‐one)	   according	   to	   the	  
following	  protocol	   (Appendix	  9).	   	  Waste	  media	  was	   removed	  and	   the	   cells	  were	  
rinsed	   with	   sterile	   PBS.	   	   Trypsin-­‐EDTA	   0.25%	   (Cat	   No.	   25200-­‐072,	   Life	  
Technologies/Gibco)	   was	   added	   to	   the	   T-­‐25	   flask	   and	   left	   for	   approximately	   3	  
minutes.	  	  When	  the	  cells	  appeared	  rounded	  and	  detached	  from	  the	  flask,	  4.5	  ml	  of	  
media	  was	  added	  to	  the	  flask,	  mixed	  with	  the	  trypsinised	  cells	  and	  transferred	  to	  a	  
T-­‐75	   flask.	   	   The	   volume	   was	   made	   up	   to	   10	   ml	   with	   media.	   	   The	   media	   was	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changed	  approximately	  three	  times	  a	  week,	  depending	  on	  cell	  growth.	  	  When	  the	  
cells	  approached	  confluence,	  they	  were	  trypsinised	  and	  split	  between	  T-­‐75	  flasks	  
according	   to	  Appendix	   9.	   	   This	   process	  was	   repeated	  until	   there	  were	   sufficient	  
cells	   for	   all	   experimental	   work.	   	   The	   number	   of	   passages	   per	   HOB	   culture	   is	  
detailed	   in	  Table	   2–4.	   	   Any	  unused	   cells	  were	  mixed	  with	   a	   cryopreservant	   and	  
stored	  in	  liquid	  nitrogen	  	  (Appendix	  10).	  
Table	  2-­‐4.	  	  Media	  changes	  and	  passages	  over	  12	  days	  between	  HOB	  retrieval	  and	  lifting	  and	  
plating	   for	   the	   three	   different	   cell	   cultures	   (HOB2,	   HOB3	   and	   HOB5).	   	   Each	   passage	   was	  
carried	  out	  at	  80	  -­‐	  90%	  confluence	  and	  occurred	  at	  different	  times	  for	  each	  culture	  due	  to	  
biological	  variation	  in	  growth	  rate	  
Day	  of	  
Culture	  
HOB2	   HOB3	   HOB5	  
1	  	   Retrieved	  –	  T25	   Retrieved	  –	  T25	   Retrieved	  –	  T25	  
2	   	   	   	  
3	   Media	  change	   T25!T75	   T25!T75	  
4	   T25!T75	   	   	  
5	   	   Media	  change	   Media	  change	  
6	   	   	   T75!2xT75	  
7	   T75	  !2xT75	   T75!2xT75	   	  
8	   	   	   	  
9	   2xT75!4xT75	   Media	  Change	   2xT75!4xT75	  
10	   	   	   	  
11	   	   	   	  
12	   Lift	  and	  plate	   Lift	  and	  plate	   Lift	  and	  plate	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2.5 VEGFR1	  and	  VEGFR2	  Inhibition	  
The	  objective	  of	   this	  experiment	  was	   to	  assess	   the	  effect	  of	  specific	   inhibitors	   to	  
the	   VEGF	   receptors	   on	   osteoblast	   growth	   and	  mineralisation.	   	   Specific	   VEGFR1,	  
VEGFR2	   and	   a	   dual	   VEGFR1/R2	   inhibitor	   were	   selected	   and	   their	   effect	   on	  
mineralised	   nodule	   formation	   and	   matrix	   production	   was	   assessed	   in	   human	  
alveolar	   osteoblasts	   after	   21	   and	   28	   days	   of	   culture.	   	   The	   protocol	   for	   treating	  
HOBs	  with	  specific	  VEGF	  receptor	  inhibitors	  is	  outlined	  below	  and	  in	  Appendix	  13.	  	  	  
Specific	   osteoblast	   mineralisation	   media	   conducive	   to	   the	   production	   of	   a	  
mineralised	   matrix	   was	   prepared	   and	   used	   for	   the	   plating.	   	   This	   media	   was	  
identical	   to	   the	  previously	  used	  osteoblast	   growth	  media	   (Appendix	  7)	  with	   the	  
addition	  of	  β-­‐glycerophosphate,	  which	  promotes	  osteoblast	  matrix	  mineralisation	  
(Coelho	   and	   Fernandes,	   2000).	   	   The	   β-­‐glycerophosphate	   stock	   solution	   was	  
prepared	   by	   adding	   2.1604	   g	   of	   β-­‐glycerophosphate	   (MW	   216.04)	   in	   10	   ml	   of	  
distilled	   water	   and	   sterile	   filtering	   at	   0.22	   μm	   (Appendix	   11).	   	   The	   media	   was	  
prepared	  according	  to	  the	  proportions	  listed	  in	  Table	  2–5	  into	  50	  ml	  of	  base	  media	  
(Appendix	  6).	  
Table	  2-­‐5.	  	  Amount	  of	  osteogenic	  differentiation	  factors,	  including	  β-­‐glycerophosphate,	  to	  be	  









in	  50	  ml	  
2-­‐phospho	  L-­‐
ascorbic	  acid	  
trisodium	  salt	  	  












10	  mM	   100	  µM	   10	  nM	   5	  µl	  
β-­‐glycerophosphate	  








Cells	  from	  each	  HOB	  culture	  were	  lifted,	  counted	  and	  plated	  in	  two	  96-­‐well	  plates	  
(Cat	   No.	   NUNC-­‐167008,	   Thermo	   Fisher	   Scientific)	   and	   eleven	   8-­‐well	   Lab-­‐Tek	   II	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chamber	   slides	   (Cat	   No.	   12-­‐565-­‐8,	   Thermo	   Fisher	   Scientific)	   according	   to	   the	  
experimental	  design	  (Figures	  2–1	  to	  2–2).	  	  	  	  
To	  lift	  the	  cells,	  a	  T75	  flask	  of	  HOB2	  cells	  was	  trypsinised	  with	  1800	  μl	  of	  Trypsin-­‐
EDTA	  0.25%	  (Cat	  No.	  25200-­‐072,	  Gibco/Life	  Technologies)	  according	  to	  Appendix	  
12.	   	   A	   15	   μl	   sample	   of	   the	   trypsinised	   cells	   and	   15	   μl	   of	   Tryphan	   blue	   were	  
combined	   in	   a	   1	   ml	   eppendorf.	   	   A	   few	   drops	   of	   this	   mix	   were	   placed	   on	   the	  
haemocytometer,	   either	   side	   of	   the	   coverslip.	   	   The	   cells	  were	   counted	   under	   an	  
inverted	  microscope	  (Nikon	  Eclipse	  Ti)	  	  (Appendix	  12).	  	  This	  number	  was	  doubled	  
to	  account	  for	  the	  dilution	  factor	  and	  give	  the	  number	  of	  cells	  x	  104	  per	  ml.	   	  This	  
process	  was	  repeated	  for	  each	  HOB	  culture.	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2.5.1 Experimental	  Layout	  	  
HOB2	   HOB2	  
HOB2	   HOB2	  
	   	  
	   	  
Test	  
	  
HOB2	   HOB3	   	   HOB5	   HOB2	  
HOB2	   HOB3	   	   HOB5	   HOB3	  
HOB2	   HOB3	   	   HOB5	   HOB5	  
HOB2	   HOB3	   	   HOB5	   	  
ZM	  306416	  	  
Flt1	  
	   ZM	  306416	  	  
Flt1	  C	  
	  
HOB2	   HOB3	   	   HOB5	   HOB2	  
HOB2	   HOB3	   	   HOB5	   HOB3	  
HOB2	   HOB3	   	   HOB5	   HOB5	  
HOB2	   HOB3	   	   HOB5	   	  
ZM	  323881	  
KDR	  
	   ZM	  323881	  
KDR	  C	  
	  
HOB2	   HOB3	   	   HOB5	   HOB2	  
HOB2	   HOB3	   	   HOB5	   HOB3	  
HOB2	   HOB3	   	   HOB5	   HOB5	  
HOB2	   HOB3	   	   HOB5	   	  
KRN633	   	   KRN633	  C	  
	   	   	  
Figure	  2-­‐1.	  	  Experimental	  layout	  for	  plating	  8-­‐well	  chamber	  slides	  according	  to	  HOB	  culture	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Figure	   2-­‐2.	   	   Layout	   for	   the	   quantitative	   mineralisation	   assay	   96-­‐well	   plates	   according	   to	  
HOB	  culture	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Osteoblasts	  in	  the	  96-­‐well	  plates	  were	  used	  in	  a	  quantitative	  mineralisation	  assay	  
where	  alizarin	  red	  S	  was	  used	  to	  measure	  calcium	  deposition.	  	  The	  surface	  area	  of	  
each	  well	  in	  the	  96-­‐well	  plates	  was	  0.33	  cm2.	  	  One	  plate	  was	  assigned	  for	  the	  21-­‐
day	  time	  point	  and	  the	  other	  for	  the	  28-­‐day	  assay.	  	  There	  were	  14	  wells	  required	  
for	  each	  HOB	  culture	  per	  time	  point	  and	  the	  cells	  were	  to	  be	  plated	  in	  a	  suspension	  
of	   200	   μl	   of	   osteogenic	  media	   per	  well,	   at	   a	   seeding	   density	   of	   8000	   cells/cm2.	  	  
During	  plating	  the	  cells	  were	  regularly	  mixed	  to	  ensure	  even	  plating	  in	  accordance	  
with	  the	  experimental	  layout	  (Figure	  2–2).	  	  
Alizarin	   red	   S	   staining	   was	   used	   to	   visualise	   the	   ability	   of	   human	   alveolar	  
osteoblasts	   plated	   in	   8-­‐well	   chamber	   slides	   to	   form	   nodules	   after	   21	   days	   of	  
exposure	   to	   VEGFR	   inhibitors.	   	   Cells	  were	   seeded	   in	   8-­‐well	   chamber	   slides	   at	   a	  
seeding	  density	  of	  8000	  cells/cm2.	  	  The	  surface	  area	  of	  each	  well	  was	  0.7	  cm2	  and	  
cells	  were	   to	   be	   plated	  with	   a	   volume	   of	   400	   μl	   of	  media	   per	  well.	   	   Due	   to	   the	  
experimental	   design	   and	   taking	   spare	   slides	   into	   account,	   30	   wells	   were	   to	   be	  
plated	   for	  HOB2	   and	   22	  wells	  were	   to	   be	   plated	   for	   each	   of	   the	   remaining	  HOB	  
cultures,	  HOB3	   and	  HOB5.	   	   Each	  HOB	   culture	  was	   gently	   swirled	   to	   ensure	   even	  
mixing	  and	  plated	  at	  400	  μl	  per	  well	  according	  to	  the	  experimental	  layout	  (Figure	  
2–1).	  	  	  
The	  plates	   and	   chamber	   slides	  were	   incubated	   at	   37°C,	   100%	  humidity	   and	  5%	  
CO2/95%	  air	  (Sanyo	  CO2	  Incubator,	  Cat	  No.	  MCO-­‐19AIC).	  	  After	  24	  h	  the	  plates	  and	  
chamber	  slides	  were	  treated	  with	  a	  VEGFR1,	  a	  VEGFR2	  or	  a	  dual	  VEGFR1/VEGFR2	  
inhibitor.	   	   Multiple	   inhibitors	   were	   investigated	   for	   their	   suitability	   for	   specific	  
inhibition	  of	  these	  pathways.	  	  The	  inhibitors	  were	  then	  chosen	  based	  on	  specificity	  
for	  the	  receptor	  of	  interest	  and	  IC50	  values	  (Table	  2–6).	  	  The	  dual	  inhibitor,	  KRN	  
633	   (Cat	   No.	   S1557,	   Selleckchem),	   was	   an	   ideal	   candidate	   as	   it	   inhibited	   both	  
VEGFR1	   and	  VEGFR2	   at	   similar	   concentrations	  with	   IC50	   values	   of	   170	  nM	  and	  
160	   nM,	   as	   reported	   in	   the	   data	   sheet.	   	   VEGFR3	   has	   a	   primary	   role	   in	  
lymphangiogenesis	  in	  adulthood	  and	  preferentially	  binds	  the	  VEGF-­‐C	  and	  VEGF-­‐D	  
ligands	   (as	   opposed	   to	   VEGFA/165)	   on	   lymphatic	   endothelial	   cells	   (Hicklin	   and	  
Ellis,	   2005).	   	   The	   ability	  of	  KRN	  633	   to	   also	   inhibit	  VEGFR3	   (IC50	  125	  nM)	  was	  
therefore	  not	  deemed	  relevant	  for	  the	  present	  experiment.	  	  The	  VEGFR2	  inhibitor,	  
ZM	  323881	  HCL	  (Cat	  No.	  S2896,	  Selleckchem),	  was	  chosen	  due	  to	  its	  potency	  and	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selectivity.	   	  The	   IC50	  value	   for	   inhibition	  of	  VEGFR2	  was	  very	   low	  at	   less	   than	  2	  
nM.	  	  The	  VEGFR1	  inhibitor,	  ZM	  306416	  (Cat	  No.	  S2897,	  Selleckchem),	  had	  an	  IC50	  
of	  330	  nM	  and	  was	  the	  only	  inhibitor	  available	  that	  was	  selective	  for	  VEGFR1.	  	  
Table	  2-­‐6.	  	  Specifications	  for	  the	  VEGF	  receptor	  inhibitors	  including	  IC50	  values	  and	  known	  
interactions	  	  


















<2	  nM	   1900	  nM	  EGF	  







170	  nM	  R1	  
160	  nM	  R2	  




The	   articles	   described	   in	   Table	   2–7	   were	   used	   to	   determine	   the	   concentration	  
intervals	   for	   each	   inhibitor	   on	   the	   96-­‐well	   plates	   in	   order	   to	   obtain	   a	   dose	  
response	  curve.	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Table	  2-­‐7.	  	  Data	  used	  to	  determine	  the	  dose	  response	  curve	  for	  each	  VEGF	  inhibitor	  
Inhibitor	   Author	  	   Title	  	   Dose	  
response	  
curve	  (µM)	  
VEGFR1	   	  
(ZM	  306416)	  
IC50	  330	  nM	  
Antczak	  et	  
al.,	  2012	  
A	  high-­‐content	  biosensor-­‐based	  
screen	  identifies	  cell-­‐permeable	  
activators	  and	  inhibitors	  of	  EGFR	  










IC50	  <2	  nM	  
Xiao	  et	  al.,	  
2007	  
Upregulation	  of	  Flk-­‐1	  by	  bFGF	  via	  
the	  ERD	  pathway	  is	  essential	  for	  
VEGF-­‐mediated	  promotion	  of	  








170	  nM	  R1	  
160	  nM	  R2	  
Hah	  et	  al.,	  
2011	  
Vascular	  endothelial	  growth	  factor	  
stimulates	  osteoblastic	  
differentiation	  of	  cultured	  human	  
periosteal-­‐derived	  cells	  expressing	  







The	   stock	   concentration	   of	   each	   inhibitor	  was	   10	  mM	   in	   DMSO.	   	   The	   inhibitors	  
were	  prepared	  by	  sterile	  filtering	  a	  10	  μM	  working	  stock	  with	  a	  0.22	  μm	  filter.	  	  For	  
the	   specific	   inhibitors,	   ZM306416	   and	   ZM323881,	   10	   μl	   of	   stock	   solution	   was	  
added	  to	  9990	  μl	  of	  osteogenic	  media	  in	  a	  1:1000	  dilution.	  	  For	  the	  dual	  inhibitor,	  
KRN633,	  12	  μl	  of	  10	  mM	  was	  added	  to	  11,988	  μl	  of	  osteogenic	  media	  in	  a	  1:1000	  
dilution.	   	   The	   10	   μM	   working	   stocks	   were	   sterile	   filtered	   and	   used	   in	   serial	  
dilutions	  (Tables	  2–8	  to	  2–10)	  to	  obtain	  the	  range	  of	  concentrations	  listed	  in	  the	  
dose	  response	  table.	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2.5.2 Experimental	  Design	  for	  the	  96-­‐well	  Micro	  Plates	  
Both	  96-­‐well	  plates	  were	  treated	  according	  to	  the	  treatment	  design	  (Figure	  2–3).	  	  
The	   existing	  media	   was	   replaced	   with	   100	   μl	   of	   the	   appropriate	   treatment	   per	  
well.	  	  Sterile	  filtered	  osteogenic	  media	  with	  0.1%	  DMSO	  was	  used	  as	  the	  control.	  
	  
VEGFR1	  inhibitor	  (μM)	  
ZM	  306416	  





HOB2	   HOB3	   HOB5	   HOB2	   HOB3	   HOB5	   HOB2	   HOB3	   HOB5	  
0.01	  	  	   0.01	  	   0.01	  	   0.001	  	   0.001	   0.001	   0.01	   0.01	   0.01	  
0.1	  	   0.1	  	   0.1	  	   0.01	  	   0.01	  	   0.01	  	   0.1	  	   0.1	  	   0.1	  
1	  	   1	  	   1	  	   0.1	  	   0.1	  	   0.1	  	   0.5	  	   0.5	  	   0.5	  















Figure	   2-­‐3.	   	   Treatment	   layout	   for	   the	   96-­‐well	   plates	   (x2)	   with	   three	   biological	   replicates	  
(HOB	  cultures	  2,	  3	  and	  5)	   for	  each	   inhibitor	  treatment	  and	  four	  different	  doses	  specific	   to	  
each	  inhibitor	  in	  a	  dose	  response	  curve	  	  
	  
2.5.3 Experimental	  Design	  for	  the	  8-­‐well	  Chamber	  Slides	  
For	  the	  8-­‐well	  chamber	  slides,	  each	  HOB	  culture	  (n=3)	  was	  investigated	  with	  the	  
inhibitor	  concentrations	  given	  in	  Table	  2–7.	  	  The	  media	  was	  pipetted	  off	  each	  well	  
and	   the	   cells	   were	   treated	   with	   200	   μl	   aliquots	   according	   to	   the	   experimental	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Figure	  2-­‐4.	  	  Treatment	  layout	  for	  8-­‐well	  chamber	  slides	  with	  an	  untreated	  test	  slide	  and	  two	  
slides	  treated	  for	  each	  inhibitor:	  one	  slide	  with	  HOB2	  and	  HOB3,	  and	  the	  second	  with	  HOB5	  
and	  untreated	  controls	  for	  each	  culture	  	  
The	  plates	  and	  slides	  were	   incubated	  at	  37°C,	  100%	  humidity	  and	  5%	  CO2/95%	  
air	   and	   the	   inhibitor	   treatment	   procedure	   detailed	   above	   for	   the	   96-­‐well	   plates	  
and	  8-­‐well	  chamber	  slides	  was	  repeated	  twice	  a	  week	  for	  21	  days.	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After	  21	  days,	  a	  mineralisation	  assay	  was	  performed	  on	  one	  of	  the	  96-­‐well	  plates.	  	  
The	  8-­‐well	  chamber	  slides	  shown	   in	  Figure	  2–4	  were	  stained	  to	  evaluate	  nodule	  
formation.	   	   The	   second	   96-­‐well	   plate	   continued	   to	   be	   treated	   for	   another	   seven	  
days.	  	  The	  media	  was	  changed	  twice	  in	  this	  time.	  	  
2.5.4 Mineralisation	  Assay	  for	  the	  Quantification	  of	  Alizarin	  Red	  S	  Binding	  	  
The	   protocol	   described	   by	   Stanford	   (1995)	   was	   used	   for	   the	   96-­‐well	  
mineralisation	   assay	   and	   is	   detailed	   in	   Appendix	   15	   (Stanford	   et	   al.,	   1995).	  	  
Functional	   osteoblasts	   cultured	   in	   osteogenic	   media	   containing	   β-­‐
glycerophosphate	  produce	  calcium-­‐rich	  nodules	  over	  time	  (Coelho	  and	  Fernandes,	  
2000).	   	  Alizarin	  red	  S	  (ARS)	  staining	  of	  mineralised	  osteoblasts	  will	  bind	  calcium	  
in	  the	  ratio	  of	  2	  mol	  of	  Ca++	  to	  each	  mol	  of	  ARS	  dye.	  	  The	  dye	  can	  be	  recovered	  and	  
quantified	  by	  spectrophotometry	  and	  interpolated	  with	  an	  ARS	  standard	  curve	  to	  
determine	  any	   functional	  changes	   to	  mineralisation	  after	  exposure	   to	  VEGFR1/2	  
inhibitors.	  
The	  first	  step	  in	  the	  mineralisation	  assay	  was	  to	  use	  a	  40	  mM	  solution	  of	  Alizarin	  
red	  S	  to	  stain	  any	  osteoblasts	  producing	  mineralised	  matrix	  in	  culture.	   	  The	  cells	  
were	  washed	  in	  PBS	  for	  30	  seconds	  and	  fixed	  in	  70%	  ice-­‐cold	  ethanol.	  	  Meanwhile,	  
the	  40	  mM	  alizarin	  red	  solution	  was	  corrected	  to	  pH	  4.2	  by	  the	  drop-­‐wise	  addition	  
of	  Ammonium	  Hydroxide	   solution.	  After	   1	   h	   of	   fixation,	   the	   cells	  were	   rinsed	   in	  
MQH2O	  and	  stained	  with	  the	  prepared	  Alizarin	  red	  S	  solution	  at	  room	  temperature	  
with	  constant	  agitation	  on	  an	  orbital	  shaker	  (LabTek).	  The	  slides	  were	  then	  rinsed	  
five	  times	  with	  MQH2O	  and	  once	  with	  PBS	  in	  order	  to	  limit	  unspecific	  binding.	  	  	  
Following	   calcium	   mineral	   deposit	   staining,	   the	   ARS	   was	   recovered	   for	  
quantification	  by	  spectrophotometry	  against	  a	  standard	  curve.	  	  In	  order	  to	  extract	  
bound	  ARS,	  the	  wells	  were	  incubated	  with	  10%	  cetylpyridinium	  chloride	   in	  a	  10	  
mM	  sodium	  phosphate	  buffer	   solution.	   	  The	  buffer	   solution	  was	  prepared	  at	  pH	  
7.0	  by	  first	  making	  up	  and	  combining	  a	  100	  mM	  NaH2PO4	  solution	  and	  a	  100	  mM	  
Na2HPO4	  solution,	  as	  shown	  below:	  
1.42	  g	  of	  Na2HPO4	  +	  100	  mL	  of	  dH20	  =	  100	  mL	  of	  100	  mM	  Na2HPO4	  solution	  
1.56	  g	  of	  NaH2PO4	  +	  100	  mL	  of	  dH2O	  =	  100	  mL	  of	  100	  mM	  NaH2PO4	  solution	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To	  make	  100	  ml	  of	  100	  mM	  sodium	  phosphate	  buffer	  solution,	  57.7	  ml	  of	  100	  mM	  
Na2HPO4	  was	  added	  to	  42.3	  ml	  of	  100	  mM	  NaH2PO4.	   	  This	  100	  mM	  solution	  was	  
added	   to	  dH2O	   in	  a	  1	   in	  10	  dilution	   to	  give	  100	  ml	  of	  10	  mM	  sodium	  phosphate	  
buffer	  solution.	  	  This	  10	  mM	  solution	  was	  added	  to	  10	  g	  of	  CPC	  to	  make	  up	  100	  ml	  
of	  10%	  CPC	  in	  10	  mM	  sodium	  phosphate	  buffer	  solution.	  	  Each	  well	  was	  incubated	  
with	  1	  ml	  of	  the	  above	  solution	  for	  20	  minutes	  at	  room	  temperature,	  with	  gentle	  
rotation	  on	  an	  orbital	  shaker	  (LabTek).	  
Two	   hundred	  microlitres	   of	   Alizarin	   red	   S	   extract	  was	   collected	   from	   each	  well	  
and	  transferred	  to	  the	  corresponding	  well	  on	  a	  new	  96-­‐well	  plate.	  	  The	  plate	  was	  
read	  by	  absorbance	  at	  562	  nm	  (Bio-­‐strategy	  Synergy	  2	  Plate	  Reader,	  BioTek	  and	  
Gen	  5	  software	  run	  on	  Windows	  XP).	  
A	  standard	  curve	   for	  high	  and	   low-­‐range	  data	  sets	  was	  generated.	   	  A	  2	  mM	  ARS	  
working	  stock	  was	  prepared	  by	  adding	  50	  µL	  of	  40	  mM	  ARS	  solution	  to	  950	  µL	  of	  
10%	  CPC	  in	  10mM	  sodium	  phosphate	  buffer	  solution.	  	  For	  the	  high-­‐range	  set,	  five	  
2-­‐fold	  serial	  dilutions	  of	  the	  2	  mM	  working	  stock	  were	  made	  up	  in	  1.5	  mL	  micro-­‐
centrifuge	   tubes.	   	   The	   concentrations	   ranged	   from	   2	  mM	   to	   62.5	   μM.	   The	   low-­‐
range	   set	   was	   prepared	   by	   first	   diluting	   the	   2	   mM	   working	   stock	   to	   a	   30	   μM	  
working	  stock	  (15	  µL	  of	  2	  mM	  stock	  Alizarin	  red	  +	  985	  µL	  of	  10%	  CPC	  in	  10	  mM	  
sodium	  phosphate	  buffer).	  	  Four	  2-­‐fold	  serial	  dilutions	  of	  the	  30	  μM	  working	  stock	  
in	  1.5	  mL	  centrifuge	  tubes	  made	  up	  the	  low-­‐range	  set,	  from	  30	  μM	  to	  1.9	  μM.	  	  Each	  
dilution	   was	   thoroughly	   mixed	   and	   vortexed	   (Cat	   No.	   VX100,	   Labnet)	   prior	   to	  
being	  transferred	  to	  a	  96-­‐well	  plate	  in	  200	  μL	  aliquots	  to	  be	  read	  at	  562	  nm	  (Bio-­‐
Strategy	  Synergy	  2	  Plate	  Reader,	  BioTek	  and	  Gen	  5	  software	  running	  on	  Windows	  
XP).	   	   Including	   the	  2	  mM	  and	  30	  μM	  working	  stock	  solutions,	   there	  were	  eleven	  
values	  comprising	  the	  standard	  curve	  data	  set.	  	  The	  blank	  was	  200	  μL	  of	  10%	  CPC	  
in	  10	  mM	  sodium	  phosphate	  buffer.	  	  	  
2.5.4.1 Statistical	  Analysis	  
The	  raw	  data	  for	  each	  HOB	  culture	  and	  inhibitor	  concentration	  was	  transformed.	  	  	  
The	  blank	  ARS	  reading	  was	  accounted	  for	  by	  subtracting	  this	  value	  from	  each	  562	  
nm	   reading	   and	   the	   transformed	   data	   was	   expressed	   as	   a	   percentage	   of	   the	  
control.	   	   GraphPad	   Prism	   software	   was	   used	   to	   analyse	   the	   21	   and	   28-­‐day	  
	   54	  
mineralisation	   assay	   data.	   	   For	   each	   VEGFR	   inhibitor,	   linear	   regression	   analysis	  
was	   performed	   for	   each	   of	   the	   HOB	   cultures.	   	   The	  mean	   slope	   across	   the	   HOB	  
cultures	   for	   each	   inhibitor	   was	   then	   used	   in	   a	   one-­‐sample	   t	   test	   against	   a	  
hypothetical	   slope	   value	   of	   zero	   to	   test	   for	   a	   dose-­‐response	   relationship.	   	   Two-­‐
tailed	  paired	  t	  tests	  were	  performed	  for	  each	  of	  the	  inhibitor	  dose-­‐response	  data	  
sets,	  expressed	  as	  a	  percentage	  of	  control	  (VEGFR1,	  VEGFR2,	  VEGFR1/R2).	  	  	  
2.5.5 Nodule	  Staining	  
The	  mineralised	  nodules	  in	  the	  8-­‐well	  chamber	  slides	  were	  stained	  with	  Alizarin	  
red	  S	  and	  for	  alkaline	  phosphatase	  using	  the	  protocol	  described	  by	  Dillon	  (2012)	  
and	  detailed	  in	  Appendix	  16	  (Dillon	  et	  al.,	  2012).	  	  
The	  stains	  and	  fixatives	  were	  first	  prepared.	  	  Two	  ethanol	  solutions	  were	  made	  up	  
with	  sterile	  water	  in	  95%	  and	  50%	  concentrations.	  	  The	  40	  mM	  ARS	  solution	  (pH	  
4.2)	  was	  made	  up	  according	  to	  Appendix	  15	   for	   the	  96-­‐well	  plate	  mineralisation	  
assay.	   	   The	   alkaline-­‐dye	   mixture	   was	   prepared	   in	   a	   falcon	   tube	   by	   combining	  
156.25	   μl	   of	   Sodium	   Nitrite	   Solution	   with	   an	   equal	   volume	   of	   FRV-­‐Alkaline	  
Solution.	  	  The	  solutions	  were	  mixed	  and	  left	  to	  stand.	  	  After	  2	  minutes,	  7.03	  ml	  of	  
deionized	  H2O	   and	   156.25	   μl	   Naphthol	   AS-­‐BL	  were	   added	   and	   the	   solution	  was	  
thoroughly	  mixed.	   	  To	  make	   the	   citrate-­‐acetone-­‐formaldehyde	   fixative,	  2.5	  ml	  of	  
citrate	  solution	  and	  0.8	  ml	  of	  37%	  formaldehyde	  were	  added	  to	  6.5	  ml	  of	  acetone	  
in	  a	  falcon	  tube.	  
The	   protocol	   was	   trialled	   on	   a	   test	   slide.	   	   Positive	   staining	   was	   confirmed	   by	  
microscopic	  observation	  and	   the	  protocol	  was	   continued	  with	   the	   remaining	   six	  
slides.	  	  	  
The	  media	  was	   replaced	  with	  PBS	   and	   the	   slides	  were	  washed	   for	   five	  minutes.	  	  
The	  PBS	  wash	  was	  discarded	  and	  the	  chamber	  well	  sides	  were	  then	  removed	  from	  
the	  8-­‐well	   chamber	   slides.	   	  The	   cells	  were	   fixed	   in	   the	  95%	  ethanol	   solution	   for	  
one	  hour	  on	  ice.	  	  The	  slides	  were	  washed	  once	  with	  PBS	  and	  a	  hydrophobic	  barrier	  
pen	  (Cat	  No.	  S2002,	  Dako	  Cytomation,	  Denmark)	  was	  used	  to	  create	  a	  wax	  barrier	  
around	  each	  well.	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Each	  well	  received	  70	  μl	  of	  40	  mM	  alizarin	  red	  solution.	  	  The	  slides	  were	  left	  in	  a	  
lightproof	  box	  for	  20	  minutes	  at	  room	  temperature.	   	  They	  were	  then	  rinsed	  with	  
the	  50%	  ethanol	  solution	  for	  one	  minute	  with	  gentle	  rotation	  on	  an	  orbital	  shaker	  
and	  washed	  in	  distilled	  water.	  
In	   preparation	   for	   alkaline	   phosphatase	   staining,	   the	   slides	   were	   immersed	   in	  
room	  temperature	  citrate-­‐acetone-­‐formaldehyde	   fixative	  solution	   for	  30	  seconds	  
and	  rinsed	  with	  deionized	  H2O	  for	  45	  seconds.	  	  The	  slides	  were	  incubated	  at	  room	  
temperature	  in	  a	  lightproof	  box	  with	  100	  μl	  of	  alkaline-­‐dye	  mixture	  per	  well.	  	  After	  
15	  minutes	   the	   slides	   were	   rinsed	   with	   deionized	   H2O	   for	   two	  minutes.	   	   Clean	  
coverslips	  (22x50)	  were	  placed	  using	  an	  80%	  glycerol/20%	  PBS	  aqueous	  mount.	  
2.5.5.1 Analysis	  
The	   slide	   labels	  were	   concealed	   to	  minimize	  examiner	  bias	  prior	   to	  microscopic	  
evaluation	   using	   a	   Leica	   CTR5000b	   microscope	   (Leica	   Microsystems,	   Wetzlar).	  	  	  
Nodules	  were	  defined	  as	  a	  distinct	  area	  of	  brown	  staining	  containing	  dark	  spots	  of	  
alizarin	   red	   with	   an	   adjacent	   area	   of	   retraction.	   	   Two	   different	   blinded	  
investigators	   who	   were	   not	   involved	   with	   staining	   the	   slides	   independently	  
counted	   the	   number	   of	   nodules	   present	   in	   each	   well	   according	   to	   the	   defined	  
criteria.	  	  For	  each	  inhibitor,	  the	  mean	  observer	  values	  for	  each	  HOB	  culture	  were	  
obtained	   and	   charted	   for	   each	   concentration.	   	   Two-­‐tailed	   paired	   t	   tests	   were	  
performed	  for	  each	  inhibitor	  to	  detect	  any	  significant	  differences	  (95%	  CI)	  in	  the	  
mean	  number	  of	  nodules	  formed	  by	  the	  untreated	  controls	  and	  the	  mean	  number	  
of	  nodules	  formed	  by	  treated	  HOBs	  at	  each	  inhibitor	  dose.	  
The	   investigator	   who	   undertook	   the	   staining	   also	   examined	   the	   slides	  
microscopically.	   	  A	   single	   representative	  area	   from	  each	  well	  was	  photographed	  
using	   a	   Spot	  RT3	  Camera	   and	  Spot	  RT	   image	   software	   at	   10x	  objective.	   	  A	   slide	  
scale	  bar	  was	  photographed	  at	  the	  same	  time.	  	  Adobe	  Photoshop	  CS6	  software	  was	  
used	  to	  overlay	  the	  images.	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2.6 VEGFR1	  Protein	  Expression	  in	  Response	  to	  ZA,	  VEGF	  and	  GGOH	  
The	   objective	   of	   this	   experiment	   was	   to	   identify	   the	   expression	   of	   VEGFR1	   by	  
human	  alveolar	  osteoblasts	  following	  treatment	  with	  various	  combinations	  of	  the	  
amino-­‐bisphosphonate	   ZA,	   the	  MVP	  downstream	  metabolite	   GGOH	   and	   the	   pro-­‐
angiogenic	  growth	  factor	  VEGF,	  which	  is	  the	  ligand	  for	  VEGFR1.	  	  
2.6.1 Plating	  
Cells	  from	  each	  HOB	  culture	  were	  counted	  and	  plated	  onto	  8-­‐well	  chamber	  slides	  
(Cat	   No.	   12-­‐565-­‐8,	   Thermo	   Fisher	   Scientific)	   at	   a	   seeding	   density	   of	   8000	  
cells/cm2.	  	  As	  for	  the	  previous	  section,	  specific	  cell	  culture	  media	  conducive	  to	  the	  
production	  of	  a	  mineralised	  matrix	  was	  prepared	  and	  used	  for	  plating.	  	  Previously	  
prepared	  sterile	   stock	  and	  working	  stock	  solutions	  of	  2-­‐phospho	  L-­‐ascorbic	  acid	  
trisodium	  salt,	  dexamethasone	  and	  β-­‐glycerophosphate	  were	  added	  to	  base	  media	  
in	  the	  proportions	  detailed	  in	  Appendix	  11.	  
The	  cells	  were	  lifted	  with	  Trypsin-­‐EDTA	  0.25%	  and	  counted	  using	  Tryphan	  blue	  as	  
previously	   described	   and	   detailed	   in	   Appendix	   12.	   	   There	   were	   3.3x105	   HOB2	  
cells/ml.	  
The	   experimental	   design	   had	   four	   8-­‐well	   slides	   per	  HOB	   culture	   (Appendix	   19).	  	  
Each	  well	  had	  a	  surface	  area	  of	  0.7	  cm2	  and	  a	  volume	  of	  300	  μl.	  	  This	  gave	  a	  total	  
surface	  area	  of	  23.1	  cm2	  and	  a	  total	  volume	  of	  9900	  μl	  after	  accounting	  for	  a	  spare	  
well.	  	  Therefore,	  the	  total	  number	  of	  cells	  required	  to	  plate	  at	  a	  seeding	  density	  of	  
8000	  cell/cm2	  was	  184,800	  (1.9	  x105	  cells)	  in	  9900	  μl.	  	  
As	  the	  total	  number	  of	  cells	  required	  (190,000)	  was	  56%	  of	  the	  number	  of	  HOB2	  
cells/ml	  (330,000),	  560	  μl	  of	  trypsinised	  cells	  were	  added	  to	  9340	  μl	  of	  media	  in	  a	  
50	   ml	   falcon	   tube	   and	   300	   μl	   of	   cells	   added	   to	   each	   well.	   	   This	   process	   was	  
repeated	   for	   each	   HOB	   culture	   and	   the	   cells	   were	   incubated	   at	   37°C,	   100%	  
humidity	  and	  5%	  CO2/95%	  air.	  
The	   media	   was	   changed	   every	   second	   day	   until	   cells	   approached	   80-­‐90%	  
confluence	  and	  were	  ready	  for	  treatment.	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2.6.2 Treatment	  Preparation	  
The	   8	   different	   treatment	   combinations	   were	   devised	   in	   order	   to	   test	   the	  
hypotheses:	  1)	  that	  VEGF	  has	  an	  autocrine	  function	  via	  VEGFR1	  on	  human	  alveolar	  
osteoblasts;	  2)	  that	  ZA	  will	  inhibit	  normal	  VEGFR1	  expression;	  and	  3)	  that	  GGOH	  
will	   mitigate	   any	   effect	   of	   ZA	   by	   restoring	   the	   MVP.	   	   The	   cells	   were	   therefore	  
cultured	   with	   and	   without	   exogenous	   VEGF,	   with	   and	   without	   ZA,	   with	   and	  
without	  GGOH	  and	  with	  different	  combinations	  of	  VEGF,	  ZA	  and	  GGOH	  as	  follows:	  
1=	  Media	  +	  PBS	  carrier	   	   5=	  Media	  +	  ZA	  
2=	  Media	  +	  VEGF	   	   	   6=	  Media	  +	  ZA	  +	  GGOH	  
3=	  Media	  +	  VEGF	  +	  ZA	  	   	   7=	  Media	  +	  GGOH	  
4=	  Media	  +	  VEGF	  +	  ZA	  +	  GGOH	   8=	  Media	  +	  GGOH	  +	  VEGF	  
Prior	   to	   treatment,	   working	   stocks	   were	   prepared	   for	   VEGF	   (Cat	   No.	   PHC9394,	  
Gibco/Life	   Technologies)	   and	   GGOH	   (Cat	   No.,	   G3278,	   Sigma-­‐Aldrich)	   in	   the	   cell	  
culture	   room,	   using	   the	   laminar	   flow	   hood,	   according	   to	   Table	   2–11	   (Appendix	  
17).	   	   It	  was	  not	  necessary	   to	  make	  up	  a	  working	   stock	   for	   the	  ZA	   (Novartis).	   	  A	  
PBS/0.1%BSA	  solution	  was	   first	  prepared.	   	   In	  a	   falcon	   tube	  31	  ml	  of	   sterile	  PBS	  
was	  added	  to	  31	  mg	  of	  BSA	  (Cat	  No.	  A7906-­‐100G,	  Sigma-­‐Aldrich)	  and	  filtered	  with	  
a	  0.22	  μm	   filter.	   	  The	  sterile	   solution	  was	   frozen	   in	  1	  ml	  aliquots	  until	   required.	  	  	  
To	  make	  the	  50	  μg/ml	  VEGF	  working	  stock,	  200	  μl	  of	  the	  PBS/0.1%BSA	  solution	  
was	   added	   to	   10	   μg	   of	   lyophilized	   VEGF	   recombinant	   human	   protein	   (Cat	   No.	  
PHC9394,	   Gibco/Life	   Technologies)	   and	   placed	   on	   ice	   for	   10	   minutes.	   	   The	  
solution	  was	  gently	  mixed	  and	  frozen	  in	  15	  μl	  aliquots.	  	  To	  make	  the	  50	  mM	  GGOH	  
working	  stock,	  1.0	  μl	  of	  GGOH	  was	  added	  to	  60.2	  μl	  of	  100%	  ethanol	  absolute	  for	  
analysis	  (Cat	  No.	  1.00983.2500,	  Merck)	  in	  a	  1.5	  ml	  eppendorf	  and	  stored	  at	  -­‐20°C.	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Table	  2-­‐11.	  	  VEGF,	  GGOH	  and	  ZA	  treatment	  concentrations	  
Treatments	   Cat	  No.,	  
Company	  















290.48	  g/mol	   50	  mM	   50	  µM	  
Zoledronic	  acid	  
(Zometa)	  
Novartis	   2.94	  mM	  (4	  
mg/ml)	  
–	   10	  µM	  
(1:100)	  
	  
2.6.3 Treatment	  Protocol	  
At	   80-­‐90%	   confluence	   the	   slides	   were	   treated	   (Appendix	   19).	   	   The	   ZA	  
concentration	  was	   decided	   according	   to	   a	   dose	   response	   curve	   established	   in	   a	  
previous	   study	   (Zafar,	   2014).	   	   Zafar	   observed	   a	   significant	   reduction	   in	   viability	  
for	   human	   alveolar	   osteoblasts	   treated	   with	   20	   to	   50	   μM	   ZA	   compared	   with	  
untreated	  controls	  at	  48	  h.	  	  To	  avoid	  these	  toxic	  effects,	  10	  μM	  was	  selected	  as	  the	  
lowest	  concentration	  to	  induce	  a	  response	  to	  treatment	  (Figure	  2–5).	  
	  
Figure	   2-­‐5.	   The	   effect	   of	   ZA	   concentration	   on	   human	   alveolar	   osteoblast	   viability.	   	   Three	  
HOB	  cell	  cultures	  for	  each	  concentration	  graphed	  with	  mean	  ±	  SEM.	  	  Dotted	  line	  represents	  
an	  untreated	  control	  (Reproduced	  with	  permission	  from,	  Zafar,	  2014)	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Twenty	  millilitres	  of	  pre-­‐warmed	  osteoblast	  mineralisation	  media	  was	  prepared	  
(Appendix	   11).	   	   The	   eight	   different	   treatments	   were	   made	   up	   in	   eight	   labelled	  
sterile	   eppendorfs	   in	   the	   laminar	   flow	  hood	   according	   to	   Table	   2–12	   (Appendix	  
18).	   	   The	   volume	   for	   the	   sterile	   PBS	   carrier	   was	   obtained	   by	   adding	   the	   VEGF	  
volume	  (1.3	  μl)	  and	  the	  ZA	  volume	  (4.4	  μl).	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4	  	   1300	  
	  









1	   4	   1300	   1299	   -­‐	   -­‐	   -­‐	   1.3	  
Media	  +	  
GGOH	  +	  
VEGF	  	  	  	  
⑧	  
1	   4	   1300	   1297	   -­‐	   1.3	  
	  
-­‐	   1.3	  
TOTAL	   8	   4	   10,400	   10,366	   5.7	   5.2	   17.6	   5.2	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Starting	  with	  the	  HOB2	  slides,	  the	  media	  was	  pipetted	  out	  of	  well	  1	  and	  replaced	  
with	  300μl	  of	  treatment	  1	  using	  a	  fresh	  pipette	  tip.	   	  When	  all	   four	  of	  these	  wells	  
had	   been	   treated,	   the	   process	   was	   repeated	   with	   the	   remaining	   wells	   and	  
corresponding	  treatments	  (2	  to	  8)	  as	  per	  the	  experimental	  layout	  in	  Figure	  2–6.	  	  	  
①	   ⑤	   	   ①	   ⑤	   	  
②	   ⑥	   	   ②	   ⑥	   	  
③	   ⑦	   	   ③	   ⑦	   	  
④	   ⑧	   	   ④	   ⑧	   	  
HOB2;	  R1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	   	   HOB2;	  IgG	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	   	  
	  
①	   ⑤	   	   ①	   ⑤	   	  
②	   ⑥	   	   ②	   ⑥	   	  
③	   ⑦	   	   ③	   ⑦	   	  
④	   ⑧	   	   ④	   ⑧	   	  
HOB2;	  R1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	   	   HOB2;	  IgG	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	   	  
	  
Figure	  2-­‐6.	   	  Experimental	   layout	   for	  HOB2	   treatments	  1	   to	  8;	   to	  be	  replicated	   for	  each	  cell	  
culture	  (HOB3	  and	  HOB5)	  
Two	  more	  sets	  of	  treatments	  were	  made	  up	  and	  the	  HOB3	  and	  HOB5	  cell	  cultures	  
were	  treated	  in	  the	  same	  way.	  	  All	  slides	  were	  incubated	  at	  37°C,	  100%	  humidity	  
and	  5%	  CO2/95%	  air	  (Sanyo	  CO2	  Incubator,	  Cat	  No.	  MCO-­‐19AIC).	  
2.6.4 Acetone	  Fixation	  
After	  48	  h	  of	  treatment,	  the	  slides	  were	  fixed	  in	  acetone	  as	  a	  means	  of	  coagulative	  
fixation	  to	  prevent	  autolysis,	  preserve	  cellular	  and	  tissue	  structure	  and	  maintain	  
antigenicity.	   	  Slides	  were	  processed	  one	  at	  a	   time;	   the	  media	  was	  decanted	   from	  
chambers	  and	  the	  chamber	  well	  sides	  were	  removed.	  	  Each	  slide	  was	  submerged	  
in	  PBS	   to	  prevent	  drying	  until	   all	  HOB2	   slides	  were	  prepared	   to	   this	   stage.	   	   The	  
slides	   were	   aligned	   in	   a	   glass	   slide	   holder	   placed	   in	   a	   balanced	   position	   on	   an	  
orbital	   shaker.	   	   Ice-­‐cold	   acetone	   was	   poured	   over	   the	   slides	   until	   they	   were	  
completely	   covered.	   	   The	   slides	  were	   fixed	   for	   10	  minutes	  with	   gentle	   agitation	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and	  allowed	  to	  air	  dry	  prior	  to	  storage	  at	  4°C.	  	  This	  process	  was	  repeated	  for	  the	  
remaining	  HOB	  cultures	  HOB3	  and	  HOB5.	  	  
2.6.5 Establishment	  of	  an	  Immunofluorescence	  Protocol	  
An	  additional	  HOB	  culture	  (HOB4)	  obtained	  by	  the	  same	  research	  group	  according	  
to	   the	   protocol	   previously	   described	   was	   used	   to	   establish	   an	  
immunofluorescence	  protocol	  for	  the	  receptor	  VEGFR1.	  	  The	  cells	  were	  retrieved	  
from	   cryopreservation	   (Appendix	   8)	   and	   transferred	   to	   a	   T25	   flask	   for	   culture.	  	  
The	  cells	  were	  incubated	  and	  the	  media	  was	  changed	  every	  second	  day	  until	   the	  
cells	   approached	   confluence.	   	   At	   80-­‐90%	   confluence	   the	   cells	   were	   trypsinised	  
(Appendix	  12)	  and	  plated	  onto	  eight	  8-­‐well	  chamber	  slides	  at	  a	  seeding	  density	  of	  
8000cells/cm2.	   	   The	   cells	   were	   incubated	   at	   37°C,	   100%	   humidity	   and	   5%	  
CO2/95%	   air	   and	   the	   media	   was	   changed	   every	   second	   day.	   	   When	   the	   cells	  
reached	   80-­‐90%	   confluence,	   three	   slides	   were	   treated	   with	   the	   eight	   different	  
treatments	   according	   to	   the	   protocol	   previously	   described	   (Appendices	   18-­‐19).	  	  
This	   provided	   three	   spare	   treatment	   slides.	   	   The	   remaining	   5	   slides	  were	   to	   be	  
used	   to	  establish	  an	   immunofluorescence	  protocol.	   	  Basi	  et	  al.	   reported	  a	   strong	  
visual	   response	   when	   HUVEC	   cells	   were	   treated	   with	   12.5μM	   ZA	   for	   48	   h,	  
incubated	   with	   VEGFR2	   antibodies	   and	   labelled	   with	   an	   Alexafluor	   isotype-­‐
specific	  secondary	  antibody	  (Basi	  et	  al.,	  2010).	  	  Therefore,	  the	  slides	  in	  this	  study	  
were	  treated	  with	  media	  +	  ZA	  (treatment	  5)	  in	  each	  well	  and	  incubated.	   	  Each	  of	  
the	  eight	  slides	  was	   fixed	   in	  acetone	  after	  48	  h	   (Appendix	  14)	  and	  stored	  at	  4°C	  
until	  required.	  	  	  
2.6.5.1 Antibody	  Selection	  	  
Immunohistochemistry	  involves	  the	  exploitation	  of	  the	  adaptive	  immune	  response	  
and	   the	   specific	   nature	   of	   antigen-­‐antibody	   binding.	   	   Sensitised	   B	   cells	   produce	  
antibody	  in	  response	  to	  repeated	  exposure	  to	  a	  specific	  antigen.	  	  The	  antigen	  and	  
corresponding	   antibody	   bind	   with	   high	   affinity	   in	   a	   lock	   and	   key	   fashion.	  	  
Immunofluorescence	  involves	  fluorescent	  labelling	  of	  specific	  antibodies	  to	  allow	  
the	   antigen	   of	   interest	   to	   be	   visually	   identified.	   	   The	   fluorescent	   label	   may	   be	  
attached	  to	  either	  the	  primary	  antibody,	  which	  is	  directly	  attached	  to	  the	  antigen	  
(direct	  method),	  or	  to	  subsequent	  antibodies	  raised	  against	  the	  primary	  antibody	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(indirect	  method)	  (Ramos-­‐Vara,	  2005).	   	  The	  indirect	  method	  was	  employed	  here	  
as	  it	  amplifies	  the	  fluorescence. 
Polyclonal	   antibodies	   for	   immunohistochemistry	   are	   obtained	   by	   immunizing	  
animals	  with	  a	  purified	  antigen	  of	   interest.	  Antibodies	  produced	  by	   this	  method	  
are	  polyclonal	  antibodies	  and	  will	  react	  with	  multiple	  epitopes	  on	  the	  antigen	  of	  
interest	   and	   can	   thus	   be	   more	   sensitive	   and	   less	   susceptible	   to	   processing	  
conditions.	   Monoclonal	   antibodies	   are	   highly	   specific,	   responding	   to	   a	   single	  
epitope	   and	   are	   produced	   in	   vitro	   by	   either	   mouse	   or	   rabbit	   hybridomas.	  
Polyclonal	   antibodies	   potentially	   show	   lower	   specificity	   (more	   false	   positives),	  
greater	   non-­‐specific	   background	   staining	   and	   have	   a	   greater	   chance	   of	   cross-­‐
reactivity	  as	  compared	  with	  their	  monoclonal	  counterparts	  (Ramos-­‐Vara,	  2005).	  	  
Two	  anti-­‐VEGFR1	  primary	  anti-­‐bodies	  were	  selected	  to	  be	  trialled	  in	  this	  study:	  a	  
polyclonal	   (Cat	   No.	   NBP1-­‐89823,	   Novus	   Biologicals)	   and	   a	  monoclonal	   (Cat	   No.	  
ab32152,	   Sapphire	   Bioscience/Abcam)	   antibody.	   	   Both	   anti-­‐bodies	   had	  
appropriate	  species	  reactivity	  (human)	  and	  were	  produced	  by	  either	  a	  rabbit	  or	  a	  
rabbit	   hybridoma.	   	   The	   concentrations	   for	   ab32152	   and	   NBP1-­‐89823	   were	  
selected	  based	  on	  the	  product	  data	  sheets.	  	  
2.6.5.2 Negative	  Control	  
A	  negative	  control	   is	  an	  antibody	  that	  does	  not	  bind	  with	  the	  antigen	  of	   interest,	  
thus	  distinguishing	  background	  from	  specific	  antigen	  staining.	  	  For	  simplicity	  and	  
consistency,	   the	   negative	   control	   for	   the	   present	   experiment	   was	   a	   rabbit	   IgG	  
antibody	  (Cat	  No.	  X0936,	  Dako).	  	  This	  allowed	  the	  same	  secondary	  antibody	  to	  be	  
used	  for	  all	  three	  primary	  antibodies	  (ab32152,	  NBP1-­‐89823	  and	  IgG	  control). 
The	   secondary	   antibody	   used	  was	   a	   goat	   anti-­‐rabbit	   IgG	   labelled	  with	   a	   bright,	  
photostable	  green-­‐fluorescent	  Alexafluor	  488	  dye	  (Cat	  No.	  A-­‐11008,	  Invitrogen)	  at	  
a	  concentration	  of	  5	  μg/ml.	  
2.6.5.3 Positive	  Control	  
A	   positive	   control	   known	   to	   express	   the	   antigen	   of	   interest	   (VEGFR1)	   was	  
required	  to	  establish	  an	  immunofluorescence	  protocol.	  	  Head	  and	  neck	  squamous	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cell	  carcinoma	  (HNSCC)	  cells	  have	  been	  shown	  to	  express	  VEGFR1	  receptors	  (tong	  
2008)	  and	  were	  therefore	  included	  in	  the	  experimental	  design.	  
2.6.5.4 Protocol	  
Detailed	  methodology	   for	   the	   immunofluorescence	   is	   given	   in	   Appendix	   20.	   	   In	  
brief,	   a	  hydrophobic	  wax	  barrier	  pen	   (Cat	  No.	   S2002,	  Dako)	  was	  used	   to	   form	  a	  
wax	  barrier	  around	  each	  of	   the	  wells.	   	  The	  slides	  were	  rehydrated	   in	  PBS	  under	  
gentle	  agitation	  on	  an	  orbital	  shaker.	  	  All	  solutions	  were	  added	  in	  a	  volume	  of	  50	  
μl/well.	   	   Blocking	   with	   1%	   BSA/10%	   goat	   serum/PBS	   blocking	   solution	   was	  
conducted	   for	   1	   h	   at	   room	   temperature.	   All	   goat	   serum	   used	   in	   the	  
immunofluorescence	  had	  previously	  been	  heat	  treated	  at	  56⁰	  C	  for	  30	  minutes.	  
The	   ab32152	  primary	   antibody	  was	  predicted	   to	  work	  at	   a	   concentration	  of	  0.5	  
μg/ml.	  	  It	  was	  therefore	  tested	  at	  concentrations	  of	  0.54	  µg/ml	  (1.2	  μl	  of	  antibody	  
and	   59	   μl	   diluent)	   and	   0.14	   µg/ml	   (1.1	   μl	   antibody	   and	   219	   μl	   of	   diluent)	   to	  
establish	   the	   effective	   concentration	   range.	   	   The	  NBP1-­‐89823	   primary	   antibody	  
was	   predicted	   to	   work	   at	   a	   concentration	   of	   4	   μg/ml	   and	   was	   made	   up	   at	  
concentrations	  of	  8	  µg/ml	  (4	  μl	  of	  antibody	  and	  46	  μl	  diluent)	  and	  4	  µg/ml	  (8.4	  μl	  
of	   antibody	   and	   201.6	   μl	   of	   diluent).	   	   The	   antibodies	  were	   diluted	   in	   a	  PBS/1%	  
BSA/5%	   goat	   serum	   diluent.	   	   The	   negative	   control	   (Rabbit	   Immunoglobulin	  
Fraction,	   Cat	   No.	   X0936,	   Dako)	   was	   made	   up	   in	   two	   concentrations	   that	  
approximated	  the	  concentration	  range	  of	  primary	  antibody	  described	  above.	  	  A	  1	  
mg/ml	   rabbit	   IgG	   (Cat	   No.	   X0936,	   Dako)	   working	   stock	   was	   first	   prepared	   by	  
adding	   100	   μl	   of	   15	  mg/ml	   stock	   solution	   to	   1400	   μl	   of	   PBS.	   	   To	   represent	   the	  
high-­‐end	   concentrations,	   a	   4	   μg/ml	   solution	   was	   made	   up	   by	   adding	   1	   μl	   of	   1	  
mg/ml	   rabbit	   IgG	   working	   stock	   to	   249	   μl	   of	   diluent.	   	   At	   the	   low	   end	   of	   the	  
concentration	  range,	  3	  μl	  of	  the	  4	  μg/ml	  solution	  was	  added	  to	  57	  μl	  of	  diluent	  to	  
make	   up	   a	   0.2	   μg/ml	   solution.	   	   The	   blocking	   solution	   was	   removed	   and	   the	  
primary	   antibodies	   were	   added	   according	   to	   the	   experimental	   layout	   shown	   in	  
Figure	  2–7.	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Figure	  2-­‐7.	  	  Experimental	  layout	  for	  establishing	  an	  immunofluorescence	  protocol	  
The	  slides	  were	  incubated	  at	  4°C	  overnight	  in	  a	  chamber	  moist	  with	  PBS.	  	  After	  24	  
h	  the	  slides	  were	  washed	  and	  treated	  with	  a	  secondary	  antibody.	  	  All	  experimental	  
work	  involving	  the	  secondary	  antibody	  was	  undertaken	  in	  a	  room	  with	  the	  lights	  
dimmed	  to	  minimize	  fluorochrome	  fading.	  	  The	  slides	  were	  washed	  three	  times	  in	  
PBS/0.5%	   non-­‐fat	   milk	   (NFM)	   powder	   (5	   min,	   20	   min,	   20	   min),	   with	   gentle	  
agitation.	   	  NFM	  powder	  is	  high	  in	  protein	  and	  was	  used	  as	  a	  blocking	  agent	  with	  
PBS	  to	  reduce	  background	  staining.	   	  Excess	  PBS/1%	  BSA/5%	  goat	  serum	  diluent	  
conserved	  from	  day	  1	  was	  used	  to	  make	  up	  a	  solution	  of	  the	  Alexa	  Fluor	  488	  Goat	  
Anti-­‐Rabbit	  IgG	  secondary	  antibody	  at	  a	  concentration	  of	  5	  μg/ml.	  Each	  well	  was	  
incubated	   with	   the	   Alexa	   Fluor	   488	   secondary	   antibody	   (Cat	   No.	   A-­‐11008,	  
Invitrogen)	   in	   a	   light	   proof	   box	   for	   1	   h	   at	   room	   temperature.	   	   Slides	  were	   then	  
washed	  three	  times	  in	  PBS,	  with	  gentle	  agitation,	  for	  a	  total	  of	  25	  minutes.	  	  Excess	  
PBS	  was	  removed	  with	  blotting	  paper.	  	  One	  drop	  of	  Vectashield	  mounting	  medium	  
for	  fluorescence	  with	  DAPI	  (Cat	  No.	  H-­‐1200,	  Vector	  Laboratories	  Inc.)	  was	  added	  
per	   well	   and	   a	   clean	   22x50	   coverslip	   (Cat	   No.	   LBS	   22x50-­‐1,	   Thermo	   Fisher	  
Scientific)	  was	  placed	  on	  each	  slide.	  	  The	  edges	  were	  blotted	  and	  sealed	  with	  clear	  
nail	  polish.	  	  The	  slides	  were	  stored	  flat	  in	  a	  lightproof	  box	  at	  4°C.	  	  	  
The	  slides	  were	  viewed	  and	  photographed	  under	  the	  Leica	  CTR5000b	  microscope	  
(Leica	  Microsystems,	  Wetzlar)	  with	  Spot	  RT	  software.	   	  The	   results	  were	  used	   to	  
establish	   the	   final	   immunofluorescence	   protocol	   for	   the	   treatment	   slides	  
(Appendix	  20).	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2.6.6 Immunofluorescence	  
2.6.6.1 Day	  1	  
The	   monoclonal	   VEGFR1	   antibody	   ab32152	   was	   selected	   at	   a	   concentration	   of	  
0.54	  μg/ml.	   	  On	  day	  1,	   1%	  BSA/10%	  goat	   serum/PBS	  blocking	   solution	  and	   the	  
PBS/1%	   BSA/5%	   goat	   serum	   diluent	   were	   prepared.	   	   Volume	   calculations	   are	  
detailed	   in	  appendix	  20.	   	  As	  per	   the	  previous	  protocol,	  a	  DAKO	  pen	  was	  used	   to	  
form	  a	  wax	  barrier	  around	  each	  well	  and	  the	  slides	  were	  rehydrated	  in	  PBS.	  	  Each	  
well	   was	   blocked	  with	   50	   μl	   of	   PBS/1%	   BSA/10%	   goat	   serum	   for	   1	   h	   at	   room	  
temperature.	   	  Meanwhile,	   the	   primary	   antibody	  VEGFR1	   (ab32152,	   Abcam)	   and	  
primary	   antibody	   negative	   control	   Rabbit	   Immunoglobulin	   Fraction	   (X0936,	  
Dako)	  were	  prepared.	  	  	  
In	  a	  2	  ml	  eppendorf,	  28.8	  μl	  of	  VEGFR1	  antibody	  (ab32152,	  Abcam)	  was	  combined	  
with	  1411.2	  μl	  of	  PBS/1%	  BSA/5%	  goat	  serum	  to	  achieve	  a	  0.54	  μg/ml	  solution.	  	  
The	   15	  mg/ml	   rabbit	   IgG	   stock	   was	   converted	   into	   1	   mg/ml	   working	   stock	   by	  
adding	  100	  μl	  to	  1400	  μl	  of	  PBS.	  	  To	  approximate	  the	  concentration	  of	  the	  VEGFR1	  
antibody,	  1	  μl	  of	  working	  stock	  was	  added	  to	  1999	  μl	  of	  diluent	  to	  achieve	  a	  final	  
concentration	  of	  0.5	  μg/ml.	  	  	  
After	  1	  h	  the	  blocking	  solution	  was	  drawn	  off	  each	  well	  and	  the	  slides	  were	  treated	  
with	  primary	  antibody.	  	  There	  were	  two,	  otherwise	  identical,	  treatment	  slides	  for	  
each	  HOB	  culture,	  one	   labelled	  R1	  and	   the	  other	   labelled	   IgG.	   	  Each	  of	   the	   three	  
slides	  labelled	  R1	  was	  treated	  with	  50	  μl	  of	  primary	  VEGFR1	  antibody	  (ab32152)	  
per	  well.	   	   The	   remaining	   slides	   labelled	   IgG	  were	   treated	  with	  50	  μl	   per	  well	   of	  
Rabbit	  Immunoglobulin	  Fraction	  control	  (Cat	  No.	  X0936),	  as	  per	  the	  experimental	  
layout	   in	  Figure	  2–8.	   	  The	   slides	  were	   stored	  overnight	   in	   a	  moist	  hybridization	  
chamber	  at	  4°C	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  –	  R1	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HOB3	  –	  R1	  
Treatment	  slide	  



















































HOB5	  –	  R1	  
Treatment	  slide	  
	   HOB5	  –	  IgG	  
Treatment	  slide	  
	  
Figure	  2-­‐8.	  	  Immunofluorescence	  experimental	  layout	  for	  VEGFR1	  antibody	  (ab32152)	  and	  
IgG	  control	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2.6.6.3 Day	  2:	  Secondary	  Antibody	  and	  Nuclear	  Staining	  
After	   24	   h	   the	   slides	   were	   washed	   three	   times	   in	   PBS/0.5%NFM	   powder	   with	  
gentle	  agitation	  for	  a	  total	  of	  45	  minutes.	   	  During	  this	  time	  a	  5	  μg/ml	  solution	  of	  
the	   secondary	   antibody	  was	   prepared	   by	   adding	   6.5	   μl	   of	   Alexa	   Fluor	   488	   goat	  
anti-­‐rabbit	  IgG	  (A11008)	  to	  2593.5	  μl	  of	  PBS/1%	  BSA/5%	  goat	  serum	  in	  a	  dimly	  
lit	  room.	  	  The	  slides	  were	  blotted	  to	  remove	  excess	  PBS/0.5%	  NFM	  and	  50	  μl	  of	  5	  
μg/ml	  Alexa	  Fluor	  488	  secondary	  antibody	  was	  applied	   to	  each	  well.	   	  The	  slides	  
were	  stored	  in	  a	  lightproof	  box	  for	  1	  h	  at	  room	  temperature.	  	  After	  1	  h	  the	  slides	  
were	  washed	   three	   times	   in	  PBS	  with	   gentle	   agitation	   for	   a	   total	   of	   25	  minutes.	  	  
The	  slides	  were	  again	  blotted	  to	  remove	  excess	  PBS	  and	  1	  drop	  of	  DAPI	  soft	  mount	  
was	  applied	  to	  each	  well.	  	  A	  clean	  22x50	  coverslip	  (Cat	  No.	  LBS	  22x50-­‐1,	  Thermo	  
Fisher	   Scientific)	   was	   placed	   on	   each	   slide	   and	   sealed	   in	   place	   with	   clear	   nail	  
polish.	  	  The	  slides	  were	  stored	  flat	  in	  a	  lightproof	  box	  at	  4°C.	  	  	  
2.6.6.4 Confocal	  Microscopy	  
The	   slides	   were	   initially	   viewed	   under	   the	   Leica	   CTR5000b	   microscope	   (Leica	  
Microsystems,	  Wetzlar).	   	  Following	  this,	  slides	  were	  viewed	  under	  the	  Zeiss	  LSM	  
710	  Confocal	  Laser	  Scanning	  Microscope	  (Carl	  Zeiss	  Microscopy	  GmbH)	  using	  the	  
488	   nm	   argon	   laser	   excitation	   line	   with	   Zeiss	   ZEN	   2009	   software	   running	   on	  
Windows	  Vista.	   	   Images	  were	   taken	   of	   representative	   areas	   at	   the	   10x	   PlanApo	  
0.45NA	   objective	   with	   identical	   gains/settings	   for	   the	   green	   excitation	  
fluorescence	  filter	  for	  each	  VEGFR1	  treated	  well	  and	  its	  corresponding	  IgG	  control	  
well.	   	   Images	   were	   also	   taken	   of	   the	   same	   area	   using	   the	   blue	   excitation	  
fluorescent	   filter	   to	   visualize	   the	   nuclear	   staining	   (DAPI).	   	   The	   blue	   and	   green	  
images	   were	   layered	   into	   a	   single	   composite	   image	   for	   each	   well	   using	   Fiji	  
software.	  	  The	  images	  were	  analysed	  qualitatively.	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Chapter	  3	  
3 Results	  
3.1 Cell	  Culture	  
The	  human	  alveolar	  osteoblast	  cultures	  used	  in	  this	  study	  (n=3)	  were	  derived	  in	  a	  
previous	  study	  from	  healthy	  adult	  females	  who	  met	  the	  predetermined	  inclusion	  
criteria	   and	   underwent	   bone	   tissue	   excision	   incidental	   to	   third	   molar	   removal.	  	  
Each	   culture	   was	   developed	   and	   phenotypically	   characterised.	   	   The	   osteoblast	  
phenotype	   was	   confirmed	   by	   the	   cells	   ability	   to	   form	   nodules,	   to	   produce	  
osteocalcin,	  and	  by	  the	  presence	  of	  both	  calcium	  and	  phosphate	  (Zafar,	  2014).	  
The	  established	  human	  alveolar	  osteoblasts	  described	  above	  were	  retrieved	  from	  
cryopreservation	  and	  cultured	   in	  osteoblast	  culture	  media	   for	  use	   in	  the	  present	  
experiments	   (Figure	  3–1).	   	  Media	   changes	  and	  passages	  were	  undertaken	  based	  
on	  the	  individual	  growth	  rates	  of	  each	  culture	  and	  are	  detailed	  in	  Table	  3–1.	  	  
	   	  
Figure	  3-­‐1.	  	  Human	  alveolar	  osteoblasts	  after	  4	  days	  of	  culture	  in	  osteoblast	  mineralisation	  
media	  showing	  a	  characteristic	  lack	  of	  contact	  inhibition	  (10x	  magnification)	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Table	  3-­‐1.	  	  Media	  changes	  and	  passages	  over	  12	  days	  between	  HOB	  retrieval	  and	  lifting	  and	  
plating	   for	   the	   three	   different	   cell	   cultures	   (HOB2,	   HOB3	   and	   HOB5).	   	   Each	   passage	   was	  
carried	  out	  at	  80	  -­‐	  90%	  confluence	  and	  occurred	  at	  different	  times	  for	  each	  culture	  due	  to	  
biological	  variation	  in	  growth	  rate	  
Day	  of	  
Culture	  
HOB2	   HOB3	   HOB5	  
1	  	   Retrieved	  –	  T25	   Retrieved	  –	  T25	   Retrieved	  –	  T25	  
2	   	   	   	  
3	   Media	  change	   T25!T75	   T25!T75	  
4	   T25!T75	   	   	  
5	   	   Media	  change	   Media	  change	  
6	   	   	   T75!2xT75	  
7	   T75	  !2xT75	   T75!2xT75	   	  
8	   	   	   	  
9	   2xT75!4xT75	   Media	  Change	   2xT75!4xT75	  
10	   	   	   	  
11	   	   	   	  
12	   Lift	  and	  plate	   Lift	  and	  plate	   Lift	  and	  plate	  
	  
3.2 VEGF	  Receptor	  Inhibitor	  Experiments	  
The	  three	  human	  alveolar	  osteoblast	  biological	  replicates	  were	  plated	  at	  a	  seeding	  
density	   of	   8000	   cells/cm2	   in	   96-­‐well	   plates	   and	   cultured	   in	   osteoblast	  
mineralisation	   media	   for	   24	   h	   prior	   to	   treatment	   with	   specific	   VEGF	   receptor	  
inhibitors	  or	   control	   conditions.	   	  The	  objective	  of	   this	  experiment	  was	   to	   inhibit	  
each	   receptor	   (R1	   or	   R2),	   individually	   or	   in	   combination,	   and	   to	   determine	   the	  
effects	  on	  osteoblast	  matrix	  mineralisation	  over	  21	  and	  28	  days	  of	   culture.	   	  The	  
concentrations	   examined	   were	   based	   on	   the	   published	   IC50	   for	   each	  
inhibitor/receptor	  interaction.	  
3.2.1 Matrix	  Mineralisation	  after	  21	  Days	  
One	   of	   the	   96-­‐well	   plates	   was	   cultured	   for	   21	   days	   with	   twice	   weekly	   media	  
changes	  (Figure	  3–2).	   	  The	  colour	  range	  observed	  in	  the	  mineralisation	  media	  at	  
this	  time	  point	   indicated	  differential	  grown	  rates	  between	  the	  three	  cell	  cultures	  
and	   within	   each	   cell	   line	   for	   the	   VEGFR1	   and	   dual	   VEGFR1/R2	   inhibitor	  
concentrations.	  	  The	  corresponding	  mineralisation	  by	  osteoblasts	  in	  each	  well	  was	  
quantified	  using	  an	  ARS	  mineralisation	  assay.	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Figure	  3-­‐2.	   	   Photograph	  of	   a	  96-­‐well	  plate	  at	  day	  21	   showing	  different	  media	   colours	  and	  
therefore	  different	  rates	  of	  media	  utilisation.	  	  A	  pink/red	  hue	  represents	  less	  media	  utilised	  
and	  corresponds	  with	  slower	  cell	  growth	  compared	  with	  the	  yellow	  hue,	  which	  represents	  
greater	  media	  utilisation	  and	  therefore	  faster	  cell	  growth.	  
	  
VEGFR1	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Figure	   3-­‐3.	   Experimental	   layout	   for	   96-­‐well	   plates	   indicating	   the	   treatment	   (ZM	   306416,	  
ZM323881	   and	   KRN	   633),	   dose	   and	   culture	   (HOB2,	   HOB3	   or	   HOB5)	   corresponding	   to	   the	  
wells	  above	  in	  Figure	  3–2	  .	  	  Control	  OM	  =	  osteoblast	  mineralisation	  media	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3.2.1.1 Mineralisation	  data	  21	  days	  
The	  raw	  data	  for	  ARS	  absorbance	  at	  562	  nm	  for	  each	  inhibitor	  at	  the	  21-­‐day	  time	  
point	  is	  provided	  in	  Appendix	  21.	  	  The	  blank	  reading	  (0.032)	  was	  subtracted	  and	  
the	   transformed	   data	   for	   each	   inhibitor	   was	   expressed	   as	   a	   percentage	   of	   the	  
untreated	  control	  for	  each	  cell	  line	  (Tables	  3–2,	  3–3	  and	  3–4).	  	  This	  accounted	  for	  
the	  biological	  variation	  between	  the	  three	  cell	  cultures	  examined	  (Figure	  3–2).	  	  	  
Table	   3-­‐2.	   	   Raw	   and	   transformed	   data	   for	   the	   VEGFR1	   inhibitor	   at	   21	   days	   of	   culture,	  













Treatment	  as	  a	  
%	  of	  the	  Control	  
HOB2	   0.01	   0.151	   0.119	   0.154	   77.5	  
	   0.1	   0.142	   0.110	   0.154	   71.7	  
	   1.0	   0.139	   0.107	   0.154	   69.7	  
	   10.0	  	   0.116	   0.084	   0.154	   54.7	  
HOB3	   0.01	   0.141	   0.109	   0.137	   79.9	  
	   0.1	   0.146	   0.114	   0.137	   83.5	  
	   1.0	   0.130	   0.098	   0.137	   71.8	  
	   10.0	   0.104	   0.072	   0.137	   52.7	  
HOB5	   0.01	   0.225	   0.193	   0.245	   78.8	  
	   0.1	   0.268	   0.236	   0.245	   96.3	  
	   1.0	   0.200	   0.168	   0.245	   68.6	  
	   10.0	   0.144	   0.112	   0.245	   45.7	  
	  
Table	   3-­‐3.	   	   Raw	   and	   transformed	   data	   for	   the	   VEGFR2	   inhibitor	   at	   21	   days	   of	   culture,	  













Treatment	  as	  a	  
%	  of	  the	  Control	  
HOB2	   0.001	   0.190	   0.158	   0.154	   102.9	  
	   0.01	   0.159	   0.127	   0.154	   82.7	  
	   0.1	   0.158	   0.126	   0.154	   82.1	  
	   1.0	   0.159	   0.127	   0.154	   82.7	  
HOB3	   0.001	   0.133	   0.101	   0.137	   74.0	  
	   0.01	   0.161	   0.129	   0.137	   94.5	  
	   0.1	   0.139	   0.107	   0.137	   78.4	  
	   1.0	   0.164	   0.132	   0.137	   96.7	  
HOB5	   0.001	   0.200	   0.168	   0.245	   68.6	  
	   0.01	   0.242	   0.210	   0.245	   85.7	  
	   0.1	   0.250	   0.218	   0.245	   89.0	  
	   1.0	   0.218	   0.186	   0.245	   75.9	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Table	  3-­‐4.	   	  Raw	  and	  transformed	  data	  for	  the	  dual	  VEGFR1/VEGFR2	  inhibitor	  at	  21	  days	  of	  













Treatment	  as	  a	  
%	  of	  the	  Control	  
HOB2	   0.01	   0.141	   0.109	   0.154	   71.0	  
	   0.1	   0.153	   0.121	   0.154	   78.8	  
	   0.5	   0.240	   0.208	   0.154	   135.5	  
	   1.0	   0.129	   0.097	   0.154	   63.2	  
HOB3	   0.01	   0.150	   0.118	   0.137	   86.4	  
	   0.1	   0.143	   0.111	   0.137	   81.3	  
	   0.5	   0.129	   0.097	   0.137	   71.1	  
	   1.0	   0.122	   0.090	   0.137	   65.9	  
HOB5	   0.01	   0.242	   0.210	   0.245	   85.7	  
	   0.1	   0.220	   0.188	   0.245	   76.7	  
	   0.5	   0.228	   0.196	   0.245	   80.0	  
	   1.0	   0.190	   0.158	   0.245	   64.5	  
	  
3.2.1.1.1 Dose-­‐response	  analysis	  
To	  test	   for	  a	  dose	  response	  relationship	   for	  each	   inhibitor,	   the	  ARS	   level	  at	  each	  
dose	  was	   plotted	   against	   the	   log	   of	   the	   dose	   and	   linear	   regression	   analysis	  was	  
used	  to	  establish	  a	  slope	  for	  each	  HOB	  culture.	  	  In	  the	  absence	  of	  a	  dose	  response,	  
the	  slope	  value	  is	  0.	  	  For	  each	  inhibitor,	  the	  mean	  slope	  of	  the	  three	  cultures	  (Table	  
3–5)	  was	  therefore	  used	  in	  a	  one-­‐sample	  t	  test	  against	  a	  theoretical	  mean	  of	  0	  (no	  
slope)	  to	  investigate	  a	  dose	  response	  relationship.	  	  
This	   analysis	   confirmed	   the	   presence	   of	   a	   dose	   response	   relationship	   for	   the	  
VEGFR1	  inhibitor	  (p	  =	  0.0276)	  at	  21	  days.	  	  As	  the	  VEGFR1	  inhibitor	  concentration	  
increased,	   the	   ARS	   reading	   at	   562	   nm,	   expressed	   as	   a	   percentage	   of	   untreated	  
control,	  decreased.	  	  A	  dose	  response	  was	  not	  detected	  for	  the	  VEGFR2	  inhibitor	  (p	  
=	   0.8898).	   	   The	   dual	   VEGFR1/VEGFR2	   inhibitor	   had	   a	   slope	   approaching	  
significance	  (p	  =	  0.0570)	  at	  21	  days	  (Table	  3–6).	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Figure	  3-­‐4.	  Mean	  HOB2,	  HOB3	  and	  HOB5	  ARS	  levels	  at	  21	  days,	  expressed	  as	  a	  %	  of	  control,	  
for	  the	  log	  value	  of	  each	  VEGFR1	  inhibitor	  concentration.	  	  	  	  Slope	  mean	  across	  all	  cultures	  =	  -­‐
9.68	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Figure	  3-­‐5.	  Mean	  HOB2,	  HOB3	  and	  HOB5	  ARS	  levels	  at	  21	  days,	  expressed	  as	  a	  %	  of	  control,	  
for	  the	  log	  value	  of	  each	  VEGFR2	  inhibitor	  concentration.	   	  Slope	  mean	  across	  all	  cultures	  =	  
0.54	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Figure	  3-­‐6.	  	  Mean	  HOB2,	  HOB3	  and	  HOB5	  ARS	  levels	  at	  21	  days,	  expressed	  as	  a	  %	  of	  control,	  
for	  the	  log	  value	  of	  each	  dual	  VEGFR1/VEGFR2	  inhibitor	  concentration.	  	  Slope	  mean	  across	  
all	  cultures	  =	  -­‐7.36	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Table	  3-­‐5.	  	  Slope	  means	  across	  the	  three	  cell	  cultures	  for	  each	  VEGF	  receptor	  inhibitor	  at	  21	  
days.	  	  
Inhibitor	   Culture	   Slope	  	   Slope	  Mean	  
VEGFR1	  
HOB2	   -­‐7.04	  
-­‐9.68	  HOB3	   -­‐9.30	  
HOB5	   -­‐12.69	  
VEGFR2	  
HOB2	   -­‐6.12	  
0.54	  HOB3	   5.20	  
HOB5	   2.53	  
VEGFR1/R2	  
HOB2	   -­‐3.91	  
-­‐7.36	  HOB3	   -­‐10.18	  
HOB5	   -­‐8.00	  
	  
Table	  3-­‐6.	  One-­‐sample	  t	  tests	  for	  each	  VEGF	  receptor	  slope	  mean	  against	  a	  theoretical	  slope	  
of	  0	  at	  21	  days.	  






95%	  CI	  of	  
discrepancy	  
Sig.	   	  P	  value	  
(two	  
tailed)	  
VEGFR1	   0	   -­‐9.68	   -­‐16.74	  to	  -­‐2.61	   Yes	   0.0276	  
VEGFR2	   0	   0.54	   -­‐14.17	  to	  15.24	   No	   0.8898	  
VEGFR1/R2	   0	   -­‐7.36	   -­‐15.27	  to	  0.55	   No	   0.0570	  
	  
For	  each	  inhibitor,	  two-­‐tailed	  pairwise	  t	  tests	  were	  conduced	  to	  detect	  differences	  
in	  mean	  ARS	  levels	  (as	  a	  %	  of	  control)	  for	  each	  dose	  concentration	  and	  ARS	  levels	  
for	   the	   untreated	   controls	   (100%).	   	   Two-­‐tailed	   pairwise	   t	   tests	   were	   also	  
conducted	   for	   each	   inhibitor	   to	   detect	   differences	   between	  mean	  ARS	   levels	   for	  
each	  dose	  and	  mean	  ARS	  levels	  for	  every	  other	  dose.	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3.2.1.1.2 VEGFR1	  inhibitor	  
The	  mean	  ARS	  level	  for	  VEGFR1	  inhibitor	  doses	  0.01	  μM,	  1	  μM	  and	  10	  μM	  but	  not	  
0.1	  μM	  were	  significantly	  different	  from	  control.	   	  Table	  3–7	  includes	  the	  95%	  CIs	  
for	   these	   differences	   and	   the	   corresponding	   p-­‐values.	   	   Significant	   differences	   in	  
ARS	  levels	  were	  also	  detected	  between	  the	  doses	  10	  μM	  and	  1	  μM	  (p	  =	  0.0141),	  10	  
μM	  and	  0.01	  μM	  (p	  =	  0.0114),	  and	  between	  1	  μM	  and	  0.01	  μM	  (p	  =	  0.0075)	  (Table	  
3–8).	  	  
Mineralisation	   by	   human	   alveolar	   osteoblasts	  was	   therefore	   inhibited	   in	   a	   dose	  
dependent	  manner	  in	  the	  presence	  of	  the	  VEGFR1	  inhibitor.	  	  
3.2.1.1.3 VEGFR2	  inhibitor	  
There	  was	  a	  significant	  difference	  between	  the	  ARS	   level	   for	   the	  control	   (100%)	  
and	   the	   ARS	   level	   for	   VEGFR2	   inhibitor	   dose	   0.1	   μM	   (p	   =	   0.0323)	   (Table	   3–9).	  	  
There	  were	  no	  other	  significant	  differences	  detected	  between	  ARS	  levels	  for	  any	  of	  
the	  other	  doses	  and	  controls,	  nor	  between	  mean	  ARS	  levels	  at	  each	  of	  the	  inhibitor	  
doses	  (Table	  3–10).	  	  	  
The	  VEGFR2	   inhibitor	  was	   therefore	  not	   shown	   to	  have	  any	  significant	  effect	  on	  
osteoblast	  mineralisation.	  
3.2.1.1.4 Dual	  VEGFR1/R2	  inhibitor	  
A	   single	   outlier	   value	   (135.5%	  of	   control)	   from	   the	   HOB2	   cell	   line	   was	   excluded	  
from	  the	  0.5	  μM	  data	  set	  prior	  to	  analysis	  due	  to	  residual	  carryover	  of	  ARS.	   	  The	  
mean	  ARS	  levels	  for	  doses	  1	  μM	  and	  0.1	  μM	  were	  significantly	  different	  from	  the	  
ARS	  levels	  for	  control	  (p	  =	  0.0005,	  p	  =	  0.0039).	   	  A	  significant	  difference	  was	  also	  
detected	   between	   mean	   ARS	   levels	   for	   doses	   1	   μM	   and	   0.1	   μM.	   	   Confidence	  
intervals	  and	  p-­‐values	  are	  described	  in	  Tables	  3–11	  and	  3–12.	  	  	  
The	   dual	   VEGFR1/R2	   inhibitor	   inhibited	   osteoblast	   mineralisation	   in	   a	   dose	  
dependent	  manner.	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Figure	  3-­‐7.	  	  Graph	  showing	  the	  ARS	  means	  for	  three	  HOB	  cell	  cultures	  in	  the	  presence	  of	  four	  
different	  VEGFR1	   inhibitor	   concentrations	  after	  21	  days	  of	   exposure,	   expressed	  as	  a	  %	  of	  
control	  (control=dotted	   line).	   	  Two-­‐tailed	  paired	  t	   tests	   for	  differences	  between	  untreated	  
controls	   and	   each	   dose	   concentration;	   the	   ARS	   values	   were	   significantly	   different	   from	  
control	  for	  0.01	  μM,	  1	  μM	  and	  10	  μM.	  	  For	  two-­‐tailed	  paired	  t	  tests	  for	  differences	  between	  
each	   dose	   concentration,	   there	  were	   significant	   differences	   between	   0.01	   μM	   and	   10	   μM,	  
0.01	  μM	  and	  1	  μM,	  and	  1	  μM	  and	  10	  μM.	   	  P-­‐values:	   *≤0.05	   	   **≤	  0.01	   	   ***≤0.001.	   	   Standard	  
deviations	  are	  given.	  
Table	   3-­‐7.	   Two-­‐tailed	   paired	   t	   tests	   for	   differences	   between	   ARS	   levels	   at	   each	   VEGFR1	  






Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0.01	   0	   -­‐21.28	   1.17	   -­‐24.18	  to	  -­‐18.39	   Yes	   0.0010	  
0.1	   0	   -­‐16.17	   12.34	   -­‐46.81	  to	  14.48	   No	   0.1513	  
1	   0	   -­‐29.98	   1.64	   -­‐34.04	  to	  -­‐25.91	   Yes	   0.0010	  
10	   0	   -­‐48.94	   4.74	   -­‐60.70	  to	  -­‐37.18	   Yes	   0.0031	  
	  
Table	   3-­‐8.	   Two-­‐tailed	   paired	   t	   tests	   for	   differences	   between	   ARS	   levels	   at	   each	   VEGFR1	  





Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0.1	   0.01	   5.12	   11.77	   -­‐24.13	  to	  34.37	   No	   0.5302	  
1	   0.01	   -­‐8.69	   1.31	   -­‐11.96	  to	  -­‐5.43	   Yes	   0.0075	  
10	   0.01	   -­‐27.66	   5.15	   -­‐40.45	  to	  -­‐14.86	   Yes	   0.0114	  
1	   0.1	   -­‐13.81	   7.52	   -­‐46.17	  to	  18.55	   No	   0.2077	  
10	   0.1	   -­‐32.77	   16.93	   -­‐74.82	  to	  9.27	   No	   0.0786	  
10	   1	   -­‐18.96	   3.94	   -­‐28.74	  to	  -­‐9.18	   Yes	   0.0141	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Figure	  3-­‐8.	  Graph	  showing	  the	  ARS	  means	  for	  three	  HOB	  cell	  cultures	  in	  the	  presence	  of	  four	  
different	  VEGFR2	   inhibitor	   concentrations	  after	  21-­‐days	  of	   exposure,	   expressed	  as	  a	  %	  of	  
control	   (control=dotted	   line).	   	   	  Two-­‐tailed	  pairwise	   t	   tests	   showed	  a	  significant	  difference	  
between	  ARS	  values	  for	  the	  0.1	  μM	  concentration	  when	  compared	  to	  the	  untreated	  control.	  	  
There	  were	  no	  significant	  differences	  in	  ARS	  values	  between	  any	  of	  the	  other	  doses	  and	  that	  
of	  the	  control,	  or	  between	  each	  of	  the	  doses.	  P-­‐value:	  *≤0.05.	  	  Standard	  deviations	  are	  given.	  	  	  
Table	   3-­‐9.	   	   Two-­‐tailed	   paired	   t	   tests	   for	   differences	   between	   mean	   ARS	   levels	   at	   each	  






Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0.001	   0	   -­‐18.17	   18.47	   -­‐64.06	  to	  27.72	   No	   0.2306	  
0.01	   0	   -­‐12.35	   6.12	   -­‐27.55	  to	  2.85	   No	   0.0730	  
0.1	   0	   -­‐16.85	   5.38	   -­‐30.20	  to	  -­‐3.50	   Yes	   0.0323	  
1	   0	   -­‐14.88	   10.60	   -­‐41.20	  to	  11.44	   No	   0.1355	  
	  
Table	   3-­‐10.	   	   Two-­‐tailed	   paired	   t	   tests	   for	   differences	   between	  ARS	   levels	   at	   each	  VEGFR2	  





Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0.01	   0.001	   5.82	   22.59	   -­‐50.30	  to	  61.94	   No	   0.6991	  
0.1	   0.001	   1.32	   20.80	   -­‐50.35	  to	  52.99	   No	   0.9226	  
1	   0.001	   3.29	   21.74	   -­‐50.72	  to	  57.29	   No	   0.8179	  
0.1	   0.01	   -­‐4.50	   10.25	   -­‐29.96	  to	  20.96	   No	   0.5263	  
1	   0.01	   -­‐2.53	   6.39	   -­‐18.39	  to	  13.33	   No	   0.5630	  
1	   0.1	   1.97	   15.73	   -­‐37.11	  to	  41.04	   No	   0.8485	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Figure	  3-­‐9.	  Graph	  showing	  the	  ARS	  means	  for	  three	  HOB	  cell	  cultures	  in	  the	  presence	  of	  four	  
different	  VEGFR1/R2	  inhibitor	  concentrations	  after	  21	  days	  of	  exposure,	  expressed	  as	  a	  %	  
of	  control	  (control=dotted	  line).	  	  For	  two-­‐tailed	  paired	  t	  tests,	  the	  ARS	  values	  for	  the	  0.1	  μM	  
and	  1	  μM	  doses	  were	  significantly	  different	  from	  control.	  	  There	  was	  a	  significant	  difference	  
in	  ARS	  value	  only	  between	  doses	  0.1	  μM	  and	  1	  μM.	  	  P-­‐values:	  **≤	  0.01	  	  ***≤0.001.	  	  Standard	  
deviations	  are	  given.	  
Table	   3-­‐11.	   	   Two-­‐tailed	   paired	   t	   tests	   for	   differences	   between	   ARS	   levels	   at	   each	   dual	  






Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0.01	   0	   -­‐18.94	   8.71	   -­‐40.58	  to	  2.69	   No	   0.0638	  
0.1	   0	   -­‐21.04	   2.30	   -­‐26.74	  to	  -­‐15.34	   Yes	   0.0039	  
0.5	   0	   -­‐24.47	   6.32	   -­‐81.25	  to	  32.31	   No	   0.1150	  
1	   0	   -­‐35.46	   1.37	   -­‐38.87	  to	  -­‐32.05	   Yes	   0.0005	  
	  
Table	   3-­‐12.	   	   Two-­‐tailed	   paired	   t	   tests	   for	   differences	   between	   ARS	   levels	   at	   each	   dual	  






Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0.1	   0.01	   -­‐2.10	   8.80	   -­‐23.96	  to	  19.76	   No	   0.7199	  
0.5	   0.01	   -­‐10.55	   6.84	   -­‐71.99	  to	  50.89	   No	   0.2736	  
1	   0.01	   -­‐16.52	   7.54	   -­‐35.26	  to	  2.22	   No	   0.0630	  
0.5	   0.1	   -­‐3.50	   9.56	   -­‐89.40	  to	  82.41	   No	   0.6962	  
1	   0.1	   -­‐14.42	   1.89	   -­‐19.11	  to	  -­‐9.73	   Yes	   0.0057	  
1	   0.5	   -­‐10.32	   7.34	   -­‐76.28	  to	  55.64	   No	   0.2967	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3.2.2 Matrix	  Mineralisation	  after	  28	  Days	  
The	   remaining	   96-­‐well	   plate	   was	   cultured	   for	   an	   additional	   7	   days.	   	   The	  
mineralisation	   media	   with	   specific	   VEGFR	   inhibitors	   was	   changed	   twice	   in	   this	  
time.	  	  The	  data	  from	  the	  28-­‐day	  plate	  was	  analysed	  as	  for	  the	  21-­‐day	  plate.	  
3.2.2.1 Mineralisation	  data	  28	  Days	  
As	  for	  the	  21-­‐day	  data,	  the	  corresponding	  raw	  data	  for	  ARS	  absorbance	  at	  562	  nm	  
for	  each	  inhibitor	  at	  the	  28-­‐day	  time	  point	  is	  provided	  in	  Appendix	  22.	  	  The	  blank	  
reading	   (0.031)	   was	   subtracted	   and	   the	   28-­‐day	   data	   was	   transformed	   and	  
analysed	  in	  the	  same	  way	  as	  the	  21-­‐day	  data.	   	  The	  transformed	  ARS	  readings	  for	  
each	   VEGFR	   inhibitor	   are	   shown	   in	   Tables	   3–13,	   3–14	   and	   3–15.	   	   Two	   outlier	  
values	  were	  excluded	  prior	  to	  analysis	  as	  shown	  in	  Tables	  3–13	  and	  3–14.	  	  As	  with	  
the	  excluded	  value	  from	  the	  21-­‐day	  data,	  these	  outliers	  were	  attributed	  to	  residual	  
ARS	   carryover	   and	   were	   therefore	   not	   considered	   representative	   values	   for	  
analysis.	  	  	  
Table	   3-­‐13.	   Raw	   and	   transformed	   data	   for	   the	   VEGFR1	   inhibitor	   at	   28	   days	   of	   culture,	  













Treatment	  as	  a	  
%	  of	  the	  Control	  
HOB2	   0.01	   0.176	   0.145	   0.134	   108.6	  
	   0.1	   0.177	   0.146	   0.134	   109.4	  
	   1.0	   0.168	   0.137	   0.134	   102.6	  
	   10	   0.110	   0.079	   0.134	   59.2	  
HOB3	   0.01	   0.199	   0.168	   0.125	   134.4	  
	   0.1	   0.191	   0.160	   0.125	   128.0	  
	   1.0	   0.189	   0.158	   0.125	   126.4	  
	   10.0	   0.100	   0.069	   0.125	   55.2	  
HOB5	   0.01	   0.267	   0.236	   0.223	   105.8	  
	   0.1	   0.611	   0.580	   0.223	   260.1!	  
	   1.0	   0.241	   0.210	   0.223	   94.2	  
	   10.0	   0.147	   0.116	   0.223	   52.0	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Table	   3-­‐14.	   Raw	   and	   transformed	   data	   for	   the	   VEGFR2	   inhibitor	   at	   28	   days	   of	   culture,	  













Treatment	  as	  a	  
%	  of	  the	  Control	  
HOB2	   0.001	   0.162	   0.131	   0.134	   98.1	  
	   0.01	   0.205	   0.174	   0.134	   130.3	  
	   0.1	   0.193	   0.162	   0.134	   121.3	  
	   1.0	   0.203	   0.172	   0.134	   128.8	  
HOB3	   0.001	   0.185	   0.154	   0.125	   123.2	  
	   0.01	   0.406	   0.375	   0.125	   300.0!	  
	   0.1	   0.212	   0.181	   0.125	   144.8	  
	   1.0	   0.167	   0.136	   0.125	   108.8	  
HOB5	   0.001	   0.279	   0.248	   0.223	   111.2	  
	   0.01	   0.316	   0.285	   0.223	   127.8	  
	   0.1	   0.251	   0.220	   0.223	   98.7	  
	   1.0	   0.265	   0.234	   0.223	   104.9	  
	  
Table	   3-­‐15.	   Raw	   and	   transformed	   data	   for	   the	   dual	   VEGFR1/R2	   inhibitor	   at	   28	   days	   of	  













Treatment	  as	  a	  
%	  of	  the	  Control	  
HOB2	   0.01	   0.256	   0.225	   0.134	   168.5	  
	   0.1	   0.189	   0.158	   0.134	   118.4	  
	   0.5	   0.167	   0.136	   0.134	   101.9	  
	   1.0	   0.148	   0.117	   0.134	   87.6	  
HOB3	   0.01	   0.199	   0.168	   0.125	   134.4	  
	   0.1	   0.156	   0.125	   0.125	   100.0	  
	   0.5	   0.132	   0.101	   0.125	   80.8	  
	   1.0	   0.142	   0.111	   0.125	   88.8	  
HOB5	   0.01	   0.263	   0.232	   0.223	   104.0	  
	   0.1	   0.251	   0.220	   0.223	   98.7	  
	   0.5	   0.336	   0.305	   0.223	   136.8	  
	   1.0	   0.195	   0.164	   0.223	   73.5	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As	  for	  the	  21	  day	  data,	  the	  ARS	  level	  at	  each	  dose	  was	  plotted	  against	  the	  log	  of	  the	  
dose	   and	   linear	   regression	   analysis	  was	   used	   to	   establish	   a	   slope	   for	   each	  HOB	  
culture.	  	  For	  each	  inhibitor,	  the	  mean	  slope	  of	  the	  three	  cultures	  (Table	  3–16)	  was	  
used	  in	  a	  one-­‐sample	  t	  test	  against	  a	  theoretical	  mean	  of	  0	  (no	  slope)	  to	  investigate	  
a	  dose	  response	  relationship.	  	  
This	   analysis	   confirmed	   the	   presence	   of	   a	   dose	   response	   relationship	   for	   the	  
VEGFR1	  inhibitor	  (95%	  CI	  -­‐30.14	  to	  -­‐6.95,	  p	  =	  0.0205)	  at	  28	  days.	  	  A	  dose	  response	  
was	  not	  detected	  for	  the	  VEGFR2	  inhibitor	  (95%	  CI	  -­‐17.12	  to	  17.75,	  p	  =	  0.9450)	  or	  
the	  dual	  VEGFR1/VEGFR2	   inhibitor	   (95%	  CI	   	   -­‐67.95	   to	  22.97,	  p	  =	  0.1671)	  at	  28	  
days	  (Tables	  3–17).	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Figure	  3-­‐10.	  Mean	  HOB2,	  HOB3	  and	  HOB5	  ARS	  levels	  at	  28	  days,	  expressed	  as	  a	  %	  of	  control,	  
for	  the	  log	  value	  of	  each	  VEGFR1	  inhibitor	  concentration.	  	  Slope	  mean	  across	  all	  cultures	  =	  -­‐
18.55	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Figure	  3-­‐11.	  Mean	  HOB2,	  HOB3	  and	  HOB5	  ARS	  levels	  at	  28	  days,	  expressed	  as	  a	  %	  of	  control,	  
for	  the	  log	  value	  of	  each	  VEGFR2	  inhibitor	  concentration.	  	  Slope	  mean	  across	  all	  cultures	  =	  -­‐
0.32	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Figure	  3-­‐12.	  	  Mean	  HOB2,	  HOB3	  and	  HOB5	  ARS	  levels	  at	  28	  days,	  expressed	  as	  a	  %	  of	  control,	  
for	  the	  log	  value	  of	  each	  dual	  VEGFR1/VEGFR2	  inhibitor	  concentration.	  	  Slope	  mean	  across	  
all	  cultures	  =	  -­‐22.49	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Table	  3-­‐16.	   	  Slope	  means	  across	  the	  three	  cell	  cultures	  for	  each	  VEGF	  receptor	  inhibitor	  at	  
28	  days.	  	  
Inhibitor	   Culture	   Slope	  	   Slope	  Mean	  
VEGFR1	  
HOB2	   -­‐15.51	  
-­‐18.55	  HOB3	   -­‐23.92	  
HOB5	   -­‐16.21	  
VEGFR2	  
HOB2	   8.32	  
0.32	  HOB3	   -­‐2.57	  
HOB5	   -­‐4.80	  
VEGFR1/R2	  
HOB2	   -­‐39.26	  
-­‐22.49	  HOB3	   -­‐25.23	  
HOB5	   -­‐2.97	  
	  
	  
Table	   3-­‐17.	   	   One-­‐sample	   t	   tests	   for	   each	   VEGF	   receptor	   slope	  mean	   against	   a	   theoretical	  









95%	  CI	  of	  
discrepancy	  
Sig.	   	  P	  value	  
(two	  
tailed)	  
R1	   0	   -­‐18.55	   -­‐30.14	  to	  -­‐6.95	   Yes	   0.0205	  
R2	   0	   -­‐3.32	   -­‐17.12	  to	  17.75	   No	   0.9450	  
R1/R2	   0	   -­‐22.49	   -­‐67.95	  to	  22.97	   No	   0.1671	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3.2.2.1.2 VEGFR1	  inhibitor	  
As	  shown	  in	  Table	  3–18,	  only	  the	  mean	  ARS	  level	  for	  the	  highest	  concentration	  (10	  
μM)	   did	   not	   exceed	   the	   ARS	   level	   for	   the	   untreated	   control	   (mean	   difference	   -­‐
44.54,	  95%	  CI	   -­‐53.44	  to	  -­‐35.63).	   	  This	  mean	  ARS	   level	  was	  significantly	  different	  
from	   the	  mean	  ARS	   levels	   for	   the	  control	   (p	  =	  0.0022)	  and	   for	   the	  0.01	  μM	  (p	  =	  
0.0225)	   and	   1	   μM	   doses	   (p	   =	   0.0313).	   	   There	   was	   also	   a	   significant	   difference	  
between	  the	  mean	  ARS	  levels	  for	  doses	  0.01	  μM	  and	  1	  μM	  (p	  =	  0.0356),	  as	  shown	  
in	  Table	  3–19.	  
3.2.2.1.3 VEGFR2	  inhibitor	  
None	  of	   the	  mean	  ARS	   levels	  differed	   significantly	   from	  control	   (Table	  3–20)	  or	  
from	  each	   other	   (Table	   3–21).	   	   The	  VEGFR2	   inhibitor	   did	   not	   have	   a	   significant	  
effect	  on	  mineralisation	  at	  28	  days.	  
3.2.2.1.4 Dual	  VEGFR1/VEGFR2	  inhibitor	  
There	  were	  no	  significant	  differences	  between	  the	  mean	  ARS	  levels	  for	  the	  control	  
and	   any	   of	   the	   dual	   VEGFR1/R2	   inhibitor	   doses	   (Table	   3–22).	   	   There	   were	   no	  
statistically	  significant	  differences	  detected	  between	  any	  of	   the	  doses’	  mean	  ARS	  
levels	  (Table	  3–23).	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Figure	  3-­‐13.	  Graph	  showing	   the	  ARS	  means	   for	   three	  HOB	  cell	   cultures	   in	   the	  presence	  of	  
four	  different	  VEGFR1	  inhibitor	  concentrations	  after	  28	  days	  of	  exposure,	  expressed	  as	  a	  %	  
of	  control	  (control=dotted	  line).	  	  For	  two-­‐tailed	  paired	  t	  tests,	  only	  the	  ARS	  value	  for	  the	  10	  
μM	   dose	   was	   significantly	   different	   from	   control.	   	   There	   were	   significant	   differences	  
between	  ARS	  values	  for	  doses	  0.01	  μM	  and	  10	  μM,	  0.01	  μM	  and	  1	  μM,	  and	  1	  μM	  and	  10	  μM.	  P-­‐
values:	  *≤0.05	  	  **≤	  0.01.	  	  Standard	  deviations	  are	  given.	  
Table	   3-­‐18.	   Two-­‐tailed	   paired	   t	   tests	   for	   differences	   between	   ARS	   levels	   at	   each	   VEGFR1	  






Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0.01	   0	   16.28	   15.75	   -­‐22.85	  to	  55.41	   No	   0.2153	  
0.1	   0	   18.68	   13.18	   -­‐99.72	  to	  137.1	   No	   0.2946	  
1	   0	   7.73	   16.71	   -­‐33.78	  to	  49.24	   No	   0.5070	  
10	   0	   -­‐44.54	   3.59	   -­‐53.44	  to	  -­‐35.63	   Yes	   0.0022	  
	  
Table	   3-­‐19.	   Two-­‐tailed	   paired	   t	   tests	   for	   differences	   between	   ARS	   levels	   at	   each	   VEGFR1	  





Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0.1	   0.01	   -­‐2.83	   5.06	   -­‐-­‐48.24	  to	  42.59	   No	   0.5742	  
1	   0.01	   -­‐8.55	   2.87	   -­‐15.69	  to	  -­‐1.41	   Yes	   0.0356	  
10	   0.01	   -­‐60.82	   16.07	   -­‐100.7	  to	  -­‐20.90	   Yes	   0.0225	  
1	   0.1	   -­‐4.17	   3.64	   -­‐36.84	  to	  28.49	   No	   0.3517	  
10	   0.1	   -­‐61.49	   15.99	   -­‐205.2	  to	  82.17	   No	   0.1158	  
10	   1	   -­‐52.27	   16.41	   -­‐93.03	  to	  -­‐11.50	   Yes	   0.0313	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Figure	  3-­‐14.	  Graph	  showing	   the	  ARS	  means	   for	   three	  HOB	  cell	   cultures	   in	   the	  presence	  of	  
four	  different	  VEGFR2	  inhibitor	  concentrations	  after	  28	  days	  of	  exposure,	  expressed	  as	  a	  %	  
of	  control	  (control=dotted	  line).	   	  There	  were	  no	  significant	  differences	  (two-­‐tailed	  paired	  t	  
tests)	  in	  ARS	  value	  between	  any	  of	  the	  doses	  and	  the	  control,	  or	  between	  each	  of	  the	  doses.	  	  
Standard	  deviations	  are	  given.	  
Table	   3-­‐20.	   Two-­‐tailed	   paired	   t	   tests	   for	   differences	   between	   ARS	   levels	   at	   each	   VEGFR2	  






Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0.001	   0	   10.85	   12.54	   -­‐20.31	  to	  42.00	   No	   0.2728	  
0.01	   0	   16.28	   15.75	   -­‐22.85	  to	  55.41	   No	   0.2153	  
0.1	   0	   21.60	   23.07	   -­‐35.72	  to	  78.92	   No	   0.2464	  
1	   0	   14.19	   12.83	   -­‐17.69	  to	  46.07	   No	   0.1955	  
	  
Table	   3-­‐21.	   Two-­‐tailed	   paired	   t	   tests	   for	   differences	   between	   ARS	   levels	   at	   each	   VEGFR2	  





Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0.01	   0.001	   24.40	   11.04	   -­‐74.82	  to	  123.6	   No	   0.1972	  
0.1	   0.001	   10.75	   20.20	   -­‐39.44	  to	  60.95	   No	   0.4539	  
1	   0.001	   3.35	   24.05	   -­‐56.39	  to	  63.08	   No	   0.8321	  
0.1	   0.01	   -­‐19.07	   14.25	   -­‐147.1	  to	  109.0	   No	   0.3096	  
1	   0.01	   -­‐12.18	   15.11	   -­‐148.0	  to	  123.6	   No	   0.4584	  
1	   0.1	   -­‐7.41	   24.77	   -­‐68.93	  to	  54.11	   No	   0.6559	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Figure	  3-­‐15.	  Graph	  showing	   the	  ARS	  means	   for	   three	  HOB	  cell	   cultures	   in	   the	  presence	  of	  
four	  different	  VEGFR1/R2	  inhibitor	  concentrations	  after	  28	  days	  of	  exposure,	  expressed	  as	  
a	   %	   of	   control	   (control=dotted	   line).	   	   There	   were	   no	   significant	   differences	   (two-­‐tailed	  
paired	  t	  tests)	  in	  ARS	  value	  between	  any	  of	  the	  doses	  and	  the	  control,	  or	  between	  each	  of	  the	  
doses.	  	  Standard	  deviations	  are	  given.	  
Table	   3-­‐22.	   	   Two-­‐tailed	   paired	   t	   tests	   for	   differences	   between	   ARS	   levels	   at	   each	   dual	  






Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0.01	   0	   35.66	   32.27	   -­‐44.51	  to	  115.8	   No	   0.1957	  
0.1	   0	   5.67	   11.00	   -­‐21.67	  to	  33.01	   No	   0.4664	  
0.5	   0	   6.48	   28.27	   -­‐63.74	  to	  76.70	   No	   0.7297	  
1	   0	   -­‐16.67	   8.49	   -­‐37.77	  to	  4.43	   No	   0.0767	  
	  
Table	   3-­‐23.	   Two-­‐tailed	   paired	   t	   tests	   for	   differences	   between	   ARS	   levels	   at	   each	   dual	  






Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0.1	   0.01	   -­‐29.99	   22.73	   -­‐86.44	  to	  26.47	   No	   0.1496	  
0.5	   0.01	   -­‐29.18	   54.01	   -­‐163.4	  to	  105.0	   No	   0.4482	  
1	   0.01	   -­‐52.33	   25.87	   -­‐116.6	  to	  11.93	   No	   0.0727	  
0.5	   0.1	   0.81	   32.34	   -­‐79.51	  to	  81.14	   No	   0.9692	  
1	   0.1	   -­‐22.34	   10.05	   -­‐47.30	  to	  2.61	   No	   0.0613	  
1	   0.5	   -­‐23.15	   36.44	   -­‐113.7	  to	  67.38	   No	   0.3859	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3.2.3 Nodule	  Formation	  after	  21	  Days	  
Human	  alveolar	  osteoblasts	  were	  plated	  at	  a	  seeding	  density	  of	  8000	  cells/cm2	  in	  
8-­‐well	   chamber	   slides	   and	   cultured	   in	   mineralisation	   media	   at	   37°C	   in	   5%	  
CO2/95%	   air	   for	   24	   h	   prior	   to	   treatment	   with	   the	   VEGF	   receptor	   inhibitors	   at	  
concentrations	  used	  in	  the	  mineralisation	  assay.	   	  The	  objective	  was	  to	  determine	  
the	  effect	  of	  inhibiting	  each	  receptor	  (R1and	  R2),	  individually	  and	  in	  combination,	  
on	  the	  ability	  of	  osteoblasts	  to	  form	  mineralised	  nodules	  over	  21	  days	  of	  culture.	  	  
Alizarin	  Red	  S	  and	  alkaline	  phosphatase	   staining	  were	  used	   to	   facilitate	  positive	  
nodule	   identification.	   	  The	  slide	   labels	  were	  concealed	   to	  minimise	  bias	  and	   two	  
examiners	  who	  were	  not	  involved	  in	  the	  staining	  process	  independently	  counted	  
the	  number	  of	  nodules	  in	  each	  well	  according	  to	  a	  predetermined	  criteria.	  	  There	  
was	  generally	  good	  agreement	  between	  the	  examiners	  and	  the	  mean	  nodule	  count	  
(Tables	   3–24,	   3–25	   and	   3–26)	   was	   used	   for	   statistical	   analysis	   to	   increase	  
reliability.	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Table	  3-­‐24.	  Mean	  number	  of	  nodules	  present	  after	  21	  days	  of	  exposure	  for	  each	  cell	  line	  at	  
each	  VEGFR1	  inhibitor	  concentration.	  
Cell	  line	   Observer	   Control	   0.01μM	   0.1μM	   1μM	   10μM	  
HOB2	   1	   2	   0	   2	   1	   1	  
2	   1	   0	   2	   2	   0	  
Mean	   1.5	   0	   2	   1.5	   0.5	  
HOB3	   1	   1	   0	   1	   0	   0	  
2	   0	   0	   1	   0	   0	  
Mean	   0.5	   0	   1	   0	   0	  
HOB5	   1	   2	   0	   3	   0	   0	  
2	   0	   0	   3	   0	   0	  
Mean	   1	   0	   3	   0	   0	  
	  
Table	  3-­‐25.	  Mean	  number	  of	  nodules	  present	  after	  21	  days	  of	  exposure	  for	  each	  cell	  line	  at	  
each	  VEGFR2	  inhibitor	  concentration.	  
Cell	  line	   Observer	   Control	   0.001μM	   0.01μM	   0.1μM	   1μM	  
HOB2	   1	   0	   3	   2	   2	   4	  
2	   0	   4	   2	   0	   3	  
Mean	   0	   3.5	   2	   1	   3.5	  
HOB3	   1	   2	   0	   0	   0	   0	  
2	   3	   0	   0	   0	   0	  
Mean	   2.5	   0	   0	   0	   0	  
HOB5	   1	   2	   0	   0	   0	   0	  
2	   1	   0	   0	   0	   0	  
Mean	   1.5	   0	   0	   0	   0	  
	  
Table	  3-­‐26.	  Mean	  number	  of	  nodules	  present	  after	  21	  days	  of	  exposure	  for	  each	  cell	  line	  at	  
each	  dual	  VEGFR1/R2	  inhibitor	  concentration.	  
Cell	  line	   Observer	   Control	   0.01μM	   0.1μM	   0.5μM	   1μM	  
HOB2	   1	   1	   0	   0	   2	   0	  
2	   0	   0	   0	   3	   0	  
Mean	   0.5	   0	   0	   2.5	   0	  
HOB3	   1	   1	   0	   0	   0	   1	  
2	   2	   1	   0	   0	   1	  
Mean	   1.5	   0.5	   0	   0	   1	  
HOB5	   1	   0	   0	   0	   0	   0	  
2	   0	   0	   0	   0	   0	  
Mean	   0	   0	   0	   0	   0	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3.2.3.1 Statistical	  analysis	  
Two-­‐tailed	  paired	  t-­‐tests	  were	  performed	  to	  identify	  any	  differences	  in	  the	  mean	  
number	  of	  nodules	  formed	  by	  the	  untreated	  HOB	  controls	  and	  the	  mean	  number	  
of	   nodules	   formed	   by	   HOBs	   treated	   with	   each	   VEGFR	   inhibitor	   at	   each	  
concentration.	  	  There	  was	  a	  significant	  difference	  (-­‐0.83,	  95%	  CI	  -­‐1.550	  to	  -­‐0.116,	  
p=0.0377)	   between	   the	   mean	   number	   of	   nodules	   present	   for	   controls	   and	   the	  
mean	  number	  of	   nodules	  present	   after	   exposure	   to	   the	  highest	   dose	   (10	  μM)	  of	  
VEGFR1	   inhibitor	   at	   21	   days	   (Table	   3–27).	   There	   were	   no	   other	   significant	  
differences	   identified	   between	   untreated	   controls	   and	   the	   mean	   number	   of	  
nodules	  formed	  at	  any	  other	  concentrations	  for	  any	  of	  the	  inhibitors	  (Tables	  3–27,	  
to	  3–29).	  	  Photographs	  were	  taken	  from	  a	  representative	  area	  of	  each	  slide	  using	  a	  
Leica	  CTR5000b	  microscope	  (Leica	  Microsystems,	  Wetzlar)	  with	  Spot	  RT	  camera	  
and	  software.	  	  A	  photograph	  was	  also	  taken	  of	  a	  scale	  bar	  at	  the	  same	  objective.	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3.2.3.2 Nodule	  Formation:	  VEGFR1	  inhibitor	  
	  
	  
Figure	  3-­‐16.	  	  Graph	  showing	  the	  mean	  number	  of	  nodules	  observed	  by	  two	  independent	  




Table	  3-­‐27.	  Two-­‐tailed	  paired	  t	  tests	  for	  differences	  between	  the	  mean	  number	  of	  nodules	  
formed	   by	   untreated	   controls	   and	   the	  mean	   number	   of	   nodules	   formed	   by	   HOBs	   treated	  





Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0	   0.01	   -­‐1.0	   0.500	   -­‐2.242	  to	  0.242	   No	   0.0742	  
0	   0.1	   1.0	   0.866	   -­‐1.151	  to	  3.151	   No	   0.1835	  
0	   1	   -­‐0.50	   0.500	   -­‐1.742	  to	  0.742	   No	   0.2254	  
0	   10	   -­‐0.83	   0.289	   -­‐1.550	  to	  -­‐0.116	   Yes	   0.0377	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Figure	  3-­‐17.	  	  ARS	  and	  alkaline	  phosphatase	  staining	  at	  21	  days	  of	  culture	  (scale	  bar	  100	  μM)	  
HOB2	   cell	   culture	   exposed	   to	   VEGFR1	   inhibitor	   at	   different	   concentrations:	   A=0.01	   μM,	  
B=0.1	  μM,	  C=1	  μM,	  D=10	  μM,	  E=control	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3.2.3.3 Nodule	  Formation:	  VEGFR2	  Inhibitor	  
	  
	  
Figure	  3-­‐18.	  Graph	  showing	  the	  mean	  number	  of	  nodules	  observed	  by	  two	  independent	  




Table	  3-­‐28.	  Two-­‐tailed	  paired	  t	  tests	  for	  differences	  between	  the	  mean	  number	  of	  nodules	  
formed	   by	   untreated	   controls	   and	   the	  mean	   number	   of	   nodules	   formed	   by	   HOBs	   treated	  





Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0	   0.001	   -­‐0.1667	   3.215	   -­‐8.152	  to	  7.819	   No	   0.9366	  
0	   0.01	   -­‐0.6667	   2.363	   -­‐6.536	  to	  5.203	   No	   0.6734	  
0	   0.1	   -­‐1.0	   1.803	   -­‐5.478	  to	  3.478	   No	   0.4380	  
0	   1.0	   -­‐0.1667	   3.215	   -­‐8.152	  to	  -­‐7.819	   No	   0.9366	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Figure	  3-­‐19.	  ARS	  and	  alkaline	  phosphatase	  staining	  at	  21	  days	  of	  culture	  (scale	  bar	  100	  μM)	  
HOB2	   cell	   culture	   exposed	   to	   VEGFR2	   inhibitor	   at	   different	   concentrations:	   A=0.001	   μM,	  
B=0.01	  μM,	  C=0.1	  μM,	  D=1	  μM,	  E=control	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3.2.3.4 Nodule	  Formation:	  VEGFR1/VEGFR2	  Inhibitor	  
	  
	  
Figure	  3-­‐20.	  Graph	  showing	  the	  mean	  number	  of	  nodules	  observed	  by	  two	  independent	  




Table	  3-­‐29.	  Two-­‐tailed	  paired	  t	  tests	  for	  differences	  between	  the	  mean	  number	  of	  nodules	  
formed	   by	   untreated	   controls	   and	   the	  mean	   number	   of	   nodules	   formed	   by	   HOBs	   treated	  





Mean	  diff.	   SD	  of	  diff.	   95%	  CI	  of	  diff.	   Sig.	   	  P	  value	  
0	   0.01	   -­‐0.500	   0.500	   -­‐1.742	  to	  0.7421	   No	   0.2254	  
0	   0.1	   0.667	   0.7638	   -­‐2.564	  to	  1.231	   No	   0.2697	  
0	   0.5	   1.667	   1.756	   -­‐4.195	  to	  4.529	   No	   0.8845	  
0	   1.0	   -­‐0.333	   0.2887	   -­‐1.050	  to	  0.3838	   No	   0.1835	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Figure	  3-­‐21.	  ARS	  and	  alkaline	  phosphatase	  staining	  at	  21	  days	  of	  culture	  (scale	  bar	  100μM)	  
HOB2	  cell	  culture	  exposed	  to	  VEGFR1/R2	  inhibitor	  at	  different	  concentrations:	  A=0.01	  μM,	  
B=0.1	  μM,	  C=0.5	  μM,	  D=1	  μM,	  E=control.	  	  Haematoxylin	  counterstaining	  is	  seen	  in	  well	  E.	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3.3 Immunofluorescence	  
The	  mineralisation	   assay	   supported	   a	   role	   for	   VEGFR1	   in	   osteoblast	  maturation	  
and	  mineralisation.	   The	   purpose	   of	   the	   immunofluorescence	   experiment	  was	   to	  
investigate	  the	  effects	  of	  the	  potent	  bisphosphonate,	  ZA,	  on	  VEGFR1	  expression	  by	  
human	  alveolar	  osteoblasts.	   	  The	   inhibitory	  mechanism	  was	  also	   investigated	  by	  
exposing	   osteoblasts	   to	   different	   combinations	   of	   ZA,	   VEGF	   and	   the	   MVP	  
metabolite	  GGOH.	  	  Immunofluorescence	  and	  confocal	  microscopy	  were	  selected	  as	  
a	  means	   of	   visualising	   the	   location	   of	   VEGFR1	   based	   on	   the	   hypothesis	   that	   ZA	  
would	   inhibit	   the	   MVP,	   leading	   to	   an	   increase	   in	   intracellular	   VEGFR1	  
accumulation.	   	   An	   immunofluorescence	   protocol	   for	   VEGFR1	   was	   established	  
using	  the	  HOB4	  cell	  line	  cultured	  in	  mineralisation	  media	  on	  8-­‐well	  chamber	  slides	  
and	  treated	  at	  80-­‐90%	  confluence	  with	  ZA	  10	  μM	  for	  48	  h.	  	  The	  VEGFR1	  antibody	  
ab32152	   (Sapphire	   Bioscience/Abcam)	   was	   selected	   at	   a	   concentration	   of	   0.54	  





Figure	  3-­‐22.	  	  HOB4	  exposed	  to	  ZA	  10	  μM	  for	  48	  h	  and	  fixed	  in	  acetone.	  The	  slide	  depicted	  in	  
the	   left	   image	   (a)	   was	   treated	   with	   VEGFR1	   antibody	   and	   Alexa	   Fluor	   488	   secondary	  
antibody,	  while	   the	  slide	  on	   the	  right	   (b)	  was	   treated	  with	  an	   IgG	  control	  and	  Alexa	  Fluor	  
488	  secondary	  antibody	  (Scale	  bar	  =	  50	  μM).	  	  Positive	  staining	  for	  slide	  (a)	  compared	  with	  
negative	   staining	   for	   slide	   (b)	   confirms	   the	   specificity	   of	   the	   VEGFR1	   antibody	   for	   the	  
protein	  of	  interest	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3.3.1.1 Treatment	  1:	  Media	  and	  PBS	  
	  
	  
Figure	   3-­‐23.	   Images	   taken	   with	   a	   Zeiss	   LSM	   710	   confocal	   laser	   scanning	   microscope	   of	  
immunofluorescence	   for	   VEGFR1	   on	   human	   alveolar	   osteoblasts	   (1a=HOB2,	   1b=HOB3,	  
1c=HOB5)	  cultured	  in	  osteoblast	  mineralisation	  media	  and	  a	  PBS	  control	  carrier	  for	  48	  hrs.	  	  
Image	  1d	  is	  the	  IgG	  control	  (HOB2).	  	  Scale	  bar=50	  μm.	  
	  
VEGFR1	   protein	   expression	   by	   HOBs	   was	   positively	   identified	   using	  
immunofluorescence	   and	   confocal	   microscopy.	   	   Alexafluor488	   staining	   (green)	  
was	   consistently	   absent	   from	   the	   IgG	   control,	   thus	   validating	   the	  
immunofluorescence	   protocol	   and	   specificity	   for	   VEGFR1.	   	   In	   this	   qualitative	  
analysis,	   although	   variation	   in	   protein	   expression	   was	   observed	   between	   the	  
different	   treatments,	   it	   was	   also	   evident	   between	   the	   three	   cultures	   for	   each	  
treatment	   (HOB2,	   HOB3	   and	   HOB5).	   	   It	   was	   not	   possible	   to	   distinguish	   with	  
certainty	   between	   VEGFR1	   protein	   intracellular	   accumulation	   and	   peripheral	  
location	  in	  the	  cell	  membrane.	  	  However,	  a	  ‘speckled’	  appearance	  characteristic	  of	  
	   103	  
intracellular	   accumulation	   was	   visible	   for	   treatment	   3	   (media,	   VEGF	   and	   ZA),	  
treatment	  4	  (media,	  VEGF,	  ZA	  and	  GGOH),	  treatment	  6	  	  (media,	  ZA	  and	  GGOH)	  and	  
treatment	  8	  (media,	  GGOH	  and	  VEGF)	  (Figures	  3–25,	  3–26,	  3–28,	  3–30).	  
3.3.1.2 Treatment	  2:	  Media	  and	  VEGF	  
	  
	  
Figure	   3-­‐24.	   	   Images	   taken	   with	   a	   Zeiss	   LSM	   710	   confocal	   laser	   scanning	   microscope	   of	  
immunofluorescence	   for	   VEGFR1	   on	   human	   alveolar	   osteoblasts	   (2a=HOB2,	   2b=HOB3,	  
2c=HOB5)	  cultured	  in	  osteoblast	  mineralisation	  media	  and	  VEGF	  for	  48	  hours.	   	  Image	  2d	  is	  
the	  IgG	  control	  (HOB2).	  Scale	  bar=50	  μm.	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3.3.1.3 Treatment	  3:	  Media,	  VEGF	  and	  ZA	  
	  
	  
Figure	   3-­‐25.	   	   Images	   taken	   with	   a	   Zeiss	   LSM	   710	   confocal	   laser	   scanning	   microscope	   of	  
immunofluorescence	   for	   VEGFR1	   on	   human	   alveolar	   osteoblasts	   (3a=HOB2,	   3b=HOB3,	  
3c=HOB5)	  cultured	  in	  osteoblast	  mineralisation	  media,	  VEGF	  and	  ZA	  for	  48	  hrs.	  	  Image	  3d	  is	  
the	  IgG	  control	  (HOB2).	  Scale	  bar=50	  μm.	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3.3.1.4 Treatment	  4:	  	  Media,	  VEGF,	  ZA	  and	  GGOH	  
	  
	  
Figure	   3-­‐26.	   	   Images	   taken	   with	   a	   Zeiss	   LSM	   710	   confocal	   laser	   scanning	   microscope	   of	  
immunofluorescence	   for	   VEGFR1	   on	   human	   alveolar	   osteoblasts	   (4a=HOB2,	   4b=HOB3,	  
4c=HOB5)	   cultured	   in	   osteoblast	   mineralisation	   media,	   VEGF,	   ZA	   and	   GGOH	   for	   48	   hrs.	  	  
Image	  4d	  is	  the	  IgG	  control	  (HOB2).	  Scale	  bar=50	  μm.	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3.3.1.5 Treatment	  5:	  Media	  and	  ZA	  
	  
	  
Figure	   3-­‐27.	   	   Images	   taken	   with	   a	   Zeiss	   LSM	   710	   confocal	   laser	   scanning	   microscope	   of	  
immunofluorescence	   for	   VEGFR1	   on	   human	   alveolar	   osteoblasts	   (5a=HOB2,	   5b=HOB3,	  
5c=HOB5)	  cultured	  in	  osteoblast	  mineralisation	  media	  and	  ZA	  for	  48	  hours.	  	  Image	  5d	  is	  the	  
IgG	  control	  (HOB2).	  Scale	  bar=50	  μm.	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3.3.1.6 Treatment	  6:	  Media,	  ZA	  and	  GGOH	  
	  
	  
Figure	   3-­‐28.	   	   Images	   taken	   with	   a	   Zeiss	   LSM	   710	   confocal	   laser	   scanning	   microscope	   of	  
immunofluorescence	   for	   VEGFR1	   on	   human	   alveolar	   osteoblasts	   (6a=HOB2,	   6b=HOB3,	  
6c=HOB5)	  cultured	  in	  osteoblast	  mineralisation	  media,	  ZA	  and	  GGOH	  for	  48	  hrs.	  	  Image	  6d	  is	  
the	  IgG	  control	  (HOB2).	  Scale	  bar=50	  μm.	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3.3.1.7 Treatment	  7:	  Media	  and	  GGOH	  
	  
	  
Figure	   3-­‐29.	   	   Images	   taken	   with	   a	   Zeiss	   LSM	   710	   confocal	   laser	   scanning	   microscope	   of	  
immunofluorescence	   for	   VEGFR1	   on	   human	   alveolar	   osteoblasts	   (7a=HOB2,	   7b=HOB3,	  
7c=HOB5)	  cultured	  in	  osteoblast	  mineralisation	  media	  and	  GGOH	  for	  48	  hrs.	  	  Image	  7d	  is	  the	  
IgG	  control	  (HOB2).	  Scale	  bar=50	  μm.	  
	  
	   	  
	   109	  
3.3.1.8 Treatment	  8:	  Media,	  GGOH	  and	  VEGF	  
	  
	  
Figure	   3-­‐30.	   	   Images	   taken	   with	   a	   Zeiss	   LSM	   710	   confocal	   laser	   scanning	   microscope	   of	  
immunofluorescence	   for	   VEGFR1	   on	   human	   alveolar	   osteoblasts	   (8a=HOB2,	   8b=HOB3,	  
8c=HOB5)	  cultured	  in	  osteoblast	  mineralisation	  media,	  GGOH	  and	  VEGF	  for	  48	  hrs.	  	  Image	  8d	  
is	  the	  IgG	  control	  (HOB2).	  Scale	  bar=50	  μm.	  
	  
	   	  
	   110	  
Chapter	  4	  
4 Discussion	  	  
1.7 Summary	  Statement	  	  
BRONJ	  typically	  presents	  as	  a	  non-­‐healing	  region	  of	  exposed,	  necrotic	  bone	  and	  is	  
often	  associated	  with	  tooth	  extraction	  or	  other	  oral	  trauma	  (Ruggiero	  et	  al.,	  2014,	  
Yamazaki	   et	   al.,	   2012).	   	   Successful	   treatment	   of	   any	   condition	   depends	   on	   the	  
patient’s	  own	  ability	  to	  respond	  and	  heal.	  	  BRONJ	  represents	  a	  treatment	  dilemma	  
as	   the	   initial	  presentation	  and	  response	   to	   treatment	  both	   reflect	  a	   fundamental	  
disturbance	  in	  wound	  healing.	  	  Intervention	  thus	  represents	  an	  additional	  trauma	  
that	   may	   exacerbate	   the	   lesion,	   rather	   than	   resolve	   it.	   	   Healing	   occurs	   in	   the	  
presence	   of	   an	   adequate	   vascular	   supply	   and	   VEGF	   is	   an	   essential	   ligand	   that	  
mediates	   angiogenesis	   and	   osteogenesis	   via	   specific	   receptors	   on	   target	   cells	  
(Gerber	  et	  al.,	  1999,	  Ferrara	  et	  al.,	  2003).	   	  Although	  the	  anti-­‐angiogenic	  effects	  of	  
ZA	   have	   been	   recognised	   (Wood	   et	   al.,	   2002),	   the	   inhibitory	   mechanisms	   and	  
effects	  on	  VEGF	  and	  its	  receptors	  on	  the	  different	  cell	  types	  that	  contribute	  to	  hard	  
and	   soft	   tissue	   oral	   wound	   healing	   have	   not	   been	   specifically	   characterised.	  	  
Therefore	  the	  pathogenesis	  of	  BRONJ	  is	  not	  precisely	  understood	  and	  an	  effective	  
prevention	  and	  treatment	  strategy	  remain	  elusive.	  	  
To	   contribute	   to	   the	   body	   of	   evidence	   in	   this	   field,	   this	   study	   investigated	   the	  
effects	   of	   ZA	   on	  VEGF	   receptors	   and	   the	   implications	   for	   osteoblast	   growth	   and	  
maturation.	   	  A	  contributory,	  but	  not	  essential	  role	  for	  VEGFR1	  in	  human	  alveolar	  
osteoblast	  maturation	  in	  vitro	  was	  confirmed	  and	  VEGFR1	  protein	  expression	  was	  
observed	   in	   the	   presence	   and	   absence	   of	   various	   combinations	   of	   recombinant	  
VEGF,	  ZA	  and	  the	  naturally	  occurring	  MVP	  metabolite	  GGOH.	   	  The	  significance	  of	  
these	  results	  in	  the	  context	  of	  methodological	  limitations,	  existing	  research	  in	  the	  
field	  and	  future	  directions	   for	  understanding	  BRONJ	  pathogenesis	  and	  treatment	  
mechanisms	  are	  the	  focus	  of	  this	  discussion.	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1.8 Limitations	  of	  the	  Research	  
1.8.1 Cell	  Culture	  Surface	  
The	  surface	  for	  attachment	  is	  influential	  in	  cell	  culture.	  	  Much	  of	  the	  research	  and	  
development	  in	  implant	  dentistry	  is	  directed	  at	  designing	  an	  implant	  surface	  that	  
encourages	   osteoblast	   attachment	   and	   healing	   with	   intimate	   bone	   to	   implant	  
contact	   (Albrektsson	   et	   al.,	   1981,	   Le	   Guéhennec	   et	   al.,	   2007,	   Buser	   et	   al.,	   1991,	  
Wennerberg	   and	   Albrektsson,	   2009).	   	   Although	   the	   bone	   microenvironment	   in	  
vivo	   does	   not	   directly	   reflect	   this	   in	   vitro	   study,	   it	   demonstrates	   that	   human	  
alveolar	   osteoblasts	   require	   a	   suitable	   culture	   surface	   for	   attachment	   and	  
mineralised	   nodule	   formation.	   	   Certain	   culture	   surfaces	   have	   been	   shown	   to	  
accelerate	  and	  promote	  nodule	   formation,	  even	   in	   the	  absence	  of	   the	  osteogenic	  
differentiation	   factors	   dexamethasone	   and	   β-­‐glycerophosphate	   (Gough	   et	   al.,	  
2004).	   	   Cell	   culture	   for	   the	   mineralisation	   assay	   was	   conducted	   on	   a	   different	  
surface	   compared	   with	   the	   nodule	   formation	   and	   immunofluorescence	  
experiments.	   	   The	   study	   design	   for	   the	  mineralisation	   assay	  was	  most	   suited	   to	  
HOB	  culture	  in	  96-­‐well	  microplates	  that	  were	  optimised	  for	  the	  plate	  reader.	  	  This	  
allowed	  replication	  of	  the	  experimental	  conditions	  for	  endpoint	  assessment	  of	  ARS	  
dye	  to	  quantitate	  the	  deposition	  of	  calcium.	   	   It	  also	  allowed	  most	  efficient	  use	  of	  
resources	   over	   the	   21	   and	   28	   days	   of	   culture.	   	   The	   Nunc	   96-­‐well	   culture	  
microplates	   were	   fabricated	   from	   Nunclon	   Delta	   cell	   culture	   treated	   clear	  
polystyrene.	   	   The	   Nunclon	   Delta	   surface	   treatment	   increased	   the	   surface	  
hydrophilicity	   to	   allow	   osteoblast	   attachment	   to	   an	   otherwise	   hydrophobic	  
material	   	   (Cat	   No.	   NUNC-­‐167008,	   Thermo	   Fisher	   Scientific).	   	   In	   contrast,	   HOBs	  
were	  cultured	  on	  8-­‐well	  chamber	  slides	  with	  a	  treated	  glass	  surface	  for	  the	  nodule	  
formation	   and	   immunofluorescence	   experiments	   (Cat	   No.	   12-­‐565-­‐8,	   Thermo	  
Fisher	  Scientific).	   	  The	  removable	  well	   sides,	   larger	  surface	  area	  and	  ease	  of	  use	  
with	   the	  microscope	  meant	   they	  were	   ideally	  suited	  to	   these	  protocols.	   	  Calcium	  
deposition	  and	  nodule	  formation	  experiments	  should	  ideally	  be	  conducted	  on	  the	  
same	  cell	  culture	  surface	  to	  minimise	  the	  potential	  influence	  of	  surface	  roughness,	  
chemistry	  and	  energy	   (Anselme,	  2000)	  on	  attachment,	   adherence	  and	  spreading	  
(Webb	  et	  al.,	  2000).	   	  The	  effect	  of	  these	  different	  surfaces	  may	  result	  in	  different	  
cell	  behaviour	  and	  needs	  to	  be	  defined	  for	  standardisation	  of	  future	  experiments.	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1.8.2 Number	  of	  Biological	  Replicates	  	  
The	  present	  experiment	  used	  repeated	  measures	  from	  three	  biological	  replicates:	  
HOB2,	  HOB3	  and	  HOB5.	  	  The	  different	  growth	  rates	  and	  the	  observed	  differences	  in	  
media	  utilisation	  under	   the	  same	  culture	  conditions	  demonstrated	   the	  biological	  
variation	   present	   between	   the	   cell	   cultures.	   	   All	   cultures	   were	   plated	   between	  
passage	  5	  and	  passage	  7.	  	  The	  ARS	  optical	  density	  readings	  were	  normalised	  as	  a	  
percentage	   of	   an	   untreated	   control	   for	   each	   culture	   prior	   to	   statistical	   analysis.	  	  
Two-­‐tailed	   paired	   t-­‐tests	   were	   used	   to	   analyse	   the	   repeated	   measures	  
mineralisation	   and	   nodule	   formation	   data.	   	   The	   nodule	   data	   was,	   however	  
represented	   graphically,	   by	   HOB	   culture,	   to	   show	   the	   extent	   of	   the	   variation	  
present.	   	   Although	   including	   a	   greater	   number	   of	   cell	   cultures	   would	   have	  
increased	  the	  external	  validity	  of	  the	  results,	  a	  balance	  has	  been	  sought	  between	  
delivering	  a	  valid	  outcome	  for	  this	  exploratory	  study	  and	  exhausting	  the	  resources	  
available.	  
1.8.3 Cell	  Source	  for	  in	  vitro	  Analysis	  
This	   study	   compares	   favourably	  with	   in	   vitro	   studies	   in	   this	   field	   as	   the	   human	  
alveolar	  osteoblasts	  were	  derived	  from	  healthy	  adult	  females	  undergoing	  routine	  
third	  molar	  removal.	   	  Possible	  age-­‐related	  changes	   in	  osteoblast	  cell	  growth	  and	  
differentiation	   (Martinez	   et	   al.,	   1999)	   were	   minimised	   by	   limiting	   the	   study	  
population	  to	  premenopausal	  women	  between	  18	  and	  45	  years	  of	  age.	  	  The	  third	  
molar	  region	  of	  the	  mandible	  was	  not	  only	  a	  convenient	  source	  of	  incidental	  bone	  
removal	  in	  the	  dental	  setting;	  there	  is	  evidence	  for	  phenotypic	  variation	  between	  
osteoblasts	   from	  different	   skeletal	   sites	   such	   as	   the	  mandible	   and	   the	   iliac	   crest	  
(Kasperk	  et	  al.,	  1995).	   	  Primary	  human	  osteoblasts	  derived	  from	  the	  mandibular	  
alveolar	   bone	  of	   healthy	   adult	  women	   represent	   a	  more	   appropriate	   cell	   source	  
than	  animals	  (Tan	  et	  al.,	  2010)	  or	  alternative	  skeletal	  sites	  (Mayer	  et	  al.,	  2005)	  and	  
are	  consistent	  in	  site	  and	  number	  of	  patients	  with	  human	  studies	  in	  this	  field	  (Hah	  
et	   al.,	   2011).	   	  However,	   this	  was	   an	   in	  vitro	  study	  performed	   in	   cell	   culture	   and	  
cannot	  be	  generalised	  to	  a	  clinical	  situation	  without	  further	  validation.	  	  In	  reality,	  
the	  risk	  for	  BRONJ	  is	  greatest	  in	  medically	  compromised	  patients	  (Ruggiero	  et	  al.,	  
2014).	   	   Clinical	   presentation	   is	   influenced	   by	   many	   factors	   including	   existing	  
health	  problems,	  the	  ZA	  dose	  in	  the	  bone	  microenvironment	  and	  the	  presence	  of	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trauma	   or	   pre-­‐existing	   infection	   (Vahtsevanos	   et	   al.,	   2009,	   Woo	   et	   al.,	   2006,	  
Ruggiero	  et	  al.,	  2014).	   	  The	  purpose	  of	  in	  vitro	  experimental	  work	  is	  to	  provide	  a	  
platform	   for	   further	   large-­‐scale	   investigation	   into	   potential	   pathogenic	  
mechanisms	   and	   to	   provide	   evidence	   to	   support	   ongoing	   research	   into	   possible	  
therapeutic	  agents.	  	  The	  present	  study	  fulfils	  this	  purpose.	  
1.8.4 Immunofluorescence	  and	  Confocal	  Microscopy	  
Confocal	   microscopy	   provided	   an	   optical	   slice	   through	   the	   sample	   and	  
immunofluorescence	  allowed	  the	  antigen	  of	  interest	  (VEGFR1)	  to	  be	  identified.	  	  It	  
was	  not	  possible	  to	  distinguish	  with	  certainty	  in	  the	  present	  experiment	  between	  
intracellular	   localisation	   (endoplasmic	   reticulum	   or	   cytoplasm)	   and	   membrane	  
anchorage	  (external	  position	  or	  internalisation)	  of	  VEGFR1.	  	  The	  balance	  between	  
pinhole	   size	   and	   the	   intensity	   of	   the	   excitation	   light	   could	   have	   been	   better	  
optimised	  to	  achieve	  a	  sharper,	  more	  defined,	  image.	  	  Basi	  et	  al.	  	  (2010)	  used	  flow	  
cytometry	   to	   specifically	   detect	   immunoreactive	   VEGFR2	   protein	   on	   the	   cell	  
surface.	   	  This	  group	  also	  determined	  the	  number	  of	   fluorescent	  pixels	  per	  cell	   to	  
quantitatively	  analyse	  the	  confocal	   images.	   	  Equivalent	  protocols	  for	  the	  VEGFR1	  
receptor	  should	  be	  employed	  in	  future	  experiments	  to	  minimise	  bias	  and	  provide	  
a	  more	  objective	  means	  of	  analysis.	  	  
1.8.5 Reagent	  Concentrations	  
The	  ZA	  concentration	  in	  the	  bone	  microenvironment	  in	  vivo	  is	  not	  known.	  	  Organ	  
specificity	  of	  a	  drug	  is	  an	  important	  determinant	  of	  biological	  effectiveness	  and	  the	  
bisphosphonates’	   generic	   structure	   consists	   of	   a	   stable	   P-­‐C-­‐P	   bond	   and	   an	   -­‐OH	  
bone	  hook	  that	  promotes	  attachment	  to	  HA.	  	  This	  gives	  rise	  to	  rapid	  accumulation	  
in	   bone	   and,	   in	   contrast	   to	   plasma	   and	   soft	   tissues,	   bisphosphonates	   have	   a	  
cumulative	   effect	   and	   long	   half-­‐life	   in	   this	   tissue	   (Kasting	   and	   Francis,	   1992,	  
Fleisch,	   1998,	   Woo	   et	   al.,	   2006,	   Grey	   et	   al.,	   2010).	   	   Epidemiological	   evidence	  
suggests	  that	  total	  cumulative	  dose	  may	  be	  a	  significant	  factor	  in	  the	  development	  
of	  BRONJ	  (Hoff	  et	  al.,	  2011,	  Woo	  et	  al.,	  2006).	  	  The	  inhibitory	  effect	  on	  resorption	  
occurs	   when	   bisphosphonates	   are	   released	   from	   the	   bone	   surface	   during	  
resorption	  and	  are	   taken	  up	  by	  osteoclasts	   (Coxon	  et	   al.,	   2008).	   	  Availability	   for	  
uptake	   by	   other	   cell	   types,	   such	   as	   osteoblasts,	   is	   therefore	   under	   complex	  
osteoclast-­‐bisphosphonate	  mediated	   regulation.	   	   Injury	   or	   tooth	   extraction	  may	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lead	  to	  a	  local	  increase	  in	  osteoclast	  recruitment	  and	  activity	  and	  a	  corresponding	  
increase	  in	  local	  bisphosphonate	  concentration.	  	  Based	  on	  this	  concept	  it	  has	  been	  
hypothesised	   that	   the	   resulting	   high	   local	   concentration	   of	   bisphosphonates	  
would	  be	  toxic	  to	  the	  adjacent	  soft	  tissues	  comprising	  the	  oral	  mucosa.	   	  This	  soft	  
tissue	   toxicity	   was	   proposed	   to	   be	   the	   cause	   of	   underlying	   bone	   exposure	   and	  
necrosis	  in	  BRONJ	  (Reid	  et	  al.,	  2007).	  	  Although	  current	  evidence	  supports	  a	  more	  
complex	   multifactorial	   pathogenesis	   (Ruggiero	   et	   al.,	   2014),	   this	   demonstrates	  
that	   the	   local	   in	   vivo	   bisphosphonate	   concentration	   may	   be	   variable	   and	   the	  
concentration	   at	   which	   the	   different	   surrounding	   cell	   types	   are	   affected	   is	   not	  
known.	   	  Despite	   this	   limitation,	   the	   concentration	  of	   ZA	   (10	  μM)	  was	   consistent	  
with	  other	  in	  vitro	  studies	  and	  with	  maintenance	  of	  cellular	  viability	  according	  to	  
an	  established	  dose-­‐response	  curve	  (Zafar,	  2014).	  	  Unlike	  ZA,	  GGOH	  is	  a	  naturally	  
occurring	  MVP	   constituent	   and	   adverse	   concentration-­‐dependent	   effects	   are	  not	  
known.	  	  The	  GGOH	  concentration	  was	  the	  same	  as	  that	  used	  in	  previous	  studies	  on	  
the	  inhibitory	  effects	  of	  ZA	  (Zafar	  et	  al.,	  2014).	  	  In	  this	  context,	  appropriate	  in	  vitro	  
doses	  of	  both	  ZA	  and	  GGOH	  were	  used.	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1.9 Significance	  of	  the	  Results	  
1.9.1 Functional	  Effects	  of	  VEGFR1	  and	  VEGFR2	  Inhibition	  
A	  non-­‐healing	  oral	  lesion	  with	  exposed,	  necrotic	  bone	  is	  pathognomonic	  for	  BRONJ	  
in	   a	   patient	   undergoing	   bisphosphonate	   therapy.	   	   Healing	   is	   a	   complex	   and	   co-­‐
ordinated	   process	   that	   depends	   on	   an	   adequate	   blood	   supply	   to	   deliver	  
inflammatory	   cells,	   progenitor	   cells,	   growth	   factors	   and	  nutrients	   to	   the	  wound.	  	  
The	  physicochemical	  effects	  of	  the	  bisphosphonates	  as	  calcium	  chelating	  agents	  in	  
solution	  are	  insufficient	  to	  explain	  the	  disturbance	  in	  bone	  matrix	  formation	  and	  
mineralisation	  in	  BRONJ.	   	  VEGF	  is	  a	  key	  regulatory	  growth	  factor	  in	  angiogenesis	  
and	   osteogenesis	   (Ferrara	   et	   al.,	   2003,	   Gerber	   et	   al.,	   1999).	   Previous	   in	   vitro	  
studies	   of	   human	   gingival	   fibroblasts	   and	   human	   alveolar	   osteoblasts	   have	  
demonstrated	  the	  upregulation	  of	  VEGF	  mRNA	  and	  protein	  in	  the	  presence	  of	  ZA	  
(Zafar,	   2014,	   Zafar	   et	   al.,	   2014).	   	   The	   functional	   effects	   of	   VEGF	   mRNA	  
upregulation	   will	   ultimately	   depend	   on	   the	   presence	   and	   activity	   of	   mediating	  
VEGF	   receptors	   (Ferrara	   et	   al.,	   2003).	   	   Osteoblasts	   express	   both	   VEGFR1	   and	  
VEGFR2,	  which	  bind	   the	  VEGF	   ligand.	   	  The	  objective	  of	   the	  mineralisation	  assay	  
was	   to	   determine	   the	   functional	   effects	   of	   VEGFR1	   and	   VEGFR2	   inhibition	   in	  
human	  alveolar	  osteoblasts.	  
1.9.1.1 Mineralisation	  at	  21	  Days	  
Exposure	   to	   a	   VEGFR1	   inhibitor	   resulted	   in	   a	   statistically	   significant	   dose	  
dependent	  decrease	  in	  calcium	  deposition	  by	  HOBs	  after	  21	  days	  of	  culture.	  	  This	  
relationship	   was	   not	   observed	   in	   the	   presence	   of	   a	   specific	   VEGFR2	   inhibitor.	  	  
Although	   the	   graphed	   linear	   regression	   data	   for	   the	   dual	   VEGFR1/VEGFR2	  
inhibitor	   appeared	   to	   follow	   an	   inhibitory	   trend,	   the	   dose-­‐response	   was	   not	  
statistically	   significant	   (p=0.057).	   	   However,	   at	   the	   0.1	   μM	   and	   1	   μM	   doses	   of	  
VEGFR1/R2	   inhibitor,	   ARS	   levels	   were	   significantly	   down-­‐regulation	   compared	  
with	   the	   control.	   	   In	   light	  of	   these	   results,	   this	  was	   the	   first	   study	   to	   specifically	  
demonstrate	  VEGFR1	  as	  the	  receptor	  of	  interest	  mediating	  calcium	  deposition	  via	  
the	  VEGF	  ligand	  by	  human	  alveolar	  osteoblasts.	  	  	  
The	  HOBs	  were	  cultured	  in	  osteoblast	  mineralisation	  media	  and	  were	  not	  exposed	  
to	  exogenous/recombinant	  VEGF.	   	   In	   line	  with	  our	   first	  hypothesis,	   these	  results	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support	  a	  role	   for	  autogenously	  produced	  VEGF	   in	  osteoblast	  differentiation	  and	  
maturation	   mediated	   by	   VEGFR1	   and	   are	   consistent	   with	   other	   studies	   in	   this	  
field.	   	   Mayer	   et	   al.	   (2005)	   demonstrated	   an	   in	   vitro	   increase	   in	   VEGF	   protein	  
expression	   by	   hTBCs	   (human	   mesenchymal	   stem	   cells	   from	   trabecular	   bone)	  
during	  mineralisation.	  	  The	  hTBCs	  were	  derived	  from	  osteoporotic	  female	  patients	  
undergoing	  hip	  replacement	  surgery	  (age	  range	  50-­‐80	  years)	  and	  were	  therefore	  
phenotypically	  distinct	  from	  the	  alveolar	  osteoblasts	  in	  the	  present	  study.	  	  Mayer	  
et	   al.	   (2005)	  also	   showed	  mRNA	  upregulation	   for	  VEGF	   (isoforms	  121	  and	  165)	  
and	   VEGFR1	   under	   hypoxic	   conditions.	   	   Hypoxia	   is	   characteristic	   of	   the	   early	  
stages	  of	   tissue	   injury	  and	  has	  been	  shown	  to	  have	  an	  essential	  role	   in	   initiating	  
the	   vascular	   response	   in	  wound	   healing	   (Street	   et	   al.,	   2000,	   Street	   et	   al.,	   2002).	  
The	   present	   study	   supports	   these	   findings	   in	   HOBs	   by	   providing	   functional	  
evidence	  for	  the	  role	  of	  VEGF,	  via	  VEGFR1	  in	  calcium	  deposition.	  	  Like	  hypoxia,	  ZA	  
also	  leads	  to	  an	  in	  vitro	  pro-­‐angiogenic	  drive	  and	  VEGF	  upregulation	  (Zafar,	  2014,	  
Zafar	  et	  al.,	  2014).	  	  This	  may	  represent	  a	  direct	  effect	  of	  ZA	  on	  VEGF,	  or	  an	  indirect	  
response	   of	   VEGF	   to	   downstream	   inhibition	   in	   key	   wound	   healing	   pathways.	  	  
Unlike	  hypoxia,	  the	  biological	  effects	  of	  VEGF	  upregulation	  are	  not	  realised	  in	  ZA	  
treated	   osteoblasts	   and	   indicate	   that	   the	   relevant	   VEGF-­‐VEGFR	   pathway	   is	   not	  
biologically	  activated.	  
Hah	  et	  al.	  also	  provided	  some	  in	  vitro	  functional	  evidence	  for	  VEGFR1	  as	  the	  main	  
mediating	   receptor	   for	   VEGF	   in	   osteoblast	   differentiation.	   	   Cultured	   human	  
periosteal-­‐derived	   cells	  were	   exposed	   to	   either	   a	   specific	  VEGFR2	   inhibitor	   or	   a	  
dual	  VEGFR1/VEGFR2	  inhibitor	   for	  21	  days	  prior	  to	  analysis.	   	  The	  dual	   inhibitor	  
was	  associated	  with	  a	  decrease	  in	  ALP	  and	  mineralisation,	  whereas	  no	  effect	  was	  
observed	   for	   the	  VEGFR2	   inhibitor	   (Hah	  et	   al.,	   2011).	   	  This	   represents	   a	   shift	   in	  
emphasis	   from	  VEGFR2,	   and	   the	   new	   emergence	   of	   a	   specific	   VEGFR1	   inhibitor	  
has	  allowed	  the	  functional	  effects	  of	  each	  receptor	  to	  be	  evaluated	  independently	  
in	   culture.	   	  The	  present	  experiment	  used	   the	   same	  dual	   inhibitor	   (KRN	  633),	   an	  
alternative	  VEGFR2	   inhibitor	   (ZM	  323881)	   and	   a	   specific	  VEGFR1	   inhibitor	   (ZM	  
306416)	   to	   investigate	   the	   hypothesis	   that	   VEGFR1	   was	   the	   main	   receptor	   of	  
interest	  in	  VEGF	  mediated	  osteoblast	  mineralisation	  and	  maturation.	   	  A	  potential	  
criticism	   of	   this	   study	  was	   the	   use	   of	   different	   doses	   for	   each	   of	   the	   inhibitors.	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However,	  it	  was	  necessary	  to	  work	  within	  the	  range	  of	  activity	  for	  each	  individual	  
inhibitor	  as	  indicated	  by	  the	  different	  IC50	  values	  (ZM	  306416	  IC50	  =	  330	  nM,	  ZM	  
323881	  IC50	  =	  <2nM,	  KRN	  633	  IC50	  =	  170nM/160nM)	  and	  the	  dose	  ranges	  were	  
also	  informed	  by	  previous	  dose-­‐response	  experiments	  (Antczak	  et	  al.,	  2012,	  Xiao	  
et	  al.,	  2007,	  Hah	  et	  al.,	  2011).	  	  In	  contrast	  to	  Hah	  et	  al.	  (2011),	  the	  strength	  of	  the	  
present	  experiment	  was	  in	  using	  a	  specific	  VEGFR1	  inhibitor	  as	  a	  direct	  measure	  
of	  this	  receptor’s	  functional	  effects.	  
1.9.1.2 Mineralisation	  at	  28	  Days	  
A	   dose-­‐dependent	   relationship	   between	   the	   VEGFR1	   inhibitor	   and	   calcium	  
deposition	  was	   observed	   after	   28	   days.	   	   Visually,	   the	   graphed	   linear	   regression	  
data	  for	  the	  dual	  VEGFR1/VEGFR2	  inhibitor	  appeared	  to	  support	  a	  dose-­‐response	  
relationship	   for	   the	  HOB2	   and	  HOB3	   cultures.	   	   This	   relationship	   failed	   to	   reach	  
statistical	  significance	  in	  a	  one-­‐sample	  t	  test	  comparing	  the	  mean	  slope	  value	  for	  
the	  three	  cultures	  with	  a	  hypothetical	  value	  of	  zero.	  	  A	  dose	  response	  relationship	  
was	  not	  observed	  for	  the	  VEGFR2	  inhibitor	  visually	  or	  statistically.	  	  	  
The	   difference	   in	   ARS	   levels	   between	   HOBs	   treated	   with	   the	   highest	   (10	   μM)	  
VEGFR1	  dose	  and	  untreated	  controls	  was	  statistically	  significant	  and	  indicated	  an	  
inhibitory	   effect.	   	   From	   the	   graphed	   data,	   this	   appeared	   to	   be	   the	   case	   for	   the	  
highest	   dose	   of	   the	   dual	   VEGFR1/VEGFR2	   inhibitor	   (1	   μM);	   however,	   the	   two-­‐
tailed	   paired	   t	   test	   gave	   a	   95%	   CI	   that	   included	   zero	   (-­‐37.77	   to	   4.43).	   	   This	  
indicated	   that	   there	   was	   no	   statistically	   significant	   difference,	   inhibitory	   or	  
otherwise,	   between	   HOBs	   treated	  with	   the	   dual	   VEGFR1/VEGFR2	   inhibitor	   and	  
untreated	  HOB	  controls.	  	  
Although	  there	  were	  no	  other	  statistically	  significant	  differences	  detected	  between	  
ARS	   levels	   for	   any	   of	   the	   remaining	   doses	   and	   untreated	   control,	   observations	  
from	   the	   VEGFR1,	   VEGFR2	   and	   VEGFR1/VEGFR2	   inhibitor	   graphs	   at	   28	   days	  
compared	   with	   21	   days	   indicated	   that	   ARS	   levels	   almost	   always	   appeared	   to	  
exceed	  100%.	   	  A	  possible	  explanation	   is	   that	  between	  21	  and	  28	  days	  of	  culture	  
the	  capacity	  of	  controls	  under	  normal	  regulatory	  mechanisms	  to	  deposit	  calcium	  
was	   exhausted.	   	   That	   is	   to	   say,	   the	   mineralisation	   process	   was	   completed	  
efficiently	   and	   the	   HOBs	   entered	   a	   state	   of	   quiescence.	   	   Treatment	  with	   VEGFR	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inhibitors	   represented	   a	   lag	   in	   calcium	   deposition,	   rather	   than	   an	   absolute	  
inhibitory	  effect.	  	  In	  the	  absence	  of	  statistically	  significant	  inhibition,	  it	  is	  possible	  
that	  treated	  cells	  ‘caught	  up’	  between	  days	  21	  and	  28	  as	  controls	  entered	  a	  plateau	  
phase.	  	  Tissue	  retraction	  was	  characteristic	  of	  mineralised	  nodule	  formation	  at	  21	  
days	  and	  supports	   the	  concept	  of	  a	  plateau	  phase,	  as	  opposed	  to	  continuous	  cell	  
proliferation	  and	  linear	  calcium	  deposition.	  	  	  
1.9.1.3 Mineralised	  Nodule	  Formation	  
The	   present	   experiment	   aimed	   to	   examine	   the	   effects	   of	   VEGF/VEGFR	   pathway	  
inhibition	  on	  bone	  nodule	  formation	  after	  21	  days	  of	  culture.	   	  The	  significance	  of	  
this	  pathway	  to	  wound	  healing	  and	  bone	  growth	  has	  been	  investigated	  in	  vivo	  in	  a	  
dog	   model	   using	   distraction	   osteogenesis	   (Byun	   et	   al.,	   2007).	   	   The	   procedure	  
involved	   fracturing	   the	   mandibles	   of	   6	   mongrel	   dogs	   and	   installing	   distraction	  
devises	  under	  general	  anaesthesia.	  	  Seven	  days	  later	  distraction	  was	  initiated	  at	  a	  
rate	  of	  1	  mm	  per	  day	   for	  10	  days.	   	  Animals	  were	  sacrificed	  and	  VEGF	  and	  VEGF	  
receptor	  expression	  was	  investigated	  at	  7,	  14	  and	  28	  days	  post-­‐distraction	  using	  
immunohistochemistry.	   The	   results	   indicated	   that,	   in	   comparison	  with	   controls,	  
VEGF	  expression	  by	  osteoblasts	  was	  elevated	  at	  all	   time-­‐points,	  but	  decreased	  at	  
28	   days.	   	   VEGFR1	   expression	   was	   more	   pronounced	   than	   VEGFR2	   at	   all	   time-­‐
points.	   	  Both	  VEGFR1	  and	  VEGFR2	  expression	  decreased	  over	   time	  and	  VEGFR2	  
expression	   was	   not	   detected	   at	   28	   days.	   	   Neither	   VEGFR1	   nor	   VEGFR2	   were	  
expressed	   in	   un-­‐distracted	   controls.	   	   Radiographic	   evidence	   of	   new	   bone	  
formation	  in	  the	  distraction	  defect	  was	  apparent	  at	  28	  days	  and	  mature	  bone	  was	  
identified	  histologically	  at	  this	  time	  point,	  but	  not	  at	  14	  days.	   	  The	  results	  of	  this	  
study	  support	  a	  role	  for	  VEGF/VEGFR1	  in	  bone	  healing	  and	  growth	  as	  indicated	  by	  
the	   observed	   temporal	   relationship	   between	   protein	   upregulation	   and	   bone	  
formation	   (Byun	   et	   al.,	   2007).	   	   Receptor	   inhibition	   and	   specific	   functional	  
endpoints	  are	  indicated	  to	  confirm	  this	  relationship	  in	  the	  absence	  of	  mechanical	  
stimulation.	  	  The	  present	  study	  used	  nodule	  formation	  as	  a	  functional	  endpoint	  to	  
determine	   the	   specific	   effects	   of	   the	   VEGFR1	   and	   VEGFR2	   in	   human	   alveolar	  
osteoblasts.	   	  To	  minimise	  bias	  and	  the	  subjective	  nature	  of	  visual	  evaluation,	   the	  
slide	  labels	  were	  concealed	  and	  two	  different	  examiners	  who	  were	  not	  involved	  in	  
the	   staining	   were	   asked	   to	   independently	   identify	   nodules	   based	   on	   a	   pre-­‐
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determined	  set	  of	  criteria.	  	  There	  was	  good	  agreement	  between	  the	  examiners	  and	  
the	   average	   number	   of	   nodules	   identified	   per	   well	   was	   used	   to	   increase	   the	  
measurement	  reliability.	   	  The	  only	  statistically	  significant	  difference	  between	  the	  
number	  of	  nodules	  formed	  by	  controls	  and	  the	  number	  formed	  by	  treated	  HOBs	  at	  
21	  days	  of	  culture	  was	  for	  the	  highest	  concentration	  (10	  μM)	  of	  VEGFR1	  inhibitor	  
(-­‐0.83).	   	  While	  this	  does	  not	  represent	  a	  clear	  dose	  response	  relationship	  for	  the	  
VEGFR1	   inhibitor,	   it	   does	   identify	   an	   inhibitory	   effect	   on	   nodule	   formation	   by	  
human	   alveolar	   osteoblasts.	   	   This	   supports	   the	   findings	   from	   the	  mineralisation	  
assay	   and	   in	  vivo	   animal	  model	   and	   indicates	   that	   VEGFR1	   plays	   a	   contributory	  
role	   in	   both	   mineralisation	   and	   bone	   nodule	   formation	   by	   human	   alveolar	  
osteoblasts	  in	  vitro.	  	  	  
1.9.2 Mechanism	  of	  VEGFR1	  Inhibition	  by	  ZA	  and	  Role	  of	  GGOH	  
VEGF	   upregulation	   has	   been	   demonstrated	   in	   vitro	   in	   ZA	   treated	   human	  
fibroblasts	   and	   osteoblasts	   (Zafar,	   2014,	   Zafar	   et	   al.,	   2014)	   and	   the	   present	  
experiment	   provides	   evidence	   for	   the	   VEGF/VEGFR1	   pathway	   in	   osteoblast	  
mineralisation	   and	  maturation.	   	   Gene	   expression	   and	   functional	   assays	   support	  
the	   MVP	   as	   an	   intracellular	   target	   for	   N-­‐BPs.	   	   Statistically	   significant	   VEGF	  
upregulation	   was	   observed	   after	   72	   h	   of	   treatment	   with	   ZA;	   however,	   when	  
osteoblasts	   were	   treated	   with	   both	   ZA	   and	   GGOH,	   no	   such	   regulation	   was	  
observed	  (Zafar,	  2014).	  	  When	  osteoblasts	  were	  exposed	  in	  vitro	  to	  high	  doses	  (50	  
μM)	  of	  ZA	  in	  the	  presence	  and	  absence	  of	  the	  MVP	  metabolite	  GGOH,	  the	  inhibitory	  
effects	  of	  ZA	  on	  cell	  viability	  and	  migration	  were	  reversed	  in	  the	  presence	  of	  GGOH	  
(Ziebart	   et	   al.,	   2011).	   	   Given	   the	   seemingly	   paradoxical	   upregulation	   of	   VEGF	  
mRNA	   in	   the	   presence	   of	   ZA,	   it	   follows	   that	   any	   functional	   effects	   observed	   in	  
osteoblasts	   may	   be	   due	   to	   inhibition	   of	   the	   mediating	   receptor	   via	   the	   MVP.	  	  
However,	   the	  VEGF/VEGFR1	  pathway	   is	  contributory,	  not	  essential	   to	  osteoblast	  
mineralisation	   and	   maturation,	   and	   the	   role	   of	   the	   MVP	   is	   not	   universally	  
supported.	  	  There	  is	  evidence	  to	  suggest	  that	  N-­‐BPs,	  specifically	  pamidronate	  and	  
alendronate,	   inhibit	  bone	  nodule	  formation	   in	  vitro	   in	  low	  doses.	   	  This	  effect	  was	  
not	   reproduced	   in	   non-­‐nitrogen	   containing	   BPs,	   yet	   was	   found	   to	   be	   largely	  
independent	  of	  protein	  prenylation	  and	  inhibition	  of	  the	  MVP	  (Idris	  et	  al.,	  2008).	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The	   present	   study	   aimed	   to	   further	   investigate	   this	   pathway	   as	   an	   intracellular	  
target.	  	  
MVP	   inhibition	   prevents	   the	   post-­‐translational	   prenylation	   of	   proteins	   with	   a	  
downstream	   effect	   on	   intracellular	   transportation	   and	   membrane	   anchorage.	  	  
Functional	   VEGF	   receptors	   are	   transported	   to	   the	   cell	   membrane,	   where	   they	  
interact	   with	   the	   VEGF	   ligand	   and	   are	   thus	   internalised.	   	   Basi	   et	   al.	   (2010)	  
demonstrated	  the	  intracellular	  accumulation	  of	  VEGFR2	  in	  ZA	  treated	  HUVECs	  and	  
the	   attenuation	   of	   this	   effect	   with	   the	   MVP	   intermediate	   geranylgeranyl	  
pyrophosphate	  (GGPP)	  (Basi	  et	  al.,	  2010).	   	  Both	  the	  intracellular	  accumulation	  of	  
the	  VEGFR2	  protein	  and	  the	  counter	  effects	  of	  GGPP	  supported	  a	  role	  for	  the	  MVP	  
as	  an	  intracellular	  target	  for	  ZA	  in	  HUVECs.	   	  Clarification	  of	  the	  mechanisms	  that	  
determine	  VEGFR	  inhibition	  by	  ZA	  in	  human	  alveolar	  osteoblasts	  may	  inform	  the	  
development	   of	   potential	   BRONJ	   therapies.	   	   The	   objectives	   of	   this	   study	   were	  
therefore	   to	   investigate	   the	   effect	   of	   the	   potent	   bisphosphonate,	   ZA,	   on	  VEGFR1	  
expression	  by	  HOBs	  and	  a	  role	   for	  the	  MVP	  as	  the	  mediating	   intracellular	  target.	  	  
The	   hypothesis	  was	   that,	   in	   the	   presence	   of	   ZA,	   there	  would	   be	   an	   intracellular	  
accumulation	   of	   VEGFR1.	   	   VEGFR1	   protein	   expression	  was	   confirmed	   in	   human	  
alveolar	   osteoblast	   cell	   culture	   in	   the	   presence	   of	   various	   VEGF,	   ZA	   and	   GGOH	  
combinations	   using	   immunofluorescent	   labelling	   and	   confocal	   microscopy.	   	   A	  
speckled	  appearance	  characteristic	  of	  intracellular	  accumulation	  was	  observed	  in	  
slide	  wells	  treated	  with	  treatment	  3	  (VEGF	  and	  ZA),	  4	  (VEGF,	  ZA	  and	  GGOH),	  6	  (ZA	  
and	   GGOH)	   and	   8	   (GGOH	   and	   VEGF).	   	   From	   these	   results,	   the	   mechanism	   of	  
VEGFR1	  inhibition	  remains	  to	  be	  elucidated.	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1.10 Future	  directions	  
Long	   term,	   in	   vivo	  models	   investigating	   GGOH	   as	   a	   potential	   therapy	   for	   BRONJ	  
would	   first	   require	   an	   in	  vitro	   dose-­‐response	   analysis	   and	   the	  potential	   for	  pro-­‐
angiogenic	  effects	  would	  also	  need	  to	  be	  investigated	  as	  a	  significant	  side	  effect	  in	  
patients	   with	   cancer	   (Ziebart	   et	   al.,	   2011).	   	   The	   critical	   role	   of	   angiogenesis	   in	  
tumour	   growth	   and	   metastasis	   is	   reflected	   in	   the	   targeting	   of	   some	   cancer	  
treatments	   to	   the	   angiogenic	   pathway,	   such	   as	   the	   anti-­‐VEGF	   antibody	  
bevacizumab	   (Ferrara	   et	   al.,	   2004).	   	   This	   antibody	   prevents	   VEGF	   from	   binding	  
with	  VEGFR1	  and	  VEGFR2	  on	  vascular	  endothelial	  cells	  and	  leads	  to	  a	  decrease	  in	  
tumour	  growth	  and	  metastasis.	  	  ZA	  may	  function	  as	  an	  anti-­‐tumour	  agent	  due	  to	  a	  
combination	   of	   effects	   including	   a	   direct	   inhibitory	   effect	   on	   tumour	   cells	  
(Shipman	  et	  al.,	  1997),	  an	   indirect	  effect	  via	   inhibition	  of	  bone	   turnover	  and	   the	  
growth	   factors	   that	   are	   ordinarily	   released	   during	   this	   process	   (Sasaki	   et	   al.,	  
1995),	   and	   an	   anti-­‐angiogenic	   effect	   via	   inhibition	   of	   the	   VEGF	   receptors	   on	  
endothelial	   cells	   (Zhao	   et	   al.,	   2010).	   	   Alongside	   reversing	   the	   effects	   of	   ZA	   that	  
inhibit	  wound	  healing	  in	  alveolar	  bone,	  therapy	  with	  GGOH	  may	  also	  reverse	  any	  
inhibitory	   effects	   of	   ZA	   on	   tumour	   angiogenesis	   and	  metastasis.	   	   In	   addition	   to	  
investigating	   the	   wider	   implications	   of	   GGOH	   administration,	   further	   in	   vitro	  
studies	   are	   indicated	   based	   on	   the	   present	   findings	   that	   investigate	   the	   specific	  
effects	  and	  relative	   importance	  of	  VEGFR1	  and	  VEGFR2	   inhibition	  on	  other	  cells	  
involved	  in	  oral	  wound	  healing,	  such	  as	  endothelial	  cells.	  	  	  	  	  
Studies	  conducted	  in	  cell	  culture	  are	  a	  starting	  point	  only.	  	  They	  do	  not	  represent	  
drug	  metabolism	   in	   the	   body,	   or	   the	   concentration	   of	   drug	   that	   reaches	   and	   is	  
taken	   up	   by	   the	   target	   tissue	   and	   specific	   cells.	   Nor	   do	   they	   represent	   the	  
complexity	   of	   interactions	   that	   occur	   during	   normal	   tissue	   turnover,	   modelling	  
and	   remodelling.	   	  Wound	   healing	   presents	   a	   further	   challenge	   to	   these	   ‘normal’	  
homeostatic	   mechanisms,	   and	   the	   medically	   compromised	   patient	   with	   an	   oral	  
wound	   is	   a	   unique	   physiological	   model.	   	   A	   wound-­‐healing	  model	   in	   ZA	   treated	  
animals	   would	   address	   some	   of	   the	   limitations	   of	   cell	   culture	   in	   assessing	   the	  
safety	  and	  efficacy	  of	  GGOH	  as	  a	  therapy	  for	  BRONJ.	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1.11 Conclusions	  
In	  conclusion,	  BRONJ	  is	  a	  complication	  of	  bisphosphonate	  exposure	  that	  is	  usually	  
associated	   with	   a	   significant	   challenge	   to	   local	   homeostasis,	   such	   as	   tooth	  
extraction,	   in	  a	  medically	  compromised	  patient.	   	  Although	  infrequent,	  BRONJ	  can	  
be	   severe	   and	   both	   the	   initial	   presentation	   and	   the	   response	   to	   treatment	  
demonstrate	  a	   failure	   to	  heal.	   	  VEGF	  has	  a	  key	  regulatory	  role	   in	  wound	  healing	  
and	   is	   involved	   in	   both	   angiogenesis	   and	   osteogenesis.	   	   VEGF	   upregulation	   in	  
response	   to	   ZA	   indicates	   a	   homeostatic	  mechanism	   and	   a	   pro-­‐angiogenic	   drive.	  	  
However,	  the	  presence	  of	  a	  ligand	  is	  not	  sufficient	  to	  determine	  a	  biological	  effect	  
as	  these	  effects	  are	  mediated	  by	  different	  receptors	  on	  different	  cells.	   	  VEGFR1	  is	  
downregulated	   in	   the	   presence	   of	   ZA	   and	   the	   present	   experiment	   has	   provided	  
functional	   evidence	   for	   VEGF	  mediated	   specifically	   by	   VEGFR1	   as	   an	   important	  
pathway	  in	  osteoblast	  mineralisation	  and	  maturation.	  	  No	  significant	  difference	  in	  
VEGFR1	   protein	   expression	  was	   observed	   between	  HOBs	   treated	  with	   different	  
combinations	   of	   ZA,	   VEGF	   and	   GGOH.	   	   The	   specific	   mechanisms	   of	   VEGFR1	  
inhibition	   in	   ZA	   treated	  HOBs	   therefore	   remain	   to	   be	   elucidated	   both	   in	   human	  
alveolar	   osteoblasts	   and	   in	   other	   cells	   involved	   in	   wound	   healing,	   such	   as	  
endothelial	   cells.	   	   However,	   the	   MVP	   has	   been	   established	   as	   an	   intracellular	  
target	  for	  the	  N-­‐BPs	  and	  GGOH	  has	  shown	  promise	  in	  vitro	  as	  a	  reversal	  agent	  for	  
the	   inhibitory	   effects	   of	   ZA.	   	   In	   reversing	   the	   unwanted	   effects	   of	   ZA,	   the	  
therapeutic	  effects	  may	  also	  be	  compromised	  and	  an	  animal	  model	  is	  the	  next	  step	  
in	   assessing	   GGOH	   in	   vivo	   as	   a	   potential	   treatment	   for	   BRONJ.	   	   Ultimately,	   the	  
results	   of	   this	   exploratory	   study	   support	   further,	   large-­‐scale	   investigation	   into	  
regulation	  of	  the	  VEGF/VEGFR1	  pathway	  in	  human	  alveolar	  osteoblast	  culture	  and	  
into	   the	   specific	   and	   relative	   effects	   of	   VEGFR1	   and	   VEGFR2	   inhibition	   in	   other	  
cells	  involved	  in	  oral	  wound	  healing.	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The Effect of Bisphosphonates on Wound Healing 
Information sheet for participants 
You	   are	   invited	   to	   take	   part	   in	   a	   study	   that	   will	   examine	   the	   effects	   of	  
bisphosphonate	  drugs	  on	   cells	   from	   the	  gum	   tissues	   and	  bone	   in	   relation	   to	   the	  
healing	  of	  mouth	  wounds.	  We	  understand	  that	  you	  have	  surgery	  planned	  that	  will	  
involve	   removal	   of	   some	   of	   your	   gum	   and/or	   bone	   tissue.	   This	   tissue	   would	  
normally	  be	  disposed	  of	  following	  your	  surgical	  procedure.	  Instead,	  we	  would	  like	  
to	   use	   this	   tissue	   in	   a	   research	   study	   which	   is	   part	   of	   the	   research	   leading	   to	  
Doctor	   of	   Philosophy.	   The	   study	  will	   involve	   growing	   cells	   from	   the	   tissue	   in	   a	  
laboratory,	   treating	   them	   with	   drugs	   including	   bisphosphonate	   and	   then	  
observing	   the	  effect	  of	   these	  drugs	  on	  genes	  responsible	   for	  wound	  healing.	  You	  
will	  not	  be	  requested	  to	  take	  any	  drug/	  medication	  at	  any	  stage	  of	  the	  study.	  It	  will	  
only	  be	  used	  in	  the	  laboratory.	  	  
	  
Please	   read	   this	   information	   sheet	   carefully	   before	   deciding	   whether	   or	   not	   to	  
participate.	  Additional	  information	  about	  the	  study	  can	  be	  provided	  upon	  request	  
by	   contacting	   us.	   Your	   participation	   is	   entirely	   your	   choice.	   You	   do	   not	   have	   to	  
take	  part	  in	  this	  study	  and	  if	  you	  decide	  not	  to	  take	  part,	  you	  will	  receive	  the	  usual	  
treatment/care	  as	  per	  normal.	  We	  appreciate	  your	  consideration	  of	  our	  request.	  
  
About  the  study  
The	   aim	   of	   this	   study	   is	   to	   attempt	   to	   establish	   whether	   there	   is	   any	   effect	   of	  
bisphosphonates	   on	   the	   wound	   healing	   potential	   of	   fibroblasts	   (gum	   cells)	   and	  
osteoblasts	   (bone	   cells).	   Bisphosphonates	   are	   a	   type	   of	   drug	   used	   to	   treat	  
osteoporosis	  and	  following	  therapy	  for	  some	  cancer.	  This	  drug	  can	  interfere	  with	  
the	  healing	  of	  wounds	   in	   the	  mouth.	   In	   this	   study,	  we	  will	   grow	   these	   cells	   in	   a	  
laboratory	   and	   observe	   how	   their	   genes	   and	   proteins	   respond	   to	   treatment	   by	  
bisphosphonates.	  It	  is	  hoped	  that	  this	  study	  will	  help	  us	  understand	  and	  therefore	  
prevent	  non-­‐healing	  wounds	  in	  the	  mouth	  in	  patients	  taking	  this	  type	  of	  drug.	  The	  
study	  is	  being	  held	  at	  the	  School	  of	  Dentistry,	  University	  of	  Otago.	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Requirements  of  Participants  
Should	  you	  agree	  to	  take	  part	  in	  this	  study,	  we	  will	  require	  your	  written	  informed	  
consent	   along	   with	   a	   short	   medical	   history	   prior	   to	   your	   surgery.	   All	   other	  
appointments	  including	  the	  surgery	  will	  still	  occur	  as	  they	  would	  if	  you	  were	  not	  
participating	  in	  the	  study.	  Gum	  and	  bone	  tissue	  that	  would	  normally	  be	  discarded	  
during	   the	   surgical	  procedures	  will	  be	   collected	  and	   stored	   for	  use	   in	   the	   study.	  
The	  surgical	  procedures	  will	  not	  be	  any	  different	  from	  what	  was	  already	  planned.	  
There	   is	   no	   requirement	   for	   you	   to	   take	   any	   medication/drug	   or	   undergo	   any	  
procedure	  other	  than	  those	  that	  have	  been	  previously	  planned.	  
  
Storage  and  use  of  tissue  for  future  research:  
At	  the	  end	  of	  the	  study	  we	  would	  like	  to	  store	  some	  of	  your	  gum	  and/or	  bone	  
tissue	  for	  use	  in	  future	  studies	  looking	  at	  these	  types	  of	  cells.	  Any	  such	  future	  
studies	  will	   only	   be	   carried	   out	  with	   appropriate	   ethical	   approval.	   Please	   notify	  
the	  researchers	  if	  you	  do	  not	  want	  this	  to	  occur.	  
  
As	  samples	  of	  human	  tissue	  will	  be	  taken	  during	  this	  study,	  there	  may	  be	  cultural	  
issues	   associated	   with	   storing	   tissue	   that	   need	   to	   be	   discussed	   with	   your	  
family/whanau.	  Some	  Iwi	  disagree	  with	  storage	  of	  human	  tissue	  citing	  whakapapa	  
and	   advise	   their	   people	   to	   consult	   prior	   to	   participation	   in	   research	  where	   this	  
occurs.	   To	   avoid	   problems	   at	   later	   stage,	   we	   suggest	   your	   family/whanau	   is	  
involved	  with	  you	  at	  all	  stages	  of	  the	  research.	  However,	  we	  also	  acknowledge	  that	  
individuals	  have	  the	  right	  to	  choose	  to	  participate.	  
  
Benefits    
This	   study	  will	   help	  us	   to	   identify	  which	  wound	  healing	   genes	  become	  active	   in	  
cells	   treated	   by	   bisphosphonates.	   Therefore	   it	   is	   hoped	   that	   this	   will	   provide	   a	  




There	  will	  be	  no	  extra	  cost	  incurred	  by	  you	  for	  participation	  in	  this	  study.	  	  
  
General  
There	  will	   be	   five	   researchers	   involved	   in	   this	   study.	   They	   are	  Mrs	   Sobia	   Zafar,	  
Associate	  Professor	  Mary	  Cullinan,	  Associate	  Professor	  Bernadette	  Drummond,	  Dr	  
Dawn	  Coates	  and	  Professor	  Gregory	  Seymour.	  Mrs	  Sobia	  Zafar	  is	  a	  PhD	  candidate	  
and	  the	  other	  researchers	  are	  staff	  in	  School	  of	  Dentistry,	  University	  of	  Otago.	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If	  you	  have	  any	  queries	  or	  concerns	  about	  your	  rights	  as	  a	  participant	  in	  this	  study	  
you	  may	  wish	  to	  contact	  a	  Health	  and	  Disability	  Services	  Consumer	  Advocate.	  This	  
is	   a	   free	   service	   provided	   under	   the	   Health	   and	   Disability	   Commissioner	   Act.	  
Telephone:	   (03)	  479	  0265	  or	   free	  phone:	  0800	  555	  050	  or	   free	   fax:	   	  0800	  2787	  
7678	  (0800	  2	  SUPPORT)	  or	  email:	  advocacy@hdc.org.nz	  
  
In	   the	  unlikely	  event	  of	  a	  physical	   injury	  as	  a	   result	  of	  your	  participation	   in	   this	  
study,	   you	   may	   be	   covered	   by	   accident	   compensation	   legislation	   with	   its	  
limitations.	   If	   you	   have	   any	   questions	   about	   ACC	   please	   feel	   free	   to	   ask	   the	  
researcher	  for	  more	  information	  before	  you	  agree	  to	  participate	  in	  this	  trial.	  	  
  
You	  are	  welcome	   to	  have	  a	   friend	  or	   family	   support	   to	  help	  you	  understand	   the	  
risk	  and	  /	  or	  benefits	  of	  this	  study	  and	  any	  other	  explanation	  you	  may	  require.	  You	  
may	  bring	  another	  person	  to	  your	  clinical	  visit.	  	  
  
Interpreter     
If	  you	  need	  an	  interpreter,	  the	  School	  of	  Dentistry	  will	  try	  to	  make	  one	  available.	  	  If	  
an	  interpreter	  cannot	  be	  found,	  you	  may	  be	  asked	  to	  bring	  your	  own.	  
  
Confidentiality  
No	  material	  that	  could	  personally	  identify	  you	  will	  be	  used	  in	  any	  reports	  in	  this	  
study.	   The	   data	   collected	   will	   be	   stored	   securely	   so	   that	   only	   those	   directly	  
involved	  in	  the	  research	  will	  have	  access	  to	  the	  records.	  At	  the	  end	  of	  the	  project,	  
we	  would	  like	  to	  store	  some	  of	  your	  gum	  tissue	  identified	  only	  by	  a	  code	  number,	  
for	  use	  in	  future	  studies	  looking	  at	  these	  types	  of	  cells.	  Furthermore,	  any	  raw	  data	  
on	  which	  the	  results	  of	  the	  study	  depend	  will	  be	  retained	  in	  secure	  storage	  for	  10	  




You	  are	  most	  welcome	  to	  request	  a	  copy	  of	  the	  results	  of	   the	  project	  should	  you	  
wish.	  There	  may	  be	  a	  delay	  between	  data	  collection	  and	  publication.	  Alternatively	  
you	  can	  discuss	  the	  outcomes	  with	  the	  researcher.	  
  
Statement  of  Approval  
This	   study	   has	   received	   ethical	   approval	   from	   the	   Lower	   South	   Regional	   Ethics	  
Committee,	  Approval	  No.	  LRS/10/09/038.	  
  
  





If	  you	  have	  any	  questions	  about	  the	  project,	  either	  now	  or	  in	  the	  future,	  please	  do	  
not	  hesitate	  to	  contact	  either:	  
  
Principal  Investigator:   Sobia  Zafar  (PhD  candidate)                                                                              03  
479  5664                                        
                          Department  of  Oral  Sciences  
                          School  of  Dentistry,  University  of  Otago  
  
Project  Supervisors:                              Associate  Professor  Mary  Cullinan                                                         03  
479  7120  
                                                                               Associate  Professor  Bernadette  Drummond                 03  
479  7128  
                                                                                 Dr.  Dawn  Coates                                                     03  
479  7111  
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Appendix	  5	  






Participation in the study “The Effect of Bisphosphonates on Wound Healing” 
 
Request for interpreter 
•  I wish to have an interpreter.   Yes / No 
 
•  I have read the Information Sheet concerning this project and 
understand what the study is about.  All my questions have been 
answered to my satisfaction. I understand that I am free to request 
further information at any stage. 
 
Yes / No 
•  I have had the opportunity to use a friend to help me ask questions 
and understand the study. 
 
Yes / No 
•  I know that my participation in the project is entirely voluntary. 
 
Yes / No 
•  I know that I am free to withdraw from the project at any time 
prior to tissue collection without any disadvantage. 
 
Yes / No 
•  I know that the results of this project may be published but my 
anonymity will be preserved. 
 
Yes / No 
•  I give consent for the collection of cells from my discarded gum 
or bone tissue during the jaw surgery. 
 
Yes / No 
•  I give consent to the use of these tissues/cells for research. 
 
Yes / No 
•  I understand that I am unable to withdraw my tissue sample once 
it has been collected. 
 
Yes / No 
•  I understand that any raw data on which the results of the study 
depend, and any health information collected about me will be 
Yes / No 
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retained in secure storage for 10 years, after which it will be 
destroyed. 
 
•  Storage and use of tissue for future research: 
- I consent to some of my gum and bone tissue being stored 
for use in future studies looking at these types of cells, any 
such study being subject to further ethical approval.  
- I wish tissue will be disposed of using appropriate tikanga 
(karakia) 
 




Yes / No 
•  Further Information 
I am aware that further questions can be directed to the following: 
 
 
Yes / No 
 Mrs Sobia Zafar, PhD Student, Department of Oral Sciences, 
School of Dentistry, University of Otago, Dunedin. Tel: (03) 479 
5664         
 
Associate Professor Mary Cullinan, Department of Oral 
Sciences, School of Dentistry, University of Otago, Dunedin. Tel: 
(03) 4797120 
 
Associate Professor Bernadette Drummond, Department of 
Oral Sciences, School of Dentistry, University of Otago, Dunedin. 
Tel: (03) 479 7128 
 
Dr. Dawn Coates, Department of Oral Sciences, School of 
Dentistry, University of Otago, Dunedin. Tel: (03) 479 7111 
 
Professor Gregory Seymour, Department of Oral Sciences, 
School of Dentistry, University of Otago, Dunedin. Tel: (03) 479 




I __________________________ (full name) hereby consent to take part in this project. 
 
 
.............................................................................   ............................... 
       (Signature of participant)      (Date) 
       
  
Project explained by Sobia Zafar, researcher. 
 
............................................................................                                ............................... 
 
(Signature of Sobia Zafar, researcher)                                                         (Date)  
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Appendix	  6	  
Base	  Media	  for	  Osteoblast	  Cell	  Culture	  
Equipment	  and	  reagents:	  
• Microbiological	  safety	  cabinet	  (Class	  II	  Hood)	  
• Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	  with	  high	  glucose,	  GlutaMAX	  
Supplement,	  pyruvate	  (Cat	  No.	  10569-­‐010,	  Life	  Technologies/Gibco)	  
• Foetal	  Bovine	  Serum	  (FBS)	  (Cat	  No.	  10091-­‐148,	  life	  Technologies/Gibco)	  
• Antibiotic-­‐Antimycotic:	  10,000	  units/ml	  penicillin,	  10,000µg/ml	  
streptomycin,	  25µg/ml	  Fungizone	  (Anti-­‐Anti)	  (Cat	  No.	  15240-­‐062,	  Life	  
Technologies/Gibco)	  
• Gentamicin	  10mg/ml.	  	  Recommended	  concentration	  0.5	  to	  50µg/ml	  (Cat	  
No.	  15710-­‐064,	  Life	  Technologies/Gibco)	  
Procedure:	  
• In	  the	  cell	  culture	  room	  under	  the	  laminar	  flow	  hood	  remove	  57.5ml	  from	  a	  
500ml	  DMEM	  bottle	  of	  Media	  
• Make	  up	  to	  500ml	  of	  osteoblast	  cell	  culture	  media	  according	  to	  the	  table	  
below	  	  
• Gently	  swirl	  to	  mix	  
Reagent	   Cat	  No.,	  Company	   Amount	  in	  500ml	  
DMEM,	  high	  glucose,	  GlutaMAX	  

















Gentamicin	  10mg/ml	   15710-­‐064,	  Life	  
Technologies/Gibco	  
2.5mls	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Appendix	  7	  
Osteoblast	  Culture	  Media	  
Equipment	  and	  reagents:	  	  
• Microbiological	  safety	  cabinet	  (Class	  II	  Hood)	  
• Base	  media	  for	  osteoblast	  cell	  culture	  (Appendix	  6)	  
• 2-­‐phospho	  L-­‐ascorbic	  acid	  trisodium	  salt,	  MW	  322.05g/mol,	  Cas	  No.	  
66170-­‐10-­‐3,	  Solubility	  0.3g/10ml	  (Cat	  No.	  49752,	  Sigma)	  
• Dexamethasone,	  MW	  392.5g/mol,	  Cas	  No.	  50-­‐02-­‐2,	  Solubility	  25mg/ml	  (Cat	  
No.	  D2915,	  Sigma)	  
Prepare	  reagents	  
2-­‐phospho	  L-­‐ascorbic	  acid	  trisodium	  salt	  100mM	  working	  stock:	  
• 1M	  stock	  solution:	  Add	  5ml	  of	  sterile	  molecule	  water	  to	  1.61g	  of	  2-­‐phospho	  
L-­‐ascorbic	  acid	  and	  sterile	  filter	  at	  0.22µm	  
• 100mM	  working	  stock	  solution:	  Add	  10µl	  of	  the	  1M	  stock	  solution	  to	  90µl	  
of	  sterile	  water	  
• Store	  at	  -­‐20°C	  in	  a	  labelled	  1ml	  eppendorf	  	  
Dexamethasone	  100µM	  working	  stock	  
• 10mM	  stock	  solution:	  	  To	  3.925mg/ml	  of	  Dexamethasone	  add	  1	  ml	  of	  
sterile	  molecule	  water	  and	  sterile	  filter	  to	  0.22µm	  
• 100µM	  working	  stock:	  Add	  5µl	  of	  the	  10mM	  stock	  to	  495µl	  of	  sterile	  water	  
and	  mix	  
• Store	  at	  -­‐20°C	  in	  a	  labelled	  1ml	  eppendorf	  protected	  from	  light	  
Procedure:	  
• Under	  the	  laminar	  flow	  hood,	  place	  50ml	  of	  base	  media	  in	  a	  sterile	  50ml	  
falcon	  tube	  
• Add	  50µl	  of	  2-­‐phosph	  L-­‐ascorbic	  acid	  trisodium	  salt	  working	  stock	  and	  5µl	  
of	  dexamethasone	  working	  stock	  to	  base	  media	  according	  to	  the	  table	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10nM	   5µl	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Appendix	  8	  
Osteoblast	  Retrieval	  from	  Cryopreservation	  
Equipment	  and	  reagents:	  	  
• Microbiological	  safety	  cabinet	  (Class	  II	  Hood)	  
• Sterile	  T25	  cell	  culture	  flask,	  50ml,	  25cm2	  (Cat	  No.	  690175,	  Grenier	  bio-­‐
one)	  	  
• Centrifuge	  swinging	  bucket	  rotor	  (Cat	  No.	  392934,	  Beckman	  Coulter)	  
• Sanyo	  CO2	  Incubator	  (Cat	  No.	  MCO-­‐19AIC)	  
• Inverted	  microscope	  (Nikon	  Eclipse	  Ti)	  	  
• Cell	  in	  cryopreservation	  labelled:	   	  
o HOB2	  ;	  10;	  Eq	  to	  T25;	  2-­‐6-­‐12	  
o HOB3	  	  ;	  11;	  Eq	  to	  T25;	  12-­‐6-­‐12	  
o HOB5	  	  ;	  1;	  Eq	  to	  T25;	  29-­‐6-­‐12	  
• Osteoblast	  culture	  media	  (Appendix	  7)	  
Procedure:	  
• Pre-­‐warm	  50ml	  of	  osteoblast	  culture	  media	  and	  place	  in	  the	  laminar	  flow	  
hood	  in	  the	  cell	  culture	  room	  
• Label	  three	  sterile	  T25	  flasks	  (HOB2,	  HOB3	  and	  HOB5)	  
• Put	  4ml	  of	  pre-­‐warmed	  osteogenic	  media	  in	  each	  T25	  flask	  	  
• Wear	  face	  shield	  and	  gloves	  and	  retrieve	  one	  vial	  of	  human	  alveolar	  
osteoblasts	  for	  each	  cell	  line	  2,	  3	  and	  5	  from	  liquid	  nitrogen	  	   	  
Start	  with	  HOB2:	  
• Warm	  cells	  quickly	  and	  immediately	  add	  1ml	  of	  media	  once	  defrosted	  	  
• Pipette	  up	  the	  media	  with	  the	  cells	  and	  place	  in	  a	  large	  falcon	  tube	  with	  an	  
additional	  2ml	  of	  media.	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• Place	  the	  falcon	  tube	  in	  the	  centrifuge	  in	  a	  balanced	  position	  with	  a	  water	  
balance.	  	  Centrifuge	  at	  150	  g	  for	  5	  min	  at	  25°C	  (programme	  1)	  
• Carefully	  transport	  to	  the	  laminar	  flow	  hood	  without	  disturbing	  the	  cell	  
pellet	  	  
• Pour	  off	  the	  media	  and	  add	  1ml	  of	  new	  media	  	  
• Flush	  to	  disrupt	  cell	  pellet	  
• Pipette	  up	  cells	  and	  gently	  add	  to	  T25	  flask	  
• Observe	  under	  the	  microscope	  and	  incubate	  at	  37°C	  in	  100%	  humidity	  and	  
5%	  CO2/95%	  air	  
• Complete	  the	  above	  steps	  for	  each	  cell	  line	  
• Observe	  under	  the	  microscope	  every	  day	  to	  assess	  confluence	  
• Under	  the	  laminar	  flow	  hood,	  pour	  off	  old	  media	  into	  waste	  and	  pipette	  
5mls	  of	  fresh,	  pre-­‐warmed	  osteogenic	  media	  (Appendix	  2)	  into	  each	  T25	  
every	  2	  days	  until	  cells	  approach	  80%	  confluence	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Appendix	  9	  
Transferring	  Cells	  from	  a	  T25	  into	  a	  T75	  Flask	  
Equipment	  and	  reagents:	  
• Microbiological	  safety	  cabinet	  (Class	  II	  Hood)	  
• Inverted	  microscope	  (Nikon	  Eclipse	  Ti)	  	  
• Sterile	  T-­‐75	  cell	  culture	  flask,	  250ml,	  75cm2	  (Cat	  No.	  658175,	  Grenier	  bio-­‐
one)	  
• Trypsin/EDTA	  0.25%	  (Cat	  No.	  25200-­‐072,	  Gibco/Life	  Technologies)	  
• Osteoblast	  culture	  media	  (Appendix	  7)	  
• Sterile	  Phosphate	  Buffered	  Saline	  (Cat	  No.	  SALB010,	  Gibco/Life	  
Technologies)	  
Procedure:	  
For	  a	  T25	  
• Under	  the	  laminar	  flow	  hood,	  pour	  off	  the	  media	  into	  waste	  
• Wash	  cells	  with	  5ml	  warm	  sterile	  PBS	  and	  discard	  PBS	  wash	  
• Add	  600µl	  of	  Trypsin/EDTA	  0.25%	  
• Leave	  at	  room	  temperature	  or	  37oC	  for	  approximately	  3	  minutes,	  or	  until	  
cell	  are	  rounded	  when	  observed	  under	  the	  microscope	  
• Bang/tap	  firmly	  on	  the	  side	  of	  the	  flask	  to	  ensure	  cells	  are	  lifted	  
• Add	  4.5mls	  of	  pre-­‐warmed	  media	  and	  swirl	  to	  mix	  
• Transfer	  to	  a	  T75	  and	  make	  up	  10ml	  volume	  with	  5.5ml	  of	  media	  
Splitting	  cells	  into	  2x	  T75	  (T75"2xT25)	  
• Under	  the	  laminar	  flow	  hood,	  pour	  off	  the	  media	  into	  waste	  
• Wash	  with	  10ml	  of	  warm	  sterile	  PBS	  and	  discard	  PBS	  wash	  
• Add	  1800µl	  of	  0.25%	  Trypsin/EDTA	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• Leave	  at	  room	  temperature	  or	  37oC	  for	  approximately	  3	  minutes,	  or	  until	  
cell	  are	  rounded	  when	  observed	  under	  the	  microscope	  
• Bang/tap	  firmly	  on	  the	  side	  of	  the	  flask	  to	  ensure	  cells	  are	  lifted	  
• Add	  8.5mls	  of	  media	  and	  swirl	  to	  mix	  
• Split	  evenly	  between	  two	  T75	  flasks	  and	  make	  up	  the	  volume	  in	  each	  flask	  
to	  10ml	  with	  media	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Appendix	  10	  
Cryopreservation	  	  (Zafar,	  2014)	  
Equipment	  and	  reagents:	  
• Microbiological	  safety	  cabinet	  (Class	  II	  Hood)	  
• Centrifuge	  swinging	  bucket	  rotor	  (Cat	  No.	  392934,	  Beckman	  Coulter)	  
• Cell	  Freezing	  Device	  (Nalgen	  Labware	  Mr.	  Frostry,	  Rochester,	  USA)	  
• Pre-­‐labelled	  sterile	  ampules/cryogenic	  vials	  (Cat	  No.	  2017-­‐09,	  Grenier	  Bio-­‐
one)	  
• Sterile	  Phosphate	  Buffered	  Saline	  (Cat	  No.	  SALB010,	  Gibco/Life	  
Technologies)	  
• Trypsin/EDTA	  0.25%	  (Cat	  No.	  25200-­‐072,	  Gibco/Life	  Technologies)	  
• Dimethyl	  Sulphoxide	  99.5%	  (DMSO)	  (Cat	  No.	  D-­‐4540	  Sigma-­‐Aldrich)	  
• Foetal	  Bovine	  Serum	  (FBS),	  (Cat	  No.	  10091-­‐148,	  life	  Technologies/Gibco)	  
Procedure	  
• Prepare	  a	  90%	  FBS/10%	  DMSO	  cell	  freezing	  medium	  	  
• Trypsinise	  cells	  at	  80-­‐90%	  confluence	  according	  to	  Appendix	  9	  
• Obtain	  a	  cell	  pellet	  by	  centrifuging	  at	  250	  x	  g	  for	  5	  minutes	  at	  18°C	  
• Decant	  the	  supernatant	  and	  resuspend	  in	  500	  μL	  of	  freezing	  medium	  per	  
T25	  equivalent	  of	  cells.	  
• Transfer	  each	  500	  μL	  cell	  suspension	  to	  1.5ml	  cryogenic	  storage	  vials	  
• Place	  in	  the	  Mr	  Frosty	  freezing	  container	  for	  cooling	  at	  1°C/min	  in	  a	  -­‐80°C	  
freezer	  overnight	  
• Transfer	  to	  liquid	  nitrogen	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Appendix	  11	  
Osteoblast	  Mineralisation	  Media	  
Equipment	  and	  reagents:	  
• Microbiological	  safety	  cabinet	  (Class	  II	  Hood)	  
• Base	  media	  for	  osteoblast	  cell	  culture	  (Appendix	  6)	  
• 100mM	  2-­‐phospho	  L-­‐ascorbic	  acid	  trisodium	  salt	  working	  stock	  in	  sterile	  
molecule	  H2O	  (Appendix	  7)	  
• 100μl	  Dexamethasone	  working	  stock	  in	  sterile	  molecule	  H2O	  (Appendix	  7)	  
• β-­‐glycerophosphate,	  MW	  216.04	  (Cat	  No.	  G9422,	  Sigma)`	  
Prepare	  reagents:	  
1M	  β-­‐glycerophosphate	  stock	  solution	  
• Add	  2.1604g	  of	  β-­‐glycerophosphate	  in	  10ml	  of	  distilled	  water	  on	  a	  
magnetic	  stirrer	  until	  dissolved	  and	  sterile	  filter	  at	  0.22μM	  
	  
Procedure:	  
• In	  the	  laminar	  flow	  hood,	  place	  40ml	  of	  base	  media	  (Appendix	  6)	  into	  a	  
sterile	  50ml	  falcon	  tube	  
• Add	  the	  working	  stock	  solutions	  for	  2-­‐phospho	  L-­‐ascorbic	  acid	  trisodium	  
salt	  and	  dexamethasone	  (Appendix	  7),	  and	  the	  stock	  solution	  for	  β-­‐
glycerophosphate	  according	  to	  the	  table	  	  
• Pipette	  up	  and	  down	  to	  mix	  
Osteogenic	  
differentiation	  factors	  	  







acid	  trisodium	  salt	  	  
	  








10mM	   100µM	  	  	  
(in	  sterile	  
MQWater)	  
10nM	   4µl	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Appendix	  12	  
Lifting,	  Counting	  and	  Plating	  Cells	  
Equipment	  and	  reagents:	  
• Microbiological	  safety	  cabinet	  (Class	  II	  Hood)	  
• Inverted	  microscope	  (Nikon	  Eclipse	  Ti)	  	  
• Nunc	  Lab-­‐Tek	  II	  Chamber	  Slide	  System;	  8-­‐well;	  Growth	  area:	  0.7cm2	  
Working	  volume	  0.2	  to	  0.5ml	  (Cat	  No.	  12-­‐565-­‐8,	  Thermo	  Fisher	  Scientific)	  
• Osteogenic	  media	  with	  β-­‐	  glycerophosphate	  (Appendix	  11)	  
• Neubauer	  Haemocytometer	  (Cat	  No.	  BS-­‐748,	  Hawksley)	  
• Trypsin/EDTA	  0.25%	  (Cat	  No.	  25200-­‐072,	  Gibco	  /Life	  Technologies)	  
• Tryphan	  blue	  solution	  (0.4%)	  (Cat	  No.	  T8154,	  Sigma-­‐Aldrich)	  
• Sterile	  Phosphate	  Buffered	  Saline	  (Cat	  No.	  SALB010,	  Gibco/Life	  
Technologies)	  
Procedure:	  
• Confirm	  microscopically	  that	  cells	  are	  approximately	  80%	  confluent	  	  
• Under	  the	  laminar	  flow	  hood,	  make	  up	  40mls	  of	  osteogenic	  media	  with	  β-­‐	  
glycerophosphate	  
• Pour	  off	  the	  media	  from	  the	  T75	  flask	  into	  the	  waste	  
• Wash	  with	  10ml	  of	  warm	  sterile	  PBS	  and	  discard	  PBS	  wash	  
• Add	  1800µl	  of	  0.25%	  Trypsin/EDTA	  	  
• Leave	  at	  room	  temperature	  or	  37oC	  for	  approximately	  3	  minutes,	  or	  until	  
cell	  are	  rounded	  when	  observed	  under	  the	  microscope	  
• Bang	  firmly	  on	  the	  side	  of	  the	  flask	  to	  ensure	  cells	  have	  lifted	  from	  the	  flask	  
• Add	  8.5	  ml	  of	  media	  and	  swirl	  to	  mix	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• Pipette	  15	  µl	  of	  this	  suspension	  into	  a	  small	  eppendorf	  tube	  and	  add	  15	  µl	  
tryphan	  blue	  
• Gently	  shake	  to	  mix	  and	  pipette	  2	  drops	  onto	  the	  haemocytometer	  either	  
side	  of	  the	  coverslip	  so	  that	  it	  runs	  underneath	  






• Add	  these	  numbers	  together	  and	  divide	  by	  the	  number	  of	  squares	  (9)	  
• Double	  this	  number	  to	  account	  for	  the	  dilution	  factor	  	  
• This	  gives	  the	  number	  of	  cells/ml	  x104	  
• Determine	  the	  total	  plating	  surface	  area	  in	  cm2	  where	  the	  surface	  area	  per	  
well	  is	  0.7cm2	  (number	  of	  wells	  x	  0.7cm2)	  
• Determine	  the	  total	  volume	  required	  where	  each	  well	  is	  plated	  with	  300	  µl	  
of	  cell	  suspension	  (number	  of	  wells	  x	  300	  µl)	  
• Multiply	  the	  seeding	  density	  in	  cells/cm2	  by	  the	  total	  plating	  surface	  area	  in	  
cm2	  to	  determine	  the	  total	  number	  of	  cells	  required	  
• From	  counting	  the	  cells,	  determine	  how	  many	  ml	  of	  cell	  suspension	  are	  
required	  to	  provide	  the	  total	  number	  of	  cells	  
• Make	  up	  the	  volume	  required	  with	  osteogenic	  mineralisation	  media	  
(appendix	  11)	  and	  gently	  swirl	  to	  mix	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• Pipette	  300µl	  of	  cell	  suspension	  into	  each	  well,	  swirling	  the	  suspension	  
occasionally	  
Example:	  
Plating	  four	  8-­‐well	  chamber	  slides	  at	  a	  seeding	  density	  of	  4000	  cells/cm2	  where	  
the	  total	  number	  of	  cells/ml	  determined	  by	  counting	  is	  e.g.	  124,000cells/ml	  
• Total	  plating	  surface	  area	  =	  25	  wells	  x	  0.7	  cm2	  =	  17.5	  cm2	  
• Total	  volume	  required	  =	  25	  wells	  x	  300	  µl	  =	  7,500	  µl	  
• Total	  number	  of	  cells	  required	  =	  4000	  cells/cm2	  x	  17.5cm2	  =	  70,000	  cells	  
• Total	  number	  of	  cells	  required	  as	  a	  percentage	  of	  the	  total	  number	  of	  
cells/ml	  =	  (100/124,000)	  x	  70,000	  =	  56%	  of	  1	  ml	  
560	  µl	  of	  cell	  suspension	  +	  6940	  µl	  of	  media	  =	  70,000	  cells	  in	  7,500	  µl	  of	  media	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Appendix	  13	  
Treating	  HOBs	  with	  VEGFR	  Inhibitors	  
Equipment	  and	  reagents	  
• Microbiological	  safety	  cabinet	  (Class	  II	  Hood)	  
• 40mls	  Osteoblast	  mineralisation	  media	  (Appendix	  11)	  
• Nunc	  Lab-­‐Tek	  II	  Chamber	  Slide	  System;	  8-­‐well;	  Growth	  area:	  0.7	  cm2	  
Working	  volume	  0.2	  to	  0.5	  ml	  (Cat	  No.	  12-­‐565-­‐8,	  Thermo	  Fisher	  Scientific)	  
• Nunc	  96-­‐well	  cell	  culture	  microplate	  with	  lid,	  flat-­‐bottom	  wells,	  Nunclon	  
delta	  cell	  culture	  treated	  clear	  polystyrene;	  Working	  volume:	  50	  to	  250	  
μl/well	  (Cat	  No.	  NUNC-­‐167008,	  Thermo	  Fisher	  Scientific)	  
• Cultured	  human	  alveolar	  osteoblasts:	  HOB2,	  HOB3,	  HOB5	  	  
• VEGFR1	  inhibitor,	  ZM	  306416,	  MW	  333.74,	  IC50	  330nM,	  10mM	  in	  DMSO	  
(Cat	  No.	  S2897,	  Selleckchem)	  
• VEGFR2	  inhibitor,	  ZM	  323881	  HCL,	  MW	  411.86,	  IC	  50	  <2nM,	  10mM	  in	  
DMSO	  (Cat	  No.	  S2896,	  Selleckchem)	  
• VEGFR1/VEGFR2	  dual	  inhibitor,	  KRN	  633,	  MW416.86,	  IC50	  VEGFR1	  
170nM	  VEGFR2	  160nM,	  10mM	  in	  DMSO	  (Cat	  No.	  S1557,	  Selleckchem)	  
• Dimethyl	  Sulphoxide	  99.5%	  (DMSO)	  (Cat	  No.	  D-­‐4540	  Sigma-­‐Aldrich)	  
• Sanyo	  CO2	  Incubator	  (Cat	  No.	  MCO-­‐19AIC)	  
• Sterile	  0.22	  μm	  Millipore	  Express	  filters	  (Cat	  No.	  SLGPO33RJ,	  Millex	  GP)	  
Procedure	  
Plating	  of	  cells	  
• 8-­‐well	  chamber	  slides	  at	  a	  seeding	  density	  of	  8000	  cells/cm2	  in	  400μl	  of	  
osteoblast	  mineralising	  medium	  per	  well	  	  
o HOB2:	  0.7	  cm2	  /well	  x	  31	  =	  21.7	  cm2	  x	  8000	  =	  17.4	  x	  104	  cells	  in	  	  	  	  
12.4	  ml	  media	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o HOB3:	  0.7	  cm2	  /well	  x	  23	  =	  16.1	  cm2	  x	  8000	  =	  12.9	  x	  104	  cells	  in	  	  	  	  	  
9.2	  ml	  media	  	  	  
o HOB5:	  0.7	  cm2	  /well	  x	  23	  =	  16.1	  cm2	  x	  8000	  =	  12.9	  x	  104	  cells	  in	  	  	  	  	  
9.2	  ml	  media	  	  	  
• 96-­‐well	  plates	  at	  a	  seeding	  density	  of	  8000	  cells/cm2	  in	  200μl	  of	  osteoblast	  
mineralising	  medium	  per	  well	  and	  cultured	  for	  21	  and	  28	  days	  
o HOB2:	  0.33cm2/well	  x	  30	  =	  9.9	  cm2	  x	  8000	  =	  7.9	  x	  104	  cells	  6	  ml	  
media	  
o HOB3:	  0.33	  cm2/well	  x	  30	  =	  9.9	  cm2	  x	  8000	  =	  7.9	  x	  104	  cells	  in	  6	  ml	  
media	  	  	  
o HOB5:	  0.33cm2/well	  x	  30	  =	  9.9	  cm2	  	  	  x	  8000	  =	  7.9	  x	  104	  cells	  in	  6	  ml	  
media	  	  	  
• Trypsinise	  and	  count	  cells	  according	  to	  Appendix	  12	  
• Plate	  each	  of	  the	  cell	  lines	  with	  400	  μl	  of	  osteogenic	  media	  per	  well	  in	  the	  8-­‐
well	  chamber	  slides	  according	  to	  the	  experimental	  layout	  
• Plate	  each	  of	  the	  cell	  lines	  with	  200	  μl	  of	  osteogenic	  media	  per	  well	  in	  the	  
96-­‐well	  chamber	  slides	  as	  per	  the	  experimental	  layout.	  	  Repeat	  with	  a	  
duplicate	  96-­‐well	  slide	  
• Incubate	  at	  37°C	  in	  100%	  humidity	  and	  5%	  CO2/95%	  air	  for	  24	  hours	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Experimental	  layout:	  8-­‐well	  chamber	  slides	  
	  
HOB2	   HOB3	   	   HOB5	   HOB2	   	   HOB2	   HOB2	  
HOB2	   HOB3	   	   HOB5	   HOB3	   	   HOB2	   HOB2	  
HOB2	   HOB3	   	   HOB5	   HOB5	   	   	   	  
HOB2	   HOB3	   	   HOB5	   	   	   	   	  
ZM	  306416	  	  
Flt1	  
	   ZM	  306416	  	  
Flt1	  C	  
	   Test	  
	  
	  
HOB2	   HOB3	   	   HOB5	   HOB2	   	   	   	  
HOB2	   HOB3	   	   HOB5	   HOB3	   	   	   	  
HOB2	   HOB3	   	   HOB5	   HOB5	   	   	   	  
HOB2	   HOB3	   	   HOB5	   	   	   	   	  
ZM	  323881	  
KDR	  
	   ZM	  323881	  
KDR	  C	  
	   	  
	  
	  
HOB2	   HOB3	   	   HOB5	   HOB2	   	   	   	  
HOB2	   HOB3	   	   HOB5	   HOB3	   	   	   	  
HOB2	   HOB3	   	   HOB5	   HOB5	   	   	   	  
HOB2	   HOB3	   	   HOB5	   	   	   	   	  
KRN633	   	   KRN633	  C	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Experimental	  layout	  –	  96-­‐well	  plates	  (x2)	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Treatment	  
• Centrifuge	  the	  inhibitor	  vials	  at	  300	  rpm	  	  
• Prepare	  50μl	  aliquots	  of	  each	  inhibitor	  in	  20	  labelled	  tubes	  	  
• Store	  excess	  at	  -­‐80°C	  degrees	  (thawed	  aliquots	  will	  keep	  for	  2	  weeks	  at	  
4°C)	  
• Label	  4	  falcon	  tubes:	  Control,	  10μM	  VEGFR1,	  10μM	  VEGFR2	  and	  10μM	  
VEGFR1/R2	  
• Prepare	  the	  0.1%	  DMSO	  control	  with	  osteogenic	  media	  according	  to	  the	  
table	  below	  
• Prepare	  a	  10μM	  working	  stock	  for	  each	  inhibitor	  (1:1000	  dilution	  in	  
osteogenic	  media)	  in	  the	  corresponding	  falcon	  tube	  according	  to	  the	  table	  
below	  
	  
Inhibitor	   10mM	  Stock	   Media	   DMSO	   Total	  Vol.	  Req	  
ZM	  306416	  10μM	   5μl	   4995μl	   -­‐	   5000μl	  
ZM	  323881	  10μM	   5μl	   4995μl	   -­‐	   5000μl	  
KRN	  633	  10μM	   6μl	   5994μl	   -­‐	   6000μl	  
Control	  	  
(0.1%	  DMSO)	  
-­‐	   7493μl	   7.5μl	   7500μl	  
	  
• Label	  a	  duplicate	  set	  of	  falcon	  tubes	  and	  sterile	  filter	  the	  above	  control	  and	  
inhibitor	  working	  stocks	  
• Label	  four	  additional	  sterile	  falcon	  tubes	  for	  each	  inhibitor	  with	  the	  four	  
different	  dose	  concentrations	  listed	  in	  the	  treatment	  table	  below	  
• Use	  the	  sterile	  filtered	  10μM	  working	  stocks	  in	  serial	  dilutions	  to	  obtain	  the	  
concentration	  range	  required	  in	  the	  corresponding	  falcon	  tube	  as	  per	  the	  
treatment	  table	  below	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Vol.	  Required	   Vol.	  from	  previous	  
conc.	  
Media	  
Working	  stock	  10μM	   5000μl	   	   	  
10μM	  
	  
1200μl	   1200μl	   -­‐	  
1μM	  
	  
1400μl	   200μl	   1800μl	  
0.1μM	  
	  
1200μl	   150μl	   1350μl	  
0.01μM	  
	  





Vol.	  Required	   Vol.	  from	  previous	  
conc.	  
Media	  
Working	  stock	  10μM	   5000μl	   -­‐	   -­‐	  
1μM	  
	  
1200μl	   200μl	   1800μl	  
0.1μM	  
	  
1400μl	   200μl	   1800μl	  
0.01μM	  
	  
1200μl	   150μl	   1350μl	  
0.001μM	  
	  





Vol.	  Required	   Vol.	  from	  previous	  
conc.	  
Media	  
Working	  stock	  10μM	  	   6000μl	   -­‐	   -­‐	  
1μM	   1200μl	   300μl	   2700μl	  
0.5μM	  
	  
1800μl	   1000μl	   1000μl	  
0.1μM	  
	  
1200μl	   300μl	   1200μl	  
0.01μM	  
	  
1200μl	   150μl	   1350μl	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• Treat	  both	  96-­‐well	  plates	  according	  to	  the	  experimental	  layout	  
o Replace	  the	  existing	  media	  with	  100μl	  of	  the	  appropriate	  treatment	  
per	  well	  
• Pipette	  the	  media	  off	  each	  well	  in	  the	  8-­‐well	  chamber	  slides	  and	  treat	  with	  
200μl	  of	  the	  appropriate	  treatment	  according	  to	  the	  experimental	  design	  
• Incubate	  at	  37°C	  in	  100%	  humidity	  and	  5%	  CO2/95%	  air	  	  
• Repeat	  the	  treatment	  procedure	  described	  above	  twice	  a	  week	  for	  23	  days	  
• Continue	  to	  treat	  one	  of	  the	  96-­‐well	  plates	  for	  an	  additional	  week	  (30	  days	  
total)	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ZM	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   1μM	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ZM	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KDR	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0.1μM	   0.1μM	   0.1μM	   0.01μM	   0.01μM	   0.01μM	   0.1μM	   0.1μM	   0.1μM	  
1μM	   1μM	   1μM	   0.1μM	   0.1μM	   0.1μM	   0.5μM	   0.5μM	   0.5μM	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Appendix	  14	  
Fixing	  Cells	  in	  Acetone	  
Equipment	  and	  reagents:	  
• Acetone	  (Cat	  No.	  1090,	  Riedel-­‐de-­‐Haen)	  
• Sterile	  Phosphate	  Buffered	  Saline	  (Cat	  No.	  SALB010,	  Gibco/Life	  
Technologies)	  
• Orbital	  shaker	  (LabTek)	  
Procedure:	  
• 48hrs	  after	  treatment	  place	  acetone	  on	  ice	  
• Pour	  the	  media	  off	  one	  slide	  into	  waste	  
• Carefully	  remove	  slide	  wells	  
• Submerge	  the	  slide	  in	  PBS	  to	  prevent	  drying	  
• Repeat	  with	  the	  next	  2	  slides	  
• Place	  slides	  into	  an	  empty	  glass	  slide	  holder	  and	  carefully	  pour	  in	  ice-­‐cold	  
acetone	  to	  cover	  completely	  
• Treat	  with	  acetone	  using	  low	  level	  rotation	  on	  an	  orbital	  shaker	  for	  10	  min	  	  
• Remove	  after	  10min	  and	  place	  on	  a	  paper	  towel	  to	  dry	  
• Repeat	  with	  the	  remaining	  slides	  
• Store	  in	  a	  slide	  box	  at	  4°C	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Appendix	  15	  
Mineralisation	  Assay	  
Equipment	  and	  reagents:	  
• 100%	  absolute	  for	  analysis	  (Cat	  No.1.00983.2500,	  Merck)	  
• Alizarin	  red	  S,	  FW=	  342.26	  (Cat	  no.	  A5533-­‐25G,	  Sigma-­‐Aldrich)	  
• Na2HPO4	  FW=	  141.96	  g	  mol-­‐1	  (Cat	  no.	  3828-­‐01,	  J.T.	  Baker)	  
• NaH2PO4	  FW=	  156.01	  g	  mol-­‐1	  (Cat	  no.	  A471-­‐500G,	  Ajax	  Finechem)	  
• Ammonium	  Hydroxide	  solution	  28	  -­‐	  30%	  NH3	  (Cat	  no.	  221228-­‐100ML-­‐A,	  
Sigma-­‐Aldrich)	  
• Cetylpyridinium	  chloride	  FW	  =	  358.00	  g	  mol-­‐1	  (Cat	  no.	  C0732-­‐100G,	  
Sigma-­‐Aldrich)	  
• Bio-­‐Strategy	  Synergy	  2	  plate	  reader	  (BioTek)	  and	  Gen	  5	  software	  run	  on	  
Windows	  XP	  
Prepare	  the	  following:	  
70%	  ethanol	  
• 70	  ml	  100%	  ethanol	  +	  30	  ml	  dH2O	  
40mM	  Alizarin	  red-­‐	  S	  solution,	  pH4.2	  
• Make	  up	  the	  following	  sequentially:	  
1. 100	  mM	  ARS	  stock	  solution	  
3.42	  g	  ARS	  +100	  ml	  dH20	  
2. 40	  mM	  ARS	  solution	  
40	  ml	  of	  100	  mM	  stock	  solution	  +	  60	  ml	  dH20	  (low-­‐level	  rotation)	  
• Correct	  pH	  to	  4.2	  with	  the	  drop-­‐wise	  addition	  of	  Ammonium	  Hydroxide	  
solution	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10mM	  Sodium	  phosphate	  buffer	  
• Make	  up	  the	  following	  sequentially:	  
1. 100	  mM	  Na2HPO4	  
1.42	  g	  of	  Na2HPO4	  +	  100	  ml	  of	  dH20	  
	  
2. 100	  mM	  NaH2PO4	  
1.56	  g	  of	  NaH2PO4	  +	  100	  ml	  of	  dH2O	  
	  
3. 100	  mM	  Sodium	  phosphate	  buffer	  
57.7	  ml	  of	  100mM	  Na2HPO4	  +	  42.3	  ml	  of	  100	  mM	  NaH2PO4	  
	  
4. 10	  mM	  Sodium	  phosphate	  buffer	  
10	  ml	  of	  100	  mM	  Sodium	  phosphate	  buffer	  +	  90	  ml	  of	  dH2O	  
10%	  Cetylpyridinium	  chloride	  in	  10mM	  sodium	  phosphate	  buffer:	  
• Place	  10	  g	  of	  cetylpyridinium	  chloride	  (CPC)	  in	  a	  flask	  and	  make	  up	  to	  100	  
ml	  of	  solution	  with	  10	  mM	  sodium	  phosphate	  buffer	  
2mM	  Alizarin	  red-­‐S	  working	  stock	  solution:	  
• A	  1:20	  dilution	  of	  40mM	  alizarin	  red-­‐S	  solution:	  
• 50μl	  of	  40mM	  alizarin	  red-­‐S	  +	  950μl	  of	  10%	  CPC	  in	  10mM	  sodium	  
phosphate	  buffer	  
Procedure:	  
Alizarin	  red-­‐S	  staining:	  
• Wash	  wells	  with	  PBS	  for	  30	  seconds	  
• Fix	  in	  ice-­‐cold	  70%	  ethanol	  for	  1	  hour	  on	  ice	  
• Rinse	  wells	  with	  MQH2O	  
• Stain	  with	  100	  μl	  of	  40	  mM	  ARS	  solution	  (pH	  4.2)	  per	  well	  for	  10	  minutes	  at	  
room	  temperature	  under	  low-­‐level	  rotation	  
• Rinse	  five	  times	  with	  MQH2O	  and	  once	  with	  PBS	  for	  15	  minutes	  under	  low	  
level	  rotation	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• Photograph	  Alizarin	  red-­‐S	  staining	  	  
Alizarin	  red-­‐S	  extraction	  and	  quantification:	  
• Incubate	  each	  well	  with	  1	  ml	  of	  the	  above	  solution	  (10%	  cetylpyridinium	  
chloride	  in	  10	  mM	  sodium	  phosphate,	  pH	  7.0)	  for	  20	  minutes	  at	  room	  
temperature	  under	  low-­‐level	  rotation	  
• Collect	  200	  μl	  of	  alizarin	  extract	  from	  each	  well	  and	  transfer	  to	  the	  same	  
position	  on	  a	  new	  96-­‐well	  plate	  
• Place	  the	  new	  96-­‐well	  plate	  with	  alizarin	  extract	  in	  the	  spectrophotometer	  
and	  read	  by	  absorbance	  at	  562	  nm	  	  
Generating	  a	  standard	  curve:	  
• Dilute	  the	  2	  mM	  alizarin	  red-­‐S	  working	  stock	  in	  2-­‐fold	  serial	  dilutions	  in	  1.5	  
ml	  micro-­‐centrifuge	  tubes	  to	  obtain	  the	  high-­‐range	  set	  
• For	  the	  low-­‐range	  set,	  start	  with	  a	  1:66	  dilution	  of	  the	  2	  mM	  alizarin	  red-­‐S	  
working	  stock	  to	  obtain	  a	  30	  μl	  alizarin	  red-­‐S	  working	  stock	  solution	  (15	  μl	  
2	  mM	  alizarin	  red-­‐S	  +	  985	  μl	  of	  10%	  CPC	  in	  10	  mM	  sodium	  phosphate	  
buffer)	  
• Dilute	  the	  30	  μl	  alizarin	  red-­‐S	  working	  stock	  in	  2-­‐fold	  serial	  dilutions	  in	  1.5	  
ml	  micro-­‐centrifuge	  tubes	  
• For	  both	  the	  high	  and	  low-­‐range	  set,	  mix	  the	  solution	  3	  times,	  spin	  and	  
repeat	  prior	  to	  each	  dilution	  
• Pipette	  200	  μl	  of	  each	  concentration,	  including	  the	  working	  stock	  solutions,	  
into	  a	  separate	  well	  on	  a	  96-­‐well	  plate	  
• Pipette	  200	  μl	  of	  the	  10%	  CPC	  in	  10	  mM	  sodium	  phosphate	  buffer	  into	  
another	  well	  on	  the	  same	  plate	  as	  per	  the	  experimental	  design	  to	  act	  as	  a	  
blank	  	  
• Place	  the	  plate	  in	  the	  spectrophotometer	  and	  read	  at	  562	  nM	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Appendix	  16	  
Mineralised	  Nodule	  Staining	  Protocol	  (Dillon	  et	  al.,	  2012)	  
Equipment	  and	  reagents:	  
• 100%	  Ethanol	  absolute	  for	  analysis	  (Cat	  No.1.00983.2500,	  Merck)	  
• Sterile	  Phosphate	  Buffered	  Saline	  (Cat	  No.	  SALB010,	  Gibco/Life	  
Technologies)	  
• Hydrophobic	  barrier	  pen	  (Cat	  No.	  S2002,	  Dako	  Cytomation)	  
• 40mM	  Alizarin	  red	  solution	  (Appendix	  15)	  
• Glycerol	  for	  analysis	  (Cat	  No.	  1.04092.2500,	  Merck)	  
• Coverslips,	  22x50	  (Cat	  No.	  LBS	  22x50-­‐1,	  Thermo	  Fisher	  Scientific)	  
• Alkaline	  phosphatase	  (AP),	  Leukocyte	  (Cat	  no.	  86R,	  Sigma-­‐Aldrich),	  kit	  
contents:	  
o Naphthol	  AS-­‐BI	  alkaline	  solution	  (Cat	  no.	  86-­‐1)	  
o FRV-­‐alkaline	  solution	  (Cat	  no.	  86-­‐2)	  
o Sodium	  nitrite	  solution	  (Cat	  no.	  91-­‐4)	  
o Citrate	  solution	  (Cat	  no.	  91-­‐5)	  
• Haematoxylin	  solution,	  gill	  no.	  3	  (Cat	  no.	  GHS-­‐3)	  
• Acetone	  (Cat	  No.	  1090,	  Riedel-­‐de-­‐Haen)	  
• 10%	  Neutral	  Buffered	  Formalin	  (Cat	  No.	  BSPFS	  426.2.5,	  Thermo	  Fisher	  
Scientific)	  
• 	  Scott’s	  tap	  water	  substitute	  (Cat	  No.	  1871)	  
Prepare	  materials	  and	  reagents:	  
95%	  ethanol	  solution	  
• 95	  ml	  of	  100%	  ethanol	  MOB	  +	  5	  ml	  of	  sterile	  H2O	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50%	  ethanol	  solution	  
• 50	  ml	  of	  100%	  ethanol	  MOB	  +	  50	  ml	  of	  sterile	  H2O	  
Aqueous	  mount	  
• 80%	  Glycerol/PBS	  
40mM	  Alizarin	  red	  stain,	  pH	  4.2	  (Appendix	  15)	  
Alkaline-­‐dye	  mixture	  
In	  a	  10	  ml	  falcon	  tube	  mix:	  
• 156.25	  μl	  of	  Sodium	  Nitrite	  Solution	  +	  156.25	  μl	  of	  FRV-­‐Alkaline	  Solution	  
by	  gentle	  inversion	  and	  stand	  for	  2	  minutes	  
• Add	  7.03	  ml	  of	  deionized	  H2O	  
• Add	  156.25	  μl	  Naphthol	  AS-­‐BL	  
• Mix	  well	  
Citrate-­‐Acetone-­‐formaldehyde	  fixative	  
In	  a	  10	  ml	  falcon	  tube	  combine:	  
• 2.5	  ml	  of	  Citrate	  Solution	  
• 6.5	  ml	  of	  Acetone	  
• 0.8	  ml	  of	  10%	  Neutral	  Buffered	  Formalin	  (37%	  Formaldehyde)	  	  
• Use	  at	  room	  temperature	  (18-­‐26°C)	  	  
• Stable	  for	  4	  weeks	  if	  capped	  and	  stored	  at	  2-­‐8°	  
Procedure:	  
Fixation:	  
• Aspirate	  medium	  from	  each	  well	  and	  replace	  with	  PBS	  wash	  for	  5	  minutes	  
• Remove	  well	  chambers	  from	  slides	  
• Place	  slides	  in	  a	  glass	  holder	  on	  ice	  and	  submerge	  in	  95%	  ethanol	  for	  1	  h	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Washing:	  
• Wash	  the	  slides	  once	  in	  PBS	  
• Mark	  the	  outside	  of	  each	  well	  with	  DAKO	  pen	  
Alizarin	  red	  staining:	  
• Pipette	  70	  μl	  of	  40	  mM	  Alizarin	  red	  solution	  onto	  each	  well	  
• Place	  slides	  in	  a	  lightproof	  box	  for	  20	  minutes	  at	  room	  temperature	  
• Rinse	  with	  50%	  ethanol	  for	  1	  minute	  on	  low-­‐level	  rotation	  	  
• Wash	  in	  distilled	  water	  
Alkaline	  phosphatase	  staining	  protocol:	  
• Place	  slides	  in	  a	  glass	  holder	  and	  immerse	  in	  room	  temperature	  citrate-­‐
acetone-­‐formaldehyde	  fixative	  solution	  for	  30	  seconds	  	  
• Replace	  the	  fixative	  with	  deionized	  H2O	  and	  rinse	  gently	  for	  45	  seconds	  
• Do	  not	  allow	  the	  slides	  to	  dry	  
• Pipette	  100	  μl	  of	  alkaline-­‐dye	  mix	  onto	  each	  well	  
• Place	  in	  a	  lightproof	  box	  at	  room	  temperature	  for	  15	  minutes	  
• Discard	  alkaline-­‐dye	  mixture	  
• Rinse	  for	  2	  minutes	  in	  deionized	  water	  
• Do	  not	  allow	  the	  slides	  to	  dry	  
• Slides	  may	  be	  either	  counterstained	  or	  mounted	  at	  this	  stage	  
Counterstaining:	  
• Pipette	  70	  μl	  of	  haematoxylin	  onto	  each	  well	  and	  leave	  for	  2	  minutes	  
• Rinse	  3	  times	  with	  tap	  water,	  Scott’s	  tap	  water	  substitute	  and	  tap	  water	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Mounting:	  
• Place	  1	  drop	  of	  aqueous	  mount	  per	  well	  
• Place	  a	  clean	  coverslip	  over	  each	  slide	  and	  seal	  with	  clear	  nail	  polish	  	  
• Evaluate	  microscopically	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Appendix	  17	  
VEGF,	  ZA	  and	  GGOH	  Working	  Stocks	  
Equipment	  and	  reagents:	  
• Microbiological	  safety	  cabinet	  (Class	  II	  Hood)	  
• VEGF	  recombinant	  human	  protein	  (Cat	  No.	  PHC9394,	  Gibco/Life	  
Technologies)	  	  
• Bovine	  Serum	  Albumin	  (BSA)	  (Cat	  No.	  A7906-­‐100G,	  Sigma)	   	  
• Geranylgeraniol	  (GGOH)	  (Cat	  No.	  G3278-­‐100MG,	  Sigma-­‐Aldrich)	  	  
• 100%	  Ethanol	  absolute	  for	  analysis	  (Cat	  No.1.00983.2500,	  Merck)	  
• Zoledronic	  acid	  (Cat	  No.	  118072-­‐93-­‐8,	  Zometa,	  Novartis)	  
Procedure:	  
Prepare	  a	  50	  µl/ml	  VEGF	  working	  stock	  with	  PBS/0.1%BSA:	  
• PBS/0.1%BSA	  
• Weigh	  31	  mg	  of	  BSA	  in	  a	  falcon	  tube	  supported	  in	  a	  beaker	  
• In	  the	  laminar	  flow	  hood	  add	  31	  ml	  of	  sterile	  PBS	  to	  BSA	  
• Place	  on	  ice	  until	  dissolved	  completely	  
• Filter	  the	  dissolved	  PBS/0.1%	  BSA	  with	  a	  0.22	  µm	  filter	  and	  a	  sterile	  
syringe	  into	  a	  sterile	  falcon	  tube	  
• Label	  5	  sterile	  eppendorfs	  and	  aliquot	  1	  ml	  of	  sterile	  filtered	  PBS/0.1%	  BSA	  
into	  each	  
• Store	  froze	  
VEGF	  PBS/0.1%BSA	  working	  stock	  	  
• In	  the	  laminar	  flow	  hood	  label	  13	  x	  0.5	  ml	  sterile	  eppendorfs	  
• Take	  one	  1ml	  aliquot	  of	  PBS/0.1%BSA	  out	  of	  the	  freezer	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• Carefully	  remove	  the	  metal	  top	  and	  rubber	  bung	  from	  the	  10	  µg	  of	  
lyophilised	  VEGF	  
• Pipette	  200	  µl	  of	  PBS/0.1%BSA	  into	  the	  VEGF,	  replace	  the	  rubber	  bung	  and	  
put	  on	  ice	  outside	  the	  hood	  for	  10	  minutes	  
• Carefully	  half	  pipette	  up	  and	  down	  to	  mix	  	  
• Pipette	  15	  µl	  aliquots	  into	  the	  labelled	  eppendorfs	  
• Store	  frozen	  
Prepare	  a	  50	  mM	  GGOH	  working	  stock	  with	  100%	  ethanol:	  
• Pour	  approximately	  10	  ml	  of	  100%	  ethanol	  into	  a	  falcon	  tube	  in	  the	  cell	  
culture	  room	  under	  the	  laminar	  flow	  hood	  
• Pipette	  60.2	  µl	  of	  the	  ethanol	  in	  the	  falcon	  tube	  into	  a	  labelled	  1.5	  ml	  
eppendorf	  	  
• Add	  1.0	  µl	  of	  stock	  GGOH	  to	  make	  50	  mM	  working	  stock	  and	  keep	  on	  ice	  
	   	  
Treatments	   Stock	   Working	  stock	   Final	  Conc.	  Required	  
VEGF	  	   10	  µg	  (lyophilised)	   50	  µg/ml	   50	  ng/ml	  
GGOH	  	   290.48	  g/mol	   50	  mM	   50	  µM	  
Zoledronic	  acid	  	   2.94	  mM	  (4	  mg/ml)	   –	   10	  µM	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Appendix	  18	  
VEGF,	  ZA	  and	  GGOH	  Treatment	  Table	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①	  





















4	  	   1300	  
	  









1	   4	   1300	   1299	   -­‐	   -­‐	   -­‐	   1.3	  
Media	  +	  
GGOH	  +	  
VEGF	  	  	  	  
⑧	  
1	   4	   1300	   1297	   -­‐	   1.3	  
	  
-­‐	   1.3	  
TOTAL	   8	   4	   10,400	   10,366	   5.7	   5.2	   17.6	   5.2	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Appendix	  19	  
VEGF,	  ZA	  and	  GGOH	  Treatment	  Protocol	  
Equipment	  and	  reagents:	  
• Microbiological	  safety	  cabinet	  (Class	  II	  Hood)	  
• Forma	  Series	  II	  Water	  Jacket	  CO2	  Incubator	  (Model	  3100)	  
• Osteoblast	  mineralisation	  media	  (Appendix	  11)	  
• Sterile	  Phosphate	  Buffered	  Saline	  (Cat	  No.	  SALB010,	  Gibco/Life	  
Technologies)	  
• VEGF	  50	  µg/ml	  working	  stock	  (Appendix	  17)	  
• GGOH	  50	  mM	  working	  stock	  (Appendix	  17)	  	  
• ZA	  2.94	  mM	  stock	  (Appendix	  17)	  	  
• 12	  x	  8-­‐well	  chamber	  slides	  with	  cultured	  human	  alveolar	  osteoblasts	  
approaching	  100%	  confluence	  (4xHOB2,	  4xHOB3	  and	  4xHOB5)	  
Procedure:	  
• Under	  the	  laminar	  flow	  hood,	  make	  up	  20mls	  of	  osteoblast	  mineralisation	  
media	  (Appendix	  11)	  
• Label	  8	  sterile	  eppendorfs	  with	  the	  8	  different	  treatments	  as	  per	  the	  
treatment	  table	  (Appendix	  18)	  	  
• Make	  up	  treatments	  in	  the	  corresponding	  eppendorf	  according	  to	  the	  
treatment	  table	  (Appendix	  18),	  where:	  	  
o PBS	  volume	  is	  VEGF	  volume	  +	  ZA	  volume	  	  
o VEGF	  is	  used	  at	  50	  ng/ml	  (total	  volume/1000)	  
o GGOH	  is	  used	  at	  50	  µM	  (total	  volume/1000)	  
o ZA	  is	  used	  at	  10	  µM	  (total	  volume/294)	  
• Pipette	  off	  media	  in	  well	  1	  from	  each	  HOB2	  slide	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• Pipette	  in	  300	  µl	  of	  treatment	  1	  to	  each	  well	  1	  
• Repeat	  with	  remaining	  treatments	  and	  wells	  (2-­‐8)	  on	  these	  four	  HOB2	  
slides,	  as	  per	  the	  experimental	  layout:	  
	  
①	   ⑤	   	   ①	   ⑤	  
②	   ⑥	   	   ②	   ⑥	  
③	   ⑦	   	   ③	   ⑦	  
④	   ⑧	   	   ④	   ⑧	  
HOB2;	  R1	  
1	  
	   HOB2;	  IgG	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  
	  
①	   ⑤	   	   ①	   ⑤	  
②	   ⑥	   	   ②	   ⑥	  
③	   ⑦	   	   ③	   ⑦	  
④	   ⑧	   	   ④	   ⑧	  
HOB2;	  R1	  
2	  




• Make	  up	  2x8	  more	  eppendorfs	  of	  treatment	  	  
• Repeat	  as	  above	  with	  remaining	  cell	  lines	  (HOB3	  and	  HOB5)	  
• Incubate	  at	  37°C	  in	  100%	  humidity	  and	  5%	  CO2/95%	  air	  for	  48	  hours	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Appendix	  20	  
Immunohistochemistry	  for	  VEGFR1	  
Equipment	  and	  reagents	  	  
• Goat	  serum	  (G9023;	  C2013/160723;	  CL	  4571,	  Sigma)	  	  
o Heat	  treated	  at	  56oC	  for	  30	  minutes	  
• Bovine	  serum	  albumin,	  BSA	  (Cat	  No.	  A7906-­‐100G,	  Sigma)	  
• Hydrophobic	  wax	  barrier	  pen	  (Cat	  No.	  S2002,	  Dako)	  
• Primary	  antibody:	  	  
o Anti-­‐VEGF	  Receptor	  1	  antibody	  [Y103],	  rabbit	  monoclonal,	  conc.	  
0.027	  mg/ml	  (Cat	  No.	  ab32152,	  Sapphire	  Bioscience)	  
o Negative	  control,	  Rabbit	  Immunoglobulin	  Fraction	  (solid-­‐phase	  
adsorbed),	  stock	  conc.	  15	  µg/ml;	  working	  stock	  conc.	  1000	  µg/ml,	  
(Cat	  No.	  X0936,	  Dako)	  
• Secondary	  antibody,	  Alexa	  Fluor	  488	  Goat	  Anti-­‐Rabbit	  IgG	  (H+L),	  conc.	  2	  
mg/mL	  (Cat	  No.	  A-­‐11008,	  Invitrogen)	  
• Cell	  lines:	  
o 3x	  treated	  human	  alveolar	  osteoblast	  cell	  cultures,	  2	  x	  8-­‐well	  
chamber	  slides	  per	  cell	  line,	  fixed	  in	  acetone	  on:	  25/7/14	  HOB2,	  
27/7/14	  HOB3,	  27/7/14	  HOB5	  	  
• Vectashield	  mounting	  media	  with	  DAPI	  1.5	  mg/ml	  (Cat	  No.	  H1200,	  Vector	  
Laboratories)	  	  
• Coverslips,	  22	  x	  50	  (Cat	  No.	  LBS	  22x50-­‐1,	  Thermo	  Fisher	  Scientific)	  
• Zeiss	  LSM	  710	  Confocal	  Laser	  Scanning	  Microscope,	  488nm	  argon	  laser	  
excitation	  line	  (Carl	  Zeiss	  Microscopy	  GmbH)	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Day	  1	  
Preparation:	  
• Box	  of	  ice	  ready	  for	  all	  BSA	  solutions	  
• Make	  up	  PBS/1%BSA:	  
o Weigh	  out	  85mg	  of	  BSA	  in	  a	  falcon	  tube	  	  	  
o Add	  8.5	  ml	  PBS	  to	  get	  PBS/1%BSA	  
• Make	  up	  the	  blocking	  solution	  PBS/1%	  BSA/10%	  goat	  serum:	  
o Put	  PBS/1%BSA	  on	  ice	  and	  mix	  on	  low	  level	  rotation	  
o 10%	  goat	  serum:	  total	  volume	  of	  solution	  for	  50	  µl	  per	  well	  	  
o =	  (48	  +	  4	  spare)	  x	  50	  =	  52	  x	  50	  =	  2600	  µl	  
o 10%	  goat	  serum	  =	  10/100	  x	  2600	  =	  260	  µl	  
o Total	  volume	  2600	  µl	  –	  goat	  serum	  volume	  260	  µl	  =2340	  µl	  
o So	  for	  2600	  µl	  add	  260	  µl	  goat	  serum	  to	  2340	  µl	  PBS/	  1%	  BSA	  
• Make	  up	  the	  diluent	  PBS/1%BSA/5%	  goat	  serum:	  
o Total	  volume	  of	  diluent	  needed	  =	  primary	  ABC	  diluent	  (1411.2	  µl)	  +	  
control	  IgG	  diluent	  (1999	  µl)	  +	  secondary	  antibody	  diluent	  for	  next	  
stage	  (2600	  µl)	  
o Add	  some	  extra	  and	  make	  up	  to	  6500	  µl	   	  
o 5%	  goat	  serum	  =	  0.05	  x	  6500	  =	  325	  µl	  goat	  serum	  +	  6175	  µl	  of	  
PBS/1%BSA	  	  
o 6500	  µl	  1%	  BSA/	  PBS/	  5%	  goat	  serum	  =	  	  
325	  µl	  of	  goat	  serum	  +	  6175	  µl	  PBS/1%	  BSA	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Procedure	  for	  primary	  antibodies	  VEGFR1	  and	  IgG	  negative	  control	  
• DAKO	  pen	  around	  the	  edges	  of	  the	  slides	  while	  still	  dry	  to	  form	  a	  wax	  
barrier	  around	  each	  well	  
• Rehydrate	  the	  slides	  in	  PBS	  for	  5	  minutes	  under	  constant	  low-­‐level	  rotation	  
• Blocking:	  to	  block	  non-­‐specific	  binding	  and	  reduce	  background	  staining	  
using	  PBS/1%BSA/10%	  goat	  serum	  
o Use	  the	  blocking	  solution	  made	  during	  preparation	  (PBS/1%	  BSA/	  
10%	  goat	  serum)	  
o 50	  µl	  per	  well	  and	  leave	  for	  1hr	  at	  18ᵒC	  
• Use	  this	  hour	  to	  prepare	  the	  primary	  antibodies:	  
Primary	  antibody	  to	  VEGFR1:	  
• Antibody	  concentration	  1/50	  dilution	  (0.54	  µg/ml)	  
• Volume	  needed	  =	  50	  µl	  per	  well	  (so	  allow	  50	  +	  10	  extra)	  
• 24	  wells	  x	  60	  µl	  =	  1440	  µl	  
• 1:50	  	   Total	  volume	  1440	  µl	  	  	   1440/50	  =	  28.8	  	  
o In	  a	  2ml	  eppendorf	  combine:	  
Antibody	  ABC	  =28.8	  µl	  	  	  	  	  Diluent	  =	  1411.2	  µl	  	  
Primary	  antibody	  negative	  control:	  
• A	  1:15	  dilution	  of	  the	  stock	  (conc.	  15	  mg/ml)	  is	  needed	  to	  get	  a	  1	  mg/ml	  
working	  stock:	  
o 100	  µl	  rabbit	  IgG	  +	  1400	  µl	  PBS	  =	  1	  mg/ml	  working	  stock	  =	  	  	  	  	  	  	  	  	  
1000	  µg/ml	  
• The	  1000	  µg/ml	  working	  stock	  needs	  to	  be	  the	  same	  concentration	  as	  the	  
primary	  antibody	  (0.5	  µg/ml)	  
o 1000/0.5	  =	  2000	  !	  1:2000	  dilution	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• 24	  wells	  of	  1:2000	  =	  24	  x	  (50	  +	  1	  extra)	  =	  1440	  µl	  
o To	  allow	  the	  IgG	  to	  be	  accurately	  pipetted	  the	  total	  volume	  
must	  be	  increased:	  
1	  µl	  of	  rabbit	  IgG	  working	  stock	  into	  1999	  µl	  of	  diluent	  	  
• After	  1	  hour,	  draw	  off	  the	  blocking	  solution	  and	  add	  the	  primary	  antibody	  
(VEGFR1,	  IgG)	  
o 50	  µl	  per	  well	  as	  per	  the	  experimental	  layout	  (3	  slides	  R1,	  3	  
slides	  IgG),	  leave	  at	  4oC	  overnight	  (make	  moist	  chamber	  with	  
PBS)	  
	   	  


















































HOB2	  –	  R1	  
Treatment	  slide	  



















































HOB3	  –	  R1	  
Treatment	  slide	  



















































HOB5	  –	  R1	  
Treatment	  slide	  
	   HOB5	  –	  IgG	  	  
Treatment	  slide	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Day	  2	  
Procedure	  for	  washing	  slides	  in	  PBS/0.5%	  non-­‐fat	  milk	  powder	  immediately	  prior	  to	  
adding	  secondary	  antibody:	  
Make	  up	  600	  ml	  of	  PBS/0.5%	  non-­‐fat	  milk	  (NFM)	  powder:	  
• 3	  g	  non-­‐fat	  milk	  powder	  +	  597	  ml	  PBS	  =	  600	  ml	  0.5%	  NFM	  powder/PBS	  
• Use	  the	  magnetic	  ‘flea’	  to	  mix	  (zero	  heat)	  
• Use	  low	  level	  rotation	  and	  100	  ml	  glass	  slide	  holder:	  
• 5	  minutes	  then	  change	  the	  solution	  
• 20	  minutes	  then	  change	  the	  solution	  again	  
• 20	  minutes	  final	  PBS/NFM	  powder	  wash	  
Procedure	  for	  adding	  the	  secondary	  antibody	  	  
• Use	  the	  PBS/1%BSA/5%	  goat	  serum	  diluent	  made	  up	  on	  day	  1(keep	  on	  ice	  
when	  not	  using)	  
• Use	  at	  a	  concentration	  of	  5	  mg/ml	  =	  1/400	  dilution	  in	  PBS/1%	  BSA/5%	  
goat	  serum	  diluent	  
o Total	  volume	  needed	  for	  48	  wells	  +	  4	  extra	  =	  52x50	  =	  2600	  µl	  
o 2600/400	  =	  6.5	  µl	  of	  secondary	  antibody	  
o 2600	  –	  6.5	  =	  2593.5	  µl	  of	  diluent	  	  
• Add	  the	  secondary	  antibody	  to	  the	  diluent	  in	  a	  dimly	  lit	  room	  	  
o 2593.5	  µl	  diluent	  +	  6.5	  µl	  secondary	  antibody	  	  
• Add	  50	  µl	  to	  each	  well	  in	  a	  dimly	  lit	  room	  and	  store	  in	  a	  light	  proof	  box	  for	  1	  
hour	  at	  room	  temp	  
• Wash	  slides	  in	  a	  PBS	  (no	  milk	  powder)	  bath	  on	  low	  level	  rotation	  
• 5	  minutes	  and	  change	  the	  PBS	  solution	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• 10	  minutes	  and	  change	  the	  PBS	  solution	  
• Final	  10	  minute	  wash	  in	  PBS	  
• Tap	  on	  a	  paper	  towel	  to	  remove	  the	  excess	  and	  blot	  the	  edges	  
• Add	  1	  drop	  of	  DAPI	  softmount	  to	  each	  well	  
• Place	  a	  clean	  coverslip	  over	  each	  slide	  and	  dab	  the	  edges	  lightly	  to	  dry	  
• Seal	  with	  clear	  nail	  polish	  at	  the	  corners	  
• Leave	  for	  1	  hour	  in	  the	  dark	  slide	  box	  
• Seal	  the	  edges	  with	  nail	  polish	  and	  store	  flat	  in	  a	  lightproof	  box	  in	  a	  cool	  
room	  
• View	  images	  using	  the	  488nm	  argon	  laser	  excitation	  line	  on	  the	  Zeiss	  LSM	  
710	  Confocal	  Laser	  Scanning	  Microscope	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Appendix	  21	  
Raw	  Data	  for	  ARS	  Absorbance	  for	  Each	  Inhibitor	  and	  Controls	  at	  21	  Days	  
Cell	  line	   VEGF	  
Inhibitor	  
Conc.	   562	   Blank	  
562	  




2	   R1	   0.01	   0.151	   0.120	  
0.141	   0.046	   32.5	  3	   R1	   0.01	   0.141	   0.109	  
5	   R1	   0.01	   0.225	   0.193	  
2	   R1	   0.1	   0.142	   0.110	  
0.153	   0.072	   46.7	  3	   R1	   0.1	   0.146	   0.114	  
5	   R1	   0.1	   0.268	   0.236	  
2	   R1	   1	   0.139	   0.107	  
0.125	   0.038	   30.8	  3	   R1	   1	   0.13	   0.098	  
5	   R1	   1	   0.2	   0.169	  
2	   R1	   10	   0.116	   0.084	  
0.09	   0.021	   23.1	  3	   R1	   10	   0.104	   0.073	  
5	   R1	   10	   0.144	   0.120	  
2	   R2	   0.001	   0.190	   0.158	  
0.143	   0.036	   25.2	  3	   R2	   0.001	   0.133	   0.102	  
5	   R2	   0.001	   0.200	   0.168	  
2	   R2	   0.01	   0.159	   0.128	  
0.156	   0.047	   30.2	  3	   R2	   0.01	   0.161	   0.130	  
5	   R2	   0.01	   0.242	   0.210	  
2	   R2	   0.1	   0.158	   0.127	  
0.150	   0.059	   39.3	  3	   R2	   0.1	   0.139	   0.107	  
5	   R2	   0.1	   0.250	   0.218	  
2	   R2	   1	   0.159	   0.128	  
0.149	   0.032	   21.8	  3	   R2	   1	   0.164	   0.133	  
5	   R2	   1	   0.218	   0.186	  
2	   R1/R2	   0.01	   0.141	   0.109	  
0.146	   0.056	   38.2	  3	   R1/R2	   0.01	   0.150	   0.118	  
5	   R1/R2	   0.01	   0.242	   0.210	  
2	   R1/R2	   0.1	   0.153	   0.121	  
0.140	   0.042	   29.9	  3	   R1/R2	   0.1	   0.143	   0.111	  
5	   R1/R2	   0.1	   0.220	   0.188	  
2	   R1/R2	   0.5	   0.240	   0.208	  
0.167	   0.061	   36.3	  3	   R1/R2	   0.5	   0.129	   0.098	  
5	   R1/R2	   0.5	   0.228	   0.196	  
2	   R1/R2	   1	   0.129	   0.097	  
0.115	   0.037	   32.5	  3	   R1/R2	   1	   0.122	   0.090	  
5	   R1/R2	   1	   0.190	   0.158	  
2	   Control	   0	   0.180	   0.148	   0.154	  
	  	  
	   	  
2	   Control	   0	   0.191	   0.159	   	   	  
3	   Control	   0	   0.169	   0.137	   	  0.137	  
	  
	   	  
3	   Control	   0	   0.168	   0.136	   	   	  
5	   Control	   0	   0.258	   0.226	   0.245	  
	  
	   	  
5	   Control	   0	   0.296	   0.264	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Appendix	  22	  
Raw	  Data	  for	  ARS	  Absorbance	  for	  Each	  Inhibitor	  and	  Control	  at	  28	  Days	  
Cell	  line	   VEGF	  
Inhibitor	  
Conc.	   562	   Blank	  
562	  




2	   R1	   0.01	   0.176	   0.145	  
0.183	   0.047	   25.9	  3	   R1	   0.01	   0.199	   0.168	  
5	   R1	   0.01	   0.267	   0.236	  
2	   R1	   0.1	   0.177	   0.146	  
0.295	   0.247	   83.5	  3	   R1	   0.1	   0.191	   0.160	  
5	   R1	   0.1	   0.611	   0.580	  
2	   R1	   1	   0.168	   0.137	  
0.169	   0.038	   22.4	  3	   R1	   1	   0.189	   0.159	  
5	   R1	   1	   0.241	   0.210	  
2	   R1	   10	   0.110	   0.079	  
0.088	   0.025	   28.2	  3	   R1	   10	   0.100	   0.069	  
5	   R1	   10	   0.147	   0.116	  
2	   R2	   0.001	   0.162	   0.132	  
0.178	   0.062	   34.8	  3	   R2	   0.001	   0.185	   0.155	  
5	   R2	   0.001	   0.279	   0.249	  
2	   R2	   0.01	   0.205	   0.175	  
0.278	   0.101	   36.1	  3	   R2	   0.01	   0.406	   0.375	  
5	   R2	   0.01	   0.316	   0.286	  
2	   R2	   0.1	   0.193	   0.162	  
0.188	   0.030	   15.8	  3	   R2	   0.1	   0.212	   0.181	  
5	   R2	   0.1	   0.251	   0.221	  
2	   R2	   1	   0.203	   0.172	  
0.181	   0.050	   27.4	  3	   R2	   1	   0.167	   0.136	  
5	   R2	   1	   0.265	   0.234	  
2	   R1/R2	   0.01	   0.256	   0.225	  
0.209	   0.035	   16.9	  3	   R1/R2	   0.01	   0.199	   0.168	  
5	   R1/R2	   0.01	   0.263	   0.233	  
2	   R1/R2	   0.1	   0.189	   0.158	  
0.168	   0.048	   28.6	  3	   R1/R2	   0.1	   0.156	   0.126	  
5	   R1/R2	   0.1	   0.251	   0.220	  
2	   R1/R2	   0.5	   0.167	   0.136	  
0.181	   0.109	   60.3	  3	   R1/R2	   0.5	   0.132	   0.101	  
5	   R1/R2	   0.5	   0.336	   0.305	  
2	   R1/R2	   1	   0.148	   0.117	  
0.131	   0.029	   22.3	  3	   R1/R2	   1	   0.142	   0.111	  
5	   R1/R2	   1	   0.195	   0.165	  
2	   Control	   0	   0.177	   0.146	   0.134	   0.018	   13.4	  2	   Control	   0	   0.152	   0.121	  
3	   Control	   0	   0.171	   0.140	   0.125	   0.021	   16.8	  3	   Control	   0	   0.141	   0.110	  
5	   Control	   0	   0.225	   0.194	   0.223	   0.041	   18.6	  5	   Control	   0	   0.283	   0.252	  
	  
